|

Industry News - Seqirus Media Monitoring - 19th Feb 2018

    View this newsletter in full

Chinese four-strain flu vaccine to hit market in 2018

A vaccine to protect people against four subtypes of seasonal influenza viruses is expected to be available on the Chinese market in the second half of 2018, a health official said. Gao Fu, director of the Chinese Center for Disease Control and Prevention, said the upcoming vaccine would be made in China. China CDC sources said that less than 2 percent of the population is vaccinated against the seasonal flu.
17th Feb 2018 - Xinhua

Chinese four-strain flu vaccine to hit market in 2018


18th Feb 2018 - China.org.cn

Chinese scientists develop new flu vaccine

A research group from Wuhan Institute of Virology, Chinese Academy of Sciences, announced that they have developed a new type of flu vaccine using nano-technology. The intranasal nano-vaccine can target broad-spectrum flu viruses and induces robust immune responses, said Cui Zongqiang, leader of the research group. "In our study, an intranasal nanovaccine worked well against infections of H1N1 and H9N2 virus in mice," Cui said. "The results suggest that the 3M2e-rHF nanoparticle is a promising, needle-free, intranasally administered, cross-protective influenza vaccine," he said.
17th Feb 2018 - Xinhua

Flu Death Puts Antiviral Drugs in the Spotlight

A Texas elementary school teacher who died almost a week after getting sick from the flu became a talking point online after her husband said she didn’t immediately fill her prescription for an antiviral drug after deeming the $116 insurance co-pay too high. . The CDC said the flu shot is the best way to prevent seasonal flu. Frank Holland said he couldn't remember whether his wife got a flu shot this season.
17th Feb 2018 - Time

Region faces flu medicine shortage

In the U.S., the FDA has not confirmed a nationwide shortage of antivirals, but released a statement at the beginning of February acknowledging “spot shortages” of antiviral treatments and the vaccine. The state’s Department of Public Health flu report for last week indicates that rates of flu-like illness are still on the rise, “an indication that flu season is not over yet and that there is still plenty of reason to get a flu shot if you haven’t done so yet.”
17th Feb 2018 - Gloucester Daily Times


Industry News - Seqirus Media Monitoring - 16th Feb 2018

    View this newsletter in full

Glaxo Gets European Approval For Expanded Influenza Vaccine Indication

GlaxoSmithKline has received European approval for the expanded indication for its influenza vaccine for those aged six months and older. The expanded indication for Fluarix Tetra in Europe has been approved to include adults and now children from the age of six months for the prevention of influenza disease caused by the two influenza A virus subtypes and the two influenza B virus types contained in the vaccine.
15th Feb 2018 - Morning Star

GSK receives European approval for expanded indication for Fluarix Tetra (Influenza Vaccine) for ages six months and older


15th Feb 2018 - 4-Traders

Blame the Flu Epidemic on a Weak Vaccine

In the U.S., an unusually resilient strain of flu called H3N2 has been the predominant assailant this season, and the vaccine rolled out last year was ill-suited to protect against it: a new report from the CDC shows that it reduced illness caused by H3N2 by only 25 percent. Still, it’s better to get a shot because it offers some protection, especially against other strains that are just starting to emerge, the CDC says. The vaccine was particularly effective for children aged six months to eight years, reducing their risk of contracting H3N2 by more than half.
15th Feb 2018 - Bloomberg

Interim Estimates of 2017–18 Seasonal Influenza Vaccine Effectiveness


16th Feb 2018 - CDC

Flu vaccines just 25% effective against worst strain this year, CDC says


15th Feb 2018 - USA Today

Flu Vaccine Efficacy Low, Interim Estimates Show


15th Feb 2018 - Medscape

Flu vaccine works better than feared, but it's still not great


15th Feb 2018 - NBC News

The much-maligned flu shot has reduced the risk of serious illness this year by 36%, CDC says


15th Feb 2018 - Los Angeles Times

This season's flu vaccine is only 36 percent effective, but experts say you should still get it


15th Feb 2018 - The Washington Post

Flu shots are 36 percent effective so far this year, but you should get one anyway, says CDC


15th Feb 2018 - CNBC

This Year's Flu Shot Only Worked a Third of the Time, CDC Says


15th Feb 2018 - Time

Flu Vax Efficacy 25% Against Predominant H3N2 Strain So Far


15th Feb 2018 - MedPage Today

Influenza: 2017 vaccine effectiveness between moderate and high in France

In France. the effectiveness of the flu vaccine for the 2017-2018 season has been rated moderate to high depending on what is being measured, between 44 and 60% effectiveness, a much higher figure than in North America. The effectiveness for the over 65s is estimated at 60% for both strains circulating in France
15th Feb 2018 - Le Figaro

Flu-stricken teacher’s death puts focus on antivirals

A Texas elementary school teacher who died almost a week after getting sick from the flu became a talking point online after her husband said she didn’t immediately fill her prescription for an antiviral drug after deeming the $116 insurance co-pay too high. The CDC said the flu shot is the best way to prevent seasonal flu. Frank Holland said he couldn’t remember whether his wife got a flu shot this season. Generally, he said, they’ve both been “pretty healthy.”
15th Feb 2018 - New York Post

Flu-stricken Texas teacher's death puts focus on antivirals


15th Feb 2018 - ABC News

Flu-stricken Texas teacher’s death puts focus on antivirals


15th Feb 2018 - Seattle Times

US study finds 36% flu vaccine protection, 25% against H3N2

An eagerly awaited estimate of flu vaccine effectiveness in the U.S. so far this season confirmed that protection against the H3N2 strain is low and not much different than a similar report from Canada. In a separate study in Eurosurveillance, Spanish researchers reported findings from primary care clinics and hospitals this season in Navarre. In October and November, the trivalent vaccine was offered for free to target populations, which included people age 60 and older and those with underlying health conditions.
15th Feb 2018 - CIDRAP


Industry News - Seqirus Media Monitoring - 15th Feb 2018

    View this newsletter in full

Quidel QuickVue Flu Test Clears FDA as Class II RIDT

Quidel announced that its test to detect and differentiate influenza types A and B has met the U.S. FDA's criteria to be reclassified as a class II rapid influenza diagnostic test and that the test has received 510(k) clearance. The QuickVue Influenza A+B assa allows for qualitative, 10-minute detection of influenza A and B antigens directly from symptomatic patients' nasal or nasopharyngeal swabs
14th Feb 2018 - 360Dx

Here's why it's so hard to make a better flu vaccine

In the U.S., the CDC plans to release preliminary data about how well the flu vaccine has been working this year. It doesn’t look good. A Canadian study showed only about 17 percent protection against H3N2, the most common strain this year, and 50 to 60 percent protection against the H1N1 and influenza B strains. That’s why teams of scientists are working on a universal flu vaccine.
14th Feb 2018 - NBC News

Sanofi looks to cell culture tech for universal flu vaccine

Sanofi Pasteur has licensed SK Chemicals' mammalian cell culture platform for vaccine production in a deal worth up to $155m (€126m). Sanofi is exploring several innovative flu vaccine technologies, including a universal flu vaccine
14th Feb 2018 - BioPharma-Reporter.com

Flu sufferers worried about steep price of Tamiflu

In the Las Vegas area, with more and more cases of flu around the valley, many are worried about the steep cost of Tamiflu. Even with insurance, the drug can still cost around $100, on top the the cost of a doctors visit for a prescription. Dr. Wachs also recommends Relenza, a drug that's inhaled but works the same as Tamiflu, and usually costs less.
14th Feb 2018 - KTNV Las Vegas

Tamiflu Shortage Across Northwest Arkansas

Pharmacies across Northwest Arkansas are experiencing a shortage of Tamiflu. Without insurance, the generic version costs around $115 dollars. The name brand costs around $170. Dr. Graham says there are currently only two manufacturers making the generic liquid and since they can't keep up with demand, local pharmacies can't either.
14th Feb 2018 - Arkansas Matters

Flu warfare may look different next year

New ways of preventing and treating the flu are on the horizon. Among them, Shionogi's experimental drug baloxavir marboxil which reduced influenza viral load to undetectable levels -- killed the virus -- within 24 hours for more than half of the 414 participants in a study. Another weapon in the armature of flu warriors may be pimodivir, an experimental drug discovered by Vertex and in development at Janssen Pharmaceuticals. Pimodivir works by targeting and inhibiting part of the virus replication process. Its mode of action is unlike that of existing antiviral drugs, so its makers say the drug may treat influenza A virus infections that have developed resistance to existing drugs.
14th Feb 2018 - CNN

Austin Regional Clinic studying anti-flu drug in high-risk patients

Austin Regional Clinic has been studying a new drug to fight the flu. The drug from Shionogi is known as baloxavir marboxil, and would be an alternative to Tamiflu. It already has been studied in otherwise healthy people with the flu, and showed promise for its rapid reduction of symptoms. This new phase is testing the anti-viral medication in people who are considered high risk.
14th Feb 2018 - Austin360

Puerto Rican Boy Suffered from Negative Side Effects After Taking Generic Tamiflu

A Puerto Rican mother announced that her child suffered from psychosis after taking antiviral medication: an adverse reaction from Oseltamivir. She attributed hallucinations and delusions in her son to medicine that he was prescribed for the treatment of the influenza virus. An ER doctor explained the child had an adverse reaction to Oseltamivir and that he should discontinue its use immediately.
14th Feb 2018 - eMax Health


Industry News - Seqirus Media Monitoring - 14th Feb 2018

    View this newsletter in full

US teacher dies after opting out of 'costly' flu medicine

A US school teacher has died from flu complications after deciding to forgo anti-viral medication because it "costs too much", her husband told US media. As her symptoms worsened, her husband bought the Tamiflu drug for $116 (£84) a day before she went to hospital. Tamiflu's manufacturers say it can prevent flu, though there is some debate over its effectiveness.
12th Feb 2018 - BBC

Texas teacher dies after opting out of Tamiflu because of costly $116 copay


13th Feb 2018 - USA Today

A Texas teacher died after delaying flu medicine she thought was too expensive. But how much does it cost?


13th Feb 2018 - The Dallas Morning News

CureVac snags new Gates Foundation backing for universal flu, malaria mRNA vaccine work

The Bill & Melinda Gates Foundation is offering two new grants to CureVac to develop vaccines against influenza and malaria. If these new Gates Foundation-funded CureVac vaccines make it to the market, they will be made available at an affordable price in low-income countries. CureVac is also developing a seasonal flu vaccine dubbed CV7302, the flu shot is slated to enter human testing this year. But the Gates grant will be directed toward a different influenza project—a universal flu vaccine, a field that’s quickly getting crowded as researchers seek better ways to effectively tackle the fast-mutating virus.
13th Feb 2018 - FiercePharma

Germany's CureVac wins new vaccine funding from Gates Foundation


13th Feb 2018 - Reuters

CureVac to Pursue Innovative mRNA Vaccines Against Flu and Malaria


13th Feb 2018 - Business Wire

SK Chemicals Inks $150 Million License Deal with Sanofi Pasteur

SK Chemicals has signed an agreement to transfer and license its high efficiency influenza vaccine production technology to Sanofi Pasteur for development of a universal influenza vaccine. SK Chemicals’ cell culture vaccine production technology uses animal cells that enable a quick and efficient production process.
13th Feb 2018 - Business Korea

SK Chemicals seals $155mn vaccine license deal with Sanofi Pasteur


13th Feb 2018 - Pulse News Korea

Could this experimental drug stop the flu in 24 hours?

Shionogi says it has an experimental pill that can kill the flu virus within a single day, according to news reports. In a clinical trial, a single dose of the drug made by the pharmaceutical company eliminated the virus from people's bodies in a median time of 24 hours. The experimental drug worked three times faster than another antiviral drug, Tamiflu, the company said
13th Feb 2018 - CBS News

Japanese Company Claims Experimental Drug Kills Flu Virus in a Single Day


13th Feb 2018 - Science Alert

Drug that cures flu, killing the virus in 24 hours could be available next year


13th Feb 2018 - The Sun

New, fast-acting drug offers novel way to combat flu virus


13th Feb 2018 - Big Country

Can you really beat the flu in a day?


13th Feb 2018 - Blasting News

High cost of Tamiflu stretching pocketbooks of many flu-stricken Louisville-area families

In the U.S., the high cost of Tamiflu is prohibitive for some patients. As the flu bounces from kids to parents in the same home, it's causing families to shell out hundreds of dollars, and reluctance to do so has already cost one Texas woman her life.
13th Feb 2018 - WDRB

Compulsory vaccinations: the 2018 schedule has been published

In France, the new schedule for compulsory and recommended vaccinations has been published for 2018. There are now 11 compulsory vaccinations for newborns. Three new flu vaccines have been authorised in France as well: Influvac Tetra, Vaxigrip Tetra and Fluarix Tetra.
13th Feb 2018 - Top Sante

Tamiflu may have odd side effects, particularly in children, experts say

For the last decade, reports have surfaced that Tamiflu may have “neuropsychiatric side effects” in some patients, particularly children and young adults. Genentech, the company that sells Tamiflu, declined to comment on specific cases in an email. But Bob Purcell, the director of corporate relations for the company, said that the most common side effects associated with the drug are nausea, vomiting, headache and pain. The email also said that "neuropsychiatric events" have been reported while using Tamiflu for patients with influenza, especially children and teens, but they also have been observed in patients with influenza who have not taken the drug.
13th Feb 2018 - USA Today

GlaxoSmithKline tops its peers with $7.16B in 2017 vaccine sales

GlaxoSmithKline turned in enough vaccine sales to lead the industry in 2017, and that was without much contribution from its newly launched shingles vaccine, Shingrix. The company's vaccines business grew sales 6% at constant exchange rates as its larger pharma and consumer healthcare units posted meager growth. The company's vaccines pulled in £5.16 billion ($7.16 billion) for the year, besting Merck's $6.5 billion, Sanofi's $6.25 billion and Pfizer's $6 billion. Flu vaccines jumped 12% to £488 million ($677 million)
13th Feb 2018 - FiercePharma

Tamiflu costs have sufferers trying alternatives, but Tamiflu still best bet

Some people who have the flu are searching for other ways to make themselves feel better because of Tamiflu’s high price tag. Tamiflu can cost you anywhere from $20 to more than $100 depending on your insurance. It can cost you even more if multiple people in your family get sick. Because of its high price tag, Pace said some patients have been reaching for an herbal medicine called Oscillococcinum instead.
12th Feb 2018 - Thv11.com


Industry News - Seqirus Media Monitoring - 13th Feb 2018

    View this newsletter in full

Lupin launches generic Tamiflu in the US

Lupin said it has launched its generic Oseltamivir Phosphate capsules used for treatment of influenza in the U.S. markets. The company said in a BSE filing that it has launched its tablets after receiving the approval from the FDA. The capsules, in the strengths of 30 mg, 45 mg and 75 mg, are generic versions of Roche's Tamiflu capsules in the same strengths, it added
12th Feb 2018 - Hindustan Times

Lupin launches gTamiflu in US


12th Feb 2018 - India Infoline

Lupin launches generic influenza treatment capsules in US


12th Feb 2018 - Live Mint

Lupin gains 3% on launch of generic Tamiflu capsules in US market


12th Feb 2018 - Money Control

SK Chemicals licenses flu vaccine technology to Sanofi Pasteur for US$155 mln

SK Chemicals has signed a US$155 million deal to license cell culture technology to Sanofi Pasteur for development of a universal influenza vaccine. "We're pleased to license this innovative technology today, as it brings us a step forward in the development of a future broadly-protective influenza vaccine, a key priority for Sanofi Pasteur," said David Loew, CEO of Sanofi Pasteur.
12th Feb 2018 - Yonhap News

SK Chemicals inks license deal with Sanofi Pasteur


12th Feb 2018 - The Investor

SK, Sanofi strike $155-mil licensing agreement for vaccine tech


12th Feb 2018 - Korea Biomedical Review

Sanofi and SK Chemicals sign flu vaccine deal


12th Feb 2018 - Market Watch

Is This Experimental Japanese Drug the Secret to Stopping the Flu?

Shionogi says it has an experimental pill that can kill the flu virus within a single day. Japanese drug regulators could approve the drug for use in Japan by early March, the WSJ reported. The drugmaker plans to apply for approval in the U.S. this summer; however, the drug likely wouldn't be available there until next year.
12th Feb 2018 - Live Science

Flu gone in a day? Japanese maker touts new drug


12th Feb 2018 - USA Today

To fill flu vaccine shortage, Hong Kong officials consider doses meant for southern hemisphere

Hong Kong health officials could introduce flu vaccines intended for the southern hemisphere in light of the city’s flu vaccine shortage this year, with private doctors saying they had no more of the immunity-fighting substance for their patients. The possibility arose after the Department of Health already bought 44,000 extra doses of flu vaccines for a government scheme over the past three weeks. However, the shortage in the private medical sector has yet to be relieved. Sanofi Pasteur would deliver 24,000 doses to the city in mid or late March to the private market only.
12th Feb 2018 - South China Morning Post

ND doctors avoiding Tamiflu for flu patients

North Dakota doctors say that only kids under two and adults over 65 should get Tamiflu. Even then, only if the need is truly there. Dr. Vanessa Nelson with Sanford Health says they only prescribe the medicine if the person has other preexisting conditions. Nelson added the flu shot is the best way to prevent getting the flu.
12th Feb 2018 - KFYR-TV

Four-strain vaccine for NZ in 2018

The influenza vaccine used in New Zealand this year will include protection against infection with four strains of the virus. This will be the first time a four-strain vaccine will be funded in New Zealand. PHARMAC will fund two quadrivalent vaccines, supplied by Mylan, from 1 March 2018. Influvac Tetra will be funded for eligible people aged 3 years and over. Fluarix Tetra will be funded for eligible children aged 6 to 35 months.
12th Feb 2018 - New Zealand Doctor Online

Mother-of-two teacher, 38, dies of flu after forgoing $116 medication, telling her husband it "cost too much"

In the U.S., a mother-of-two, 38, died from complications stemming from the flu after deciding the medication to treat the virus was too expensive. In order to treat her ailment, doctors prescribed her Tamiflu. However, she thought it 'cost too much' according to her husband, who eventually bought his wife the medication when her symptoms did not ease up.
12th Feb 2018 - Daily Mail


Industry News - Seqirus Media Monitoring - 12th Feb 2018

    View this newsletter in full

The hunt for a better flu vaccine

In the search for a universal flu vaccine, researchers at the University of California, Los Angeles, have developed a new approach for a vaccine that tested successfully in animals. GlaxoSmithKline is in the early stages of testing another promising approach in people. And the newly launched Universal Influenza Vaccine Initiative is sequencing the blood of individuals who receive the current flu vaccine or are infected with the virus. The group hopes to shed light on the body’s immune response to ultimately develop better treatments.
12th Feb 2018 - The Australian

Collier CVS and Walgreens stores out of flu vaccines, with no plans to restock

In Collier County, in the U.S., employees at CVS and Walgreens confirmed that they are out of the influenza vaccine and do not plan to get more shipments. A Walgreens employee at Vanderbilt and U.S. 41 said the pharmacy’s distributor, Amerisource, is out and not making any more of the influenza vaccinations right now. Flu shots are available at local Publix, Walmart and Costco locations.
10th Feb 2018 - Naples Daily News

Experts insist flu vaccines are "66 per cent effective" amid doubts cast by another Hong Kong celebrity Leon Lai

More Hong Kong doctors and two pharmaceutical giants weighed in on the effectiveness of the current flu vaccine – estimated at 66 per cent by a team of researchers – as a second celebrity cast doubt on Friday. In a Facebook post, Canto-pop singer Leon Lai Ming said “flu vaccines currently available in the market are very likely to be stocks from the previous season”. “They are not flu vaccines targeting the new strain,” he claimed. GlaxoSmithKline said in a statement: “GSK’s quadrivalent influenza vaccines are in single dose pre-filled syringes and do not contain mercuric compounds as preservative, and also do not contain aluminium.” Sanofi Pasteur said that their flu vaccines also did not contain mercuric compounds and aluminium and that the virus strains in their vaccines “totally fit the recommendations of the WHO”.
10th Feb 2018 - South China Morning Post

Generic Tamiflu For Children Is In Short Supply Locally

In Pittsburgh, with influenza still on the rise, it was inevitable that one medication used to reduce the flu’s severity would be in short supply. “We do have some pharmacies in the area that will tell us they are out this week of Tamiflu,” Dr. Patrick Tate, a South Hills pediatrician, said. Tate says it’s not a manufacturing issue but a supply issue, and it’s especially acute for children with the flu.
10th Feb 2018 - CBS Pittsburgh

Spot Shortages Of Antiviral Drugs Seen As Flu Season Drags On

In the U.S., the peak of the flu season could still be several weeks away, federal health officials cautioned Friday. The CDC recommends antiviral medications, such as Tamiflu or oseltamivir, for vulnerable populations hit by flu. There are spot shortages of the antiviral drugs, Dr. Anne Schuchat, acting director of the CDC, said. People seeking them may need to call multiple pharmacies to fill their prescriptions. The CDC has been working with insurers and pharmacies to alleviate those shortages and to make brand-name drugs available at a lower cost when generics aren't available.
10th Feb 2018 - NPR

Historic Flu Season Drives Sales Across the Health-Care Industry

A historically bad flu season has sent Americans to the doctor in droves -- and given a boost to companies across the health-care business. For pharmaceutical giants like GlaxoSmithKline and Sanofi, vaccine sales have surged. Glaxo saw flu-vaccine sales increase 86 percent in the last quarter, while Sanofi sold 21 percent more flu vaccines last quarter. “We delivered a strong performance in flu vaccines,” said Olivier Brandicourt, Sanofi’s CEO. “This was driven by pandemic purchases in the U.S.”
10th Feb 2018 - Bloomberg

Experimental Drug Promises to Kill the Flu Virus in a Day

A Japanese drugmaker says it has developed a pill that can kill the flu virus within a day. But even if the experimental drug lives up to the claim, it likely won’t be available in the U.S. until next year at the earliest. A late-stage trial on Japanese and American flu patients found that for the people who took the Shionogi compound, the median time taken to wipe out the virus was 24 hours. That is much quicker than any other flu drug on the market, including Roche’s Tamiflu, which the trial showed took three times longer to achieve the same result
10th Feb 2018 - Wall Street Journal

The flu - here is the drug that can treat it in a single day


10th Feb 2018 - il Giornale

Sanofi Pasteur posts 8.3% growth despite 2017 vaccine setbacks

Despite numerous challenges that cropped up during the year, Sanofi's vaccines outfit grew revenues 8.3% in 2017 to Euro5.1 billion ($6.25 billion), helping the drug giant as its pharma segment struggled. Sanofi grew flu vaccine sales 8.2% for the year to Euro1.59 billion ($1.95 billion), maintaining its leadership position in that market. Sanofi's $6.25 billion in vaccine sales came short of GSK's 2017 haul of $7.24 billion and Merck's total of $6.5 billion. Pfizer, another large vaccine player, generated $6 billion in vaccine sales for the year.
9th Feb 2018 - FiercePharma


Industry News - Seqirus Media Monitoring - 9th Feb 2018

    View this newsletter in full

New Drugs Are Coming to Fight Nasty Flu Seasons

Almost two decades after Roche’s Tamiflu first reached pharmacy shelves, researchers around the world are pushing ahead with a raft of new options. None will arrive in time to help sufferers this winter, but the most advanced -- developed by Roche and Shionogi -- could be on the market in Japan within months. Baloxavir, the flu drug discovered by Shionogi, received preliminary approval in Japan last week. Co-developer Roche aims to file for regulatory review in the U.S. and Europe later this year. J&J is also pressing ahead with the development of a universal flu vaccine.
8th Feb 2018 - Bloomberg

Flu Relief Is Coming as Successors to Aging Tamiflu Near Market


8th Feb 2018 - Swissinfo.ch

FDA Clears Tests from Alere, Roche, Cepheid in January

Abbott's Alere business, along with Roche, Becton Dickinson, and Danaher's Cepheid each received US Food and Drug Administration clearances for tests in January, according to the FDA's website. Alere, acquired by Abbott in October 2017, received clearances for four tests. They include the Alere i Influenza A & B, which is a rapid, instrument-based isothermal test for the qualitative detection and differentiation of influenza A and influenza B in patients presenting with symptoms of respiratory infection. The firm received clearance for Alere i Strep A, a rapid, instrument-based isothermal test for the qualitative detection of Group A Strep from throat swab specimens, and for Alere i RSV, a rapid, instrument-based isothermal test for the qualitative detection and differentiation of respiratory syncytial virus viral RNA in patients with symptoms of respiratory infection
8th Feb 2018 - 360Dx

Pharmacist says natural drugs can work as well as Tamiflu to fight flu

Channel 2’s Craig Lucie spoke with the pharmacist and owner of Little Five Points Pharmacy who recommended some natural alternatives you can buy to keep the flu at bay. “There are some shortages of Tamiflu, it is available but not quite as readily as a lot of people would like for it to be but you may have to make a couple phone calls,” Katz said. If you’re looking for alternatives, Katz said he has them. But he warns people to contact their doctor before making any major changes.
8th Feb 2018 - WSB Atlanta

Tamiflu and generic version can be hard to find this flu season

Neither version is cheap, particularly for individuals who do not have health insurance coverage. "The only generic shortages we have experienced to date are with the Tamiflu suspension, and only sporadically," said Jennifer Tryon, chief pharmacy officer at Wake Forest Baptist Medical Center. "In these cases where the generic is unavailable, most patients are simply buying the brand due to the severity of the flu this year, and the small window of opportunity when this medication will be effective."
8th Feb 2018 - Winston-Salem Journal

Flu vaccine yields solid growth for Sanofi Pasteur

For Sanofi Pasteur, full year 2017 net sales were Euro 5.101 billion and fourth quarter 2017 net sales were Euro 1.385 billion. Within the Sanofi Pasteur unit, fourth quarter influenza vaccine sales increased 28.4 percent, driven by a strong performance in the U.S., while full year sales were Euro 1.589 billion, up 8.2 percent.
8th Feb 2018 - 69 WFMZ TV News

Parents warn their children are having hallucinations, threatening suicide while taking Tamiflu

As flu cases are on the rise across the U.S., parents are raising concerns after their children started hallucinating after taking Tamiflu. Kristina Sloan said her 8-year-old son, Rylee, even threatened suicide after taking the drug. Sloan said she took Rylee to the hospital for a psychological evaluation and doctors told her that his behavior may be a result of the medicine he was taking: Tamiflu. Roche says they cannot comment on specific cases but "Neuropsychiatric events" have been reported as a side effect of Tamiflu in some patients, especially children and adolescents
8th Feb 2018 - ABC15 Arizona

Eurocine Vaccines Takes Advantage of Yet Another Influenza Season, Launching its Second Clinical Study on Immunose FLU

Eurocine Vaccines initiates a phase I/II clinical study in older adults with its quadrivalent nasal influenza vaccine candidate Immunose FLU. The purpose of the study is to evaluate safety, tolerability, as well as serological and mucosal immune responses against four influenza antigens in older adults aged 50-75. Recruitment of subjects is ongoing and about 300 subjects will be divided into seven treatment groups. The study is planned to be conducted at five locations throughout Sweden during the present influenza season.
8th Feb 2018 - Markets Insider

Glaxo Earnings and Revenues Surpass Estimates in Q4

GlaxoSmithKline reported core earnings of 72 cents per American depositary share in the fourth quarter of 2017, surpassing the Zacks Consensus Estimate of 69 cents. While the Vaccine segment is estimated to register a mid-to-high-single-digit growth through 2020 despite competition for pediatric and flu vaccines, the Consumer Healthcare segment is expected to deliver low-to-mid-single-digit top-line CAGR through 2020.
8th Feb 2018 - Nasdaq


Industry News - Seqirus Media Monitoring - 8th Feb 2018

    View this newsletter in full

Mesa Biotech Receives FDA 510(k) Clearance and CLIA Waiver for Its Accula Point of Care Flu A/Flu B Test

Mesa Biotech, a molecular diagnostic company that has developed an affordable PCR (polymerase chain reaction) testing platform designed specifically for point-of-care infectious disease diagnosis, announced that it has received 510(k) clearance and Clinical Laboratory Improvements Amendments (CLIA) waiver from the U.S. Food and Drug Administration for its Accula Flu A/Flu B test. The company's Flu A/Flu B test cassette will be its first available test in the U.S. market.
8th Feb 2018 - MENAFN.COM

Mesa Biotech Receives FDA 510(k) Clearance and CLIA Waiver for Its Accula Point of Care Flu A/Flu B Test


7th Feb 2018 - Advfn.com

Natco Pharma Q3 PAT up by 11.54%

Natco Pharma has reported a consolidated profit after tax (PAT) of Rs. 217.4 crore for the quarter that ended in December 2017, which is an increase of 11.54% over the year-earlier period’s Rs. 194.9 crore. The consolidated total revenues, however, came down by 16.27% to Rs. 573.6 crore (Rs. 685.1 crore). The decline was predominantly due to large stocking quantities of oseltamivir (generic Tamiflu) during last year’s period
7th Feb 2018 - The Hindu

Strong results but cautious outlook again the story for prudent GSK - The Pharma Letter

Just as it was a year ago, satisfaction with a strong set of financial results was tempered by concern over the upcoming impact of generic competition as UK pharma major GlaxoSmithKline presented its fourth-quarter and full-year 2017 figures. In its vaccine division there was some news. Fluarix/FluLaval: fourth-quarter sales of £111 million, an increase of 76%; full-year sales of £488 million, an increase of 18%.
7th Feb 2018 - The Pharma Letter

No official Tamiflu shortage, yet pharmacies still face low supplies: 4 things to know

In the U.S., drug stores and pharmacy chains nationwide are experiencing spot shortages of Tamiflu and its generic version amid a severe flu season. A spokesman for Genentech, which sells Tamiflu, last week told GHN "we have a robust national supply of Tamiflu." However, increased demand for the flu medication has left pharmacies with low supplies, especially for the children's version of Tamiflu in liquid form.
7th Feb 2018 - Beckers Hospital Review

Price of Tamiflu an obstacle for some flu patients

In the U.S., with a severe flu season, many are keen to treat the illness with Tamiflu. However the cost of the drug can be prohibitive, leading to patients in desperate need unable to afford it. Health insurers vary in the cover they offer so not all patients will be charged the same
7th Feb 2018 - FOX 4 News

Pharmacists struggle to stock Tamiflu in Central Virginia

In Virginia, pharmacists in Metro Richmond struggled to stock the antiviral medication Tamiflu amidst a deadly flu season. Cities like Washington D.C. and Raleigh both reported a shortage of Tamiflu for patients. The antiviral medications Tamiflu (oseltamivir) and Relenza (zanamivir) can reduce the severity of symptoms and the length of illness, but the drug has to be taken within 48 hours of the first appearance of symptoms
7th Feb 2018 - Wtvr.com

Social Seniors Benefit From Multiple Flu Shots

A recent clinical trial reported the superiority of non-egg based flu vaccines over the traditional egg-based quadrivalent inactivated vaccine. A recent study published in the New England Journal of Medicine showed that Seniors given Flublok Quadrivalent were over 40% less likely to develop culture-confirmed influenza. Flublok was reported to contain three times more active ingredients than traditional vaccines and produced significantly higher immune responses to the A strains of influenza, especially H3N2, according to a study.
7th Feb 2018 - Precision Vaccinations


Industry News - Seqirus Media Monitoring - 7th Feb 2018

    View this newsletter in full

Doctors warn people not to take Tamiflu if they don't have the flu

U.S. doctors are warning not to take Tamiflu unless you really have the flu. Tamiflu is one of the most prescribed medications to battle the flu, but doctors at Beaumont Hospital say it's not for everyone. Dr. Chittick says it's not too late to get a flu shot.
6th Feb 2018 - WXYZ

Madison-based company will test ‘revolutionary’ universal flu vaccine this spring

FluGen, a Madison company founded by globally recognized virus researchers, will test their universal influenza vaccine on 100 volunteers this spring. Paul Radspinner, who founded the company in 2007 with Yoshihiro Kawaoka and Gabriele Neumann, said the clinical study will be highly predictive of how the vaccine will work in the real world.
6th Feb 2018 - Badger Herald

Four more Hong Kong primary schools hit by flu as expert warns of post-Lunar New Year outbreak

In Hong Kong, four more primary schools were hit by flu outbreaks, as the city recorded more than 100 deaths during the winter flu peak season so far, and an expert warned of outbreaks of another flu strain after the Lunar New Year. Some private doctors have lamented that there has been a shortage of flu vaccines for weeks owing to the surge in patients. The supply of extra flu vaccines to the city from Sanofi Pasteur, one of the major suppliers, began last Friday.
6th Feb 2018 - South China Morning Post

A biotech out of Oxford is developing a vaccine to fight every type of flu

A biotech spun out of Oxford University is aiming to develop a universal flu vaccine — and phase 2 trials could be completed by the end of next year. Vaccitech says the vaccine does not target surface antibodies. Instead, it works from the center of the virus where there are few components which can change the virus strain. Vaccitech co-founder Adrian Hill hopes any Vaccitech success will make pharmaceutical giants take an interest and get involved.
6th Feb 2018 - CNBC

New Molecular Test to Impact Influenza Pandemic Preparedness

InDevR announced plans to launch a Research Use Only version of their FluChip-8G technology to aid in pandemic preparedness. The new molecular test addresses an unmet need for more detailed information about flu viruses found in human specimens without the data management complexities associated with current sequencing approaches. FluChip-8G offers viral subtype-specific insight with the ease of use of an RT-PCR assay and unmatched simplicity in results interpretation.
6th Feb 2018 - PR Newswire

New molecular test to impact influenza pandemic preparedness


6th Feb 2018 - EurekAlert


Industry News - Seqirus Media Monitoring - 6th Feb 2018

    View this newsletter in full

Number of Austin flu-related death grows; rapid flu test in short supply

Austin doctors saw a distribution shortage of the drug that eases flu symptoms. Now, health workers nationwide are running out of rapid flu tests. This comes as the Austin-Travis County Health Authority released new numbers for flu-related deaths in the area. So far, 28 people have died in Travis County, said Dr. Phil Huang, the authority’s medical director. All of the victims are in their 30s and older. Of those, 19 were 80 years old and older, he said. Those numbers show the severity of this year’s flu season as dozens more have died nationwide.
4th Feb 2018 - Kxan.com

Parents blame Tamiflu for son's suicide, but doctors say it's not likely

12 News reached out to the company that makes the drug, but at this time they told us they cannot comment on the specific case. However, they did add the following: “The most common side effects associated with Tamiflu are nausea, vomiting, headache and pain. Neuropsychiatric events have been reported during administration of Tamiflu in patients with influenza, especially in children and adolescents. These events are also experienced by patients with influenza without Tamiflu administration. Patients should be closely monitored for behavioral changes, and the benefits and risks of continuing treatment with Tamiflu should be carefully evaluated for each patient. We take all such reports very seriously and undertake thorough investigations. Data is provided to regulatory authorities for their independent review and to date there is no data suggesting a link with antiviral treatment."
5th Feb 2018 - Kvoa.com

Pharmacies Experiencing Flu Vaccine, Tamiflu Shortage

The severe flu outbreak gripping Chicago and the rest of the country has doctors urging everyone to get their flu shot. One problem: some local parents are now finding out flu shots are in short supply. Some pharmacies across the region are experiencing a shortage of Tamiflu, a prescription medicine used to treat influenza, as well as test kits and flu vaccines.
5th Feb 2018 - CBS Chicago

PositiveID’s Chief Science Officer Discusses Company’s Detection of Flu Virus on its FireflyDX Prototype in Interview with CEOLIVE.TV

PositiveID, a life sciences company focused on detection and diagnostics, and its ExcitePCR subsidiary announced that Chief Science Officer, Dr. Kimothy Smith, discussed the Company’s successful detection of influenza virus on its FireflyDX real-time polymerase chain reaction breadboard prototype system
5th Feb 2018 - Globe Newswire

Inside Rx Provides Savings on Influenza Medications

Inside Rx announced that it is now offering better pricing on the brand and generic versions of Tamiflu (oseltamivir phosphate) to help Americans affected by what the Centers for Disease Control and Prevention has called the worst recorded influenza season in almost a decade.
5th Feb 2018 - PR Newswire

No major shortage of flu drugs, but pharmacies face supply gap

U.S. drug stores have scrambled to keep up with demand for Tamiflu and its generic brand, and that’s resulting in spot shortages. A spokesman for Genentech, which makes Tamiflu, told GHN last week that “we have a robust national supply of Tamiflu.” Genentech only makes the brand-name medication, but company spokesman Bob Purcell said generic Tamiflu capsules, usually taken by adults, have been widely available since December 2016.
5th Feb 2018 - Northwest Georgia News


Industry News - Seqirus Media Monitoring - 5th Feb 2018

    View this newsletter in full

SAB Capra Awarded $225K from NIH to Broaden Novel Immunotherapy Platform

SAB Capra has been awarded a $225,000 grant from the National Institutes of Health to advance its novel immunotherapy platform targeting pandemic influenza in collaboration with Utah State University. The company will use the funds to continue development and optimization of its transchromosomal (Tc) goats to broaden the Tc animal platform developed by SAB Biotherapeutics, to small ungulate species. The award outlines evaluation of Tc goat produced human antibodies to fight the pandemic influenza (H7N9) with which the goats were vaccinated to generate the natural immune response.
3rd Feb 2018 - Business Wire

Recipe for an advocacy campaign: Just add media and stir things up

CBC's Second Opinion looks into a case study: Sanofi Pasteur's campaign to get governments to purchase an expensive new high-dose flu vaccine for seniors over 65, using the media. In Canada, so far Ontario has announced it will pay for the high-dose vaccine next year. And Manitoba is already covering it for seniors in long-term care facilities.
3rd Feb 2018 - Cbc.ca

Shionogi to offer single-dose drug that combats influenza

Shionogi & Co. is set to market a one-step medication to contain influenza viruses. The new drug as yet to be named in English needs to be ingested only once, compared with Tamiflu, which must be taken twice daily over a five-day period. Shionogi said it has high expectations the drug will combat influenza viruses that are resistant to current medicines on the market. The company also expects that the drug will reduce the risk of contagion.
3rd Feb 2018 - Asahi


Industry News - Seqirus Media Monitoring - 2nd Feb 2018

    View this newsletter in full

Should I take Tamiflu? Concerns raised about drug used to ease flu symptoms

Some areas of the U.S. may have shortages of Tamiflu. The drug manufacturer and the CDC say there is enough supply overall. But, on top of the flu epidemic, some parents are worried about reports of rare, severe side effects from Tamiflu, such as seizures, self-injury and hallucinations among children who have taken the medication. It is not clear if Tamiflu can cause suicidal behavior. Genentech notes that flu itself "hallucinations, delirium and abnormal behavior, in some cases resulting in fatal outcomes".
1st Feb 2018 - Today.com

Flu Season Expected to Benefit GlaxoSmithKline’s 4Q17 Revenues

In 3Q17, GlaxoSmithKline’s influenza vaccine, Fluarix/FluLaval, reported sales close to 343 million pounds, which is year-over-year growth of 6% on a reported basis, but a 2% drop on a constant exchange rate basis.
1st Feb 2018 - Market Realist

Independent Pharmacies Report Underpayments for Flu Drugs

In the U.S., pharmacies are reporting underpayment for flu medication such as Tamiflu, or generic oseltamivir, according to a recent survey administered by the National Community Pharmacists Association. The NCPA stated that this underpayment leaves pharmacies in jeopardy as they continue to dispense the flu medication. The findings showed that 88% of independent pharmacy owners who responded to the survey have experienced numerous cases of reimbursement for Tamiflu or oseltamivir that fell below their acquisition costs.
1st Feb 2018 - Pharmacy Times

Local pharmacy turning generic Tamiflu capsules into liquid during drug shortage

In the U.S., a spike in flu cases has many people searching for Tamiflu. However, it may be hard to find the drug due to a nationwide shortage. At her Pharmacy in Palm Harbor, Nicolette Mathey says the generic liquid form of Tamiflu is back ordered at many pharmacies, which is why they are coming up with an alternative. Pharmacists call it "compounding." They take the powder out of the capsule and put it into a liquid. From there, they sell it at a fraction of the price.
1st Feb 2018 - ABC Action News

Families raise concern about Tamiflu side effects

One Indiana family claims the drug Tamiflu had an extreme side effect that prompted their teenager to kill himself. Genentech, the manufacturer of Tamiflu, declined to comment on Charlie Harp's death but offered this statement: "Neuropsychiatric events have been reported during administration of Tamiflu in patients with influenza, especially in children and adolescents. These events are also experienced by patients with influenza without Tamiflu administration."
1st Feb 2018 - CBS News

Influenza vaccines announced for NZ flu season

The Ministry of Health has announced the funded influenza vaccines for the New Zealand 2018 flu season. The INFLUVAC TETRA vaccine, for adults and children aged three years or older, will be available in early to mid-March 2018, while the FLUARIX TETRA for children aged six to 35 months is likely to be available in mid-April 2018.
1st Feb 2018 - New Zealand Doctor Online

Shot in the dark: Why does the flu vaccine vary and is there an alternative approach?

Vaccitech has already begun its two-year Phase II clinical trial of a universal flu vaccine. More than 2,000 people aged 65 years and older have been registered at six general practices to take part in the trial over the course of the winter season. Those who participate will be randomised to either receive the current vaccine in addition to a placebo jab or the new universal flu shot. It is expected to be completed in 2019. Although this is not the only universal vaccine for influenza out there, it is the first one that has made it into the second phase of clinical study.
1st Feb 2018 - EPM Magazine

Flu Vaccine Shortage Sparks Worries Amid Surge In Cases

In New York, new fears are mounting about the flu, with people rushing to get protected and finding that providers are running out of the vaccine. CBS2 checked with 12 pharmacies in Manhattan and Westchester County. They all said they were out of vaccine and did not know when or if they would get more. Doctors’ offices and pharmacies have also reported they are running out of the antiviral Tamiflu
1st Feb 2018 - CBS New York

Vaxart Announces Its Oral Flu Vaccine Significantly Reduced Rate of Influenza Infection in Phase 2 Challenge Study

Vaxart, which develops oral recombinant vaccines administered by tablet rather than by injection, announced that its investigational H1 influenza oral tablet vaccine demonstrated a statistically significant reduction in the rate of influenza infection compared with placebo, and compared favorably with the market-leading injectable quadrivalent influenza vaccine (QIV) in a Phase 2 challenge trial.
1st Feb 2018 - Business Wire

Big Pharma has the flu

We've long known that our flu vaccines aren't built to last, or to tackle every strain. But pharma companies don't have an incentive to research drugs that will make them less money—not while current vaccines are good enough to make them $3 billion a year. To drive those new vaccines forward, medicine needs a Manhattan Project-style investment, pulling on resources outside the drug industry to force a new generation of vaccines into existence.
1st Feb 2018 - Wired


Industry News - Seqirus Media Monitoring - 1st Feb 2018

    View this newsletter in full

NHS should consider expanding quadrivalent flu jab after fourth strain hits Europe

The NHS and other European healthcare providers should start administering quadrivalent vaccines to better protect against the influenza virus according to GlobalData. In the UK, the NHS recommends that adults receive the trivalent flu vaccine, but data suggests that the fourth strain – sometimes known as ‘Japanese flu’ – is now the most prevalent in Europe. The quadrivalent influenza vaccines that are currently available in the UK are GlaxoSmithKline’s Fluarix Tetra, and Sanofi Pasteur’s quadrivalent influenza vaccine
31st Jan 2018 - Practice Business

NHS should administer quadrivalent flu jabs, according to GlobalData


31st Jan 2018 - EPM Magazine

Analyst urges expanding quadrivalent flu jab after fourth strain hits Europe


31st Jan 2018 - The Pharma Letter

Investing in vaccines


31st Jan 2018 - ITIJ

Family believes Tamiflu led to 16-year-old boy's suicide

An Indiana teen took his own life just days after being diagnosed with the flu and his family believes the medicine Tamiflu had something to do with it. The 16-year-old was diagnosed with the flu last week and was quickly prescribed Tamiflu. Less than 24 hours later, he had killed himself
31st Jan 2018 - KOAT Albuquerque

Family believes Tamiflu led to teen's suicide


31st Jan 2018 - Fox6now.com

Family says Tamiflu may have caused their child's suicide


31st Jan 2018 - ABC13.com

Flu vaccine updated after record deaths in northern winter

The Ministry of Health has announced the funded influenza vaccines for the New Zealand 2018 flu season. The INFLUVAC TETRA vaccine, for adults and children aged three years or older, will be available in early to mid-March 2018, while the FLUARIX TETRA for children aged six to 35 months is likely to be available in mid-April 2018.
31st Jan 2018 - New Zealand Doctor Online

EU proposes joint studies to speed acceptance of new medicine

The European Commission has proposed joint clinical assessments to determine whether approved new drugs and medical devices offer value for money and should be prescribed for patients within national healthcare systems. The joint action, set to take more than three years to enter into force, would replace a largely national approach to health technology assessment that duplicates work, limits transparency and impedes market access for innovation.
31st Jan 2018 - Reuters

Local pharmacies feeling impact of national Tamiflu shortage

With the Iowa Department of Public Health saying the flu has not yet reached its peak, popular influenza medication Tamiflu is in high demand nationwide. Tamiflu is a prescribed drug that helps cut down the symptoms of influenza, but several local pharmacies are running low.
31st Jan 2018 - KIMT 3

Tamiflu causes hallucinations for some but doctors still urge its use

A handful of kids from across the U.S. say they've experienced dangerous hallucinations from Tamiflu. One 6-year-old in Texas reportedly tried jumping out of window after her parents say she was taking Tamiflu. Doctors say hallucinations are indeed a side effect of Tamiflu. But the chance of your child suffering from them is slim. Doctors say less than one percent of kids who take the drug may suffer from negative side effects.
31st Jan 2018 - WQOW TV News 18

NCPA Survey: Tamiflu Underpayments Cited by 88% of Independent Pharmacists

In a Jan. 22-24, 2018 National Community Pharmacists Association survey of independent pharmacy owners, 88 percent of respondents said that in the past 60 days they have experienced multiple incidences of reimbursements for Tamiflu or oseltamivir at rates below the pharmacy's acquisition cost for the medication. "Many PBM contracts require pharmacists to dispense to a patient a medication they have in stock, regardless of whether it is at a loss," said NCPA CEO B. Douglas Hoey, Pharmacist, MBA. "As a result, many community pharmacies are having to eat the loss in order to see that their patients are cared for during one of the worst flu seasons in years. Some respondents are citing losses in excess of $60, even $70 per prescription.
31st Jan 2018 - PR Newswire

Hemispherx's Ampligen Highlighted in Review of Role of TLR3 Agonist Support for “Universal” Flu Immunization

David R. Strayer, MD, chief scientific and medical officer of Hemispherx, said that, “proven technology exists to create and make vaccines to protect against the specific strain of flu virus predicted to be the most prevalent for the coming season. However, the source of seasonal vaccine ineffectiveness rests in the lengthy manufacturing lead time and the potential of the selected strain to mutate, rendering the vaccine less effective or not effective at all. The quest is for a ‘universal’ vaccine that can protect against all major known classes of the virus, a goal which may be achieved only by introducing, through an agent like Ampligen, elements of cross reactivity and cross protection. After decades of research to develop a safe and effective universal flu vaccine, the goal is still unfulfilled. Ampligen may with additional testing be a relatively quick way to provide a safe and effective approach against the debilitating, costly and frequently lethal influenza viruses.”
31st Jan 2018 - GlobeNewswire


Industry News - Seqirus Media Monitoring - 31st Jan 2018

    View this newsletter in full

DNA-based flu test provides more accurate diagnosis, could help prevent spread of the virus

A company in Indianapolis has developed a DNA-based test for the flu which could help reduce the spread of the virus in the future by providing a more accurate diagnosis. Only about half of patients who get a rapid flu test get a correct diagnosis, according to a spokesperson for Roche Diagnostics, which means someone with a false negative could go to work or school and spread the virus.
30th Jan 2018 - WRTV Indianapolis

Woman (26) suing the State after developing sleep disorder from swine flu vaccine

In Ireland, the Minister for Health and Children's "intransigence" over document disclosure is delaying efforts to get on with the first of a number of cases in which a woman claims she developed a sleep disorder as a result of getting the swine flu vaccine, the High Court heard. Ms Bennett's case is among a number of similar cases being brought against the Minister, the HSE, Glaxosmithkline, which produced the vaccine, and the Health Products Regulatory Authority.
30th Jan 2018 - Independent.ie

Why this year's bad flu season is good for the flu vaccine

In the U.S., every year, the CDC says everyone 6 months old and older should get a flu vaccine — but every year, not even half of people do. Many doses of vaccine go unused and get sent back to the makers, such as GSK and Sanofi. This year may be different. While there is still a supply of vaccine across the country, the headlines about the epidemic mean more people are asking for vaccines.
30th Jan 2018 - NBCNews.com

As flu numbers rise, expect temporary, local Tamiflu shortages

In Florida, the state Department of Health in Palm Beach County, confirmed the existence of localized shortages of Tamiflu. An agency spokesman said the supply shortfalls were temporary, and there is plenty of the antivirals available.
30th Jan 2018 - WPEC

Pharmacies selling out of Tamiflu, drug used to treat flu virus


30th Jan 2018 - WJHG-TV

Oseltamivir prescriptions up 640% from last year

An analysis from GoodRx reveals that prescriptions for oseltamivir (Tamiflu—Roche) saw a more than six-fold increase this influenza season compared with the last one. Researchers examined a large sample of U.S. pharmacy fills, finding that prescriptions for oseltamivir increased by 640% from the same time last year. Fills for oseltamivir peaked in February 2017, indicating that prescriptions could keep increasing during the next few weeks
30th Jan 2018 - Pharmacist.com

No shortage of Tamiflu locally

The Pharmacists Association of Western New York says the pharmacies they've spoken with have plenty of Tamiflu and the generic version of the medication. That's not the case in places such as Jacksonville, Florida and Springfield, Massachusetts, where news reports have said Tamiflu is in short supply.
30th Jan 2018 - WGRZ-TV

Does Tamiflu work and should it be used at all?

With influenza at widespread levels across the country, fears about adverse psychiatric side effects of the prescription drug Tamiflu have also gone viral on social media. Pharmacist Brian McCullough specializes in infectious diseases and says Tamiflu is an effective treatment to slow the spread of flu.
30th Jan 2018 - WRCB-TV

Can we make a better flu vaccine? This San Diego biotech says yes

A San Diego biotech is working on a new way to produce seasonal flu vaccine that could speed up the process and provide better protection against infection. Vaccine manufacturing time can ultimately be reduced from the current six to nine months to several weeks, said Oliver Fetzer, CEO of Synthetic Genomics. The first step in vaccine manufacture, transmission and production of “seed” flu viruses, has been reduced from 35 days to less than 5 days in a proof of concept study. The digitized biological information can be quickly adjusted to make vaccines for new or developing strains. A prototype machine that turns computer code into biological material could eventually make the vaccine directly from the digitized information.
30th Jan 2018 - The San Diego Union-Tribune


Industry News - Seqirus Media Monitoring - 30th Jan 2018

    View this newsletter in full

It is time for the UK to adopt the US flu vaccine?

Flu season now is in full swing, with four strains in circulation this year. The UK’s NHS however recommends that adults receive a jab that only protects against three strains. Data suggests the fourth strain — sometimes known as Japanese flu — is now the most prevalent in Europe. It is time for the NHS and European services to start administering vaccines to provide better protection against the virus.
29th Jan 2018 - Verdict

PositiveID Corporation Publishes White Paper and Data on its Successful Detection of Influenza Virus

PositiveID Corporation has published a white paper and data on its successful detection of the influenza virus on its FireflyDX polymerase chain reaction breadboard prototype pathogen detection system. The FireflyDX family of products is designed to provide accurate, rapid pathogen detection at the point-of-care/point-of-need using real-time PCR in less than 30 minutes, with minimally trained personnel and at a lower cost than existing systems
29th Jan 2018 - Globe Newswire

Tamiflu supply short with flu cases spiking at emergency rooms

In the Wellington area of Florida, Tamiflu supplies are running low at pharmacies as the flu season continues to grip the U.S. "Just recently, I have heard that there’s a shortage at some of the pharmacies for Tamiflu because of the increased numbers of influenza," said Dr. Christopher Muenchen of Wellingon Regional Medical Center.
29th Jan 2018 - WPTV.com

Google venture arm backs UK universal flu vaccine company

Vaccitech, a private British company developing a vaccine that could be the first in the world to fight all types of flu has raised 20 million pounds ($27 million) from investors including GV, the venture capital arm of Google parent Alphabet. Reuters corrects this 2 week-old story and removes a reference to the first time that a universal flu vaccine has progressed beyond Phase I
29th Jan 2018 - Reuters

Surge in flu cases causing Tamiflu shortages around western Massachusetts

In Massachusetts, the Big Y Pharmacy in Springfield told 22News the generic version of the drug Tamiflu is in short supply. Pharmacists are having to compound the drug from ingredients due to the surge in flu cases. The brand name drug Tamiflu is dealing with an issue of supply and demand.
28th Jan 2018 - wwlp.com


Industry News - Seqirus Media Monitoring - 29th Jan 2018

    View this newsletter in full

Top medical supplier says doctors are begging for flu tests after FDA banned the two top brands

Physicians across the US are outraged that the FDA has banned the two top rapid flu tests at the peak of this deadly season leaving them 'begging' distributors for supplies. The largest medical suppliers in the US are completely out of the rapid flu test kits that detect the virus within 10 minutes after the FDA pulled the top brands from the market on January 12 due to false positives
27th Jan 2018 - Daily Mail

New York doctors desperate for high-speed flu tests


26th Jan 2018 - New York Post

FluGen to launch new test of its universal flu vaccine in May

FluGen is gearing up for a new round of studies on human volunteers this spring, to be held in Europe. Of 100 people, half will get FluGen’s nasal spray vaccine, RedeeFlu; the other half will get a placebo of saline solution sprayed into the nose. Then all 100 will get a nasal dose of live flu virus. “They’ll be in ‘flu camp’ for 11 days in an isolation facility in Belgium. We will measure how well our vaccine protected against the flu challenge, based on infection and symptoms, and we’ll look at a broad range of safety indicators, as well,” CEO Paul Radspinner said.
27th Jan 2018 - Madison.com

Scientists are now rushing to develop a universal flu vaccine

Producing and distributing current flu vaccines is a relatively small market for a only a few major pharmaceutical companies, and the industry as a whole is not yet willing to invest heavily in universal vaccine R&D. "When we look at the vaccine area, this is not an area of high profits," Michael Osterholm, an epidemiologist and head of the Center for Infectious Disease Research and Policy at the University of Minnesota, told PBS NewsHour last fall. "The industry has no appetite for that right now, unless there's assurances of support throughout the process and there's a market at the end of it." While optimistic that a universal vaccine can be developed, Osterholm has warned against the strong probability of a flu pandemic on the horizon if private and public entities don't dedicate energy and resources toward ongoing efforts.
26th Jan 2018 - CNBC

NorCal girl suffers hallucinations after taking Tamiflu, mother says

A San Francisco Bay Area mother is warning parents about the alleged side effects of Tamiflu after she said her daughter suffered hallucinations. Nora said her 15-year-old daughter started hallucinating shortly after taking the medication given to flu patients. This is not the first time this particular side effect was reported from taking Tamiflu. Parents in Texas said their 6-year-old daughter had hallucinations and possibly tried to harm herself after taking Tamiflu.
26th Jan 2018 - KABC-TV


Industry News - Seqirus Media Monitoring - 26th Jan 2018

    View this newsletter in full

Some pharmacies run out of Tamiflu as flu cases increase

Some Central Florida parents and patients say they are struggling to find Tamiflu, as flu diagnoses increase. Dr. Tim Hendrix, a physician at a Central Florida Centra Care, said these local shortages are happening because of an increase in flu cases within the last week.
25th Jan 2018 - WESH Orlando

Flu spike leads to Jacksonville-area Tamiflu shortage


25th Jan 2018 - Action News Jax.com

Tamiflu shortage affects Central Florida


25th Jan 2018 - WFTV Orlando


Industry News - Seqirus Media Monitoring - 25th Jan 2018

    View this newsletter in full

Another Claim: Tamiflu Caused Child To Twitch, Hallucinate, Bang Head

Another North Texas family is speaking out about what they believe are side effects from Tamiflu, saying their nearly 2-year-old son was twitching, hallucinating and slamming his head in pain after taking Tamiflu this month. The odd reactions only stopped they said, when they stopped giving him prescribed doses of the drug
23rd Jan 2018 - CBS DFW

Tamiflu causes another child to hallucinate: Two-year-old slapped his mother and twitched uncontrollably


24th Jan 2018 - Daily Mail

Parents: Tamiflu caused child to twitch, hallucinate, bang head


24th Jan 2018 - KHOU

Inovio's Influenza Vaccine Shows Potential, Shares Rally

Inovio's shares increased 22.6% after it announced that its universal influenza vaccine has demonstrated protective antibody responses against all major strains of H1N1 influenza viruses from the last 100 years. Although the candidate is in pre-clinical study and response were reported against a particular virus, investors were encouraged by the universal nature of response.
23rd Jan 2018 - Nasdaq

As flu epidemic spreads, popular medication Tamiflu gets hard to find at metro pharmacies

In the U.S., the flu is still running rampant around the Kansas City metro area. Making matters worse, Tamiflu is getting harder to find. The University of Kansas Health said its hospital pharmacy has plenty of Tamiflu in stock, but the popular medicine is running in short supply at many area pharmacies. Most national chains said they have plenty of the pills, but at times, spikes in demand for the oral suspension can wipe out supply.
24th Jan 2018 - Fox4kc.com

No deal "uniquely damaging" to health sector, warns UK minister

Failing to reach a Brexit deal for the medical sector would be “uniquely damaging” to both the UK and EU, UK Health Secretary Jeremy Hunt told MPs. Appearing at a hearing of the UK Parliament’s Health committee, Hunt sounded confident that a deal would be struck. Questioned by MPs, Hunt said that the UK would maintain “as close as possible relationship with the EU, meaning a continuation of the arrangements [the UK] currently has, but with a different legal structure underpinning them.”
24th Jan 2018 - Euractiv


Industry News - Seqirus Media Monitoring - 24th Jan 2018

    View this newsletter in full

Inovio Pharmaceuticals’ synthetic flu vaccine could be an all-in-one solution

Inovio Pharmaceuticals announced that its synthetic flu vaccine, which uses synthetic DNA antigens, has generated “broad protective antibody responses” against all major deadly strains of H1 influenza viruses from the last 100 years -- including the virus that caused Spanish Flu in 1918 and killed 500 million people worldwide. It also proved effective in multiple animal tests including mice, guinea pigs and non-human primates, the company said
23rd Jan 2018 - Proactive Investors

Here's Why Inovio Pharmaceuticals Rose as Much as 26.7% Today


23rd Jan 2018 - Motley Fool

A universal flu vaccine


23rd Jan 2018 - International Travel & Health Insurance Journal (ITIJ)

Inovio's universal flu vaccine data shows protective responses against all major, lethal H1N1 viruses


23rd Jan 2018 - Pharmabiz.com

Doctors' offices, pharmacies begin to receive back-ordered Tamiflu shipments

In the U.S., a nationwide backorder of the antiviral flu medication Tamiflu concerned both patients and doctors, but there is some good news from health officials. Doctors and pharmacies were told not to expect shipments of the medication until the end of January, but days early, some pharmacies and hospitals have restocked their shelves.
23rd Jan 2018 - KSBY San Luis Obispo News

Local pharmacies stocking up on Tamiflu as flu reason reaches peak

Pharmacies across the Carolinas are stocking up on flu medication as the season reaches its peak. According to the North Carolina Department of Health and Human Services, at least 42 people have died from complications related to the flu in the Tar Heel State since October 1, 2017.
23rd Jan 2018 - WCNC

Can Flu Medicine Affect Ovulation? Here's What You Need To Know

There is currently a dearth of any published studies that examine the effects of drugs like Tamiflu on TTC or the menstrual cycle. However, based on years of longitudinal research and historical data, it can be inferred that the prolonged illness that these antivirals seek to combat is a greater threat to a woman's fertility than the drugs themselves, according to a 2012 Danish Study that examined years of pandemic flu and the birth and fecundity rates of populations impacted by the flu. The current CDC recommendation for women who are pregnant or TTC is that they receive antiviral medication as soon as possible to begin treatment for the potentially deadly flu virus.
23rd Jan 2018 - Romper

Quebec: plant-based vaccine could tame the flu virus

Quebec company Medicago already produces vaccines, including a quadrivalent flu vaccine. Now, it is testing on 10,000 people around the world a plant-based flu vaccine it hopes will prove more effective than existing products, and could be on the shelves by 2020. The plants produce more doses of vaccine than eggs do, and do it faster.
22nd Jan 2018 - Journal de Montreal


Industry News - Seqirus Media Monitoring - 23rd Jan 2018

    View this newsletter in full

Inovio Pharmaceuticals' Published Universal Flu Vaccine Data Demonstrates Protective Responses Against All Major, Lethal H1N1 Influenza Viruses From the Last 100 Years in Animal Models

Inovio announced that its synthetic vaccine approach using a collection of synthetic DNA antigens generated broad protective antibody responses against all major deadly strains of H1 influenza viruses from the last 100 years including the virus that caused “Spanish Flu” in 1918 in multiple animal models including mice, guinea pigs and non-human primates.
22nd Jan 2018 - Markets Insider

Inovio Pharmaceuticals' Published Universal Flu Vaccine Data Demonstrates Protective Responses Against All Major, Lethal H1N1 Influenza Viruses From the Last 100 Years in Animal Models


22nd Jan 2018 - Globe Newswire.com

Inovio's investigational flu vaccine shows broad protection in preclinical studies; shares up 4%


22nd Jan 2018 - Seeking Alpha

Novavax's stock is edging higher today on speculation that its experimental flu vaccine might trigger a buyout

Novavax is on track to release new data from NanoFlu's early to mid-stage clinical program sometime in February. Although these data probably won't lead to an accelerated approval, it's no secret that both Sanofi and Glaxo are actively hunting for new sources of revenue to boost their long-term outlooks. In other words, a positive data readout for NanoFlu might transform Novavax into a hot buyout target next month. However, Novavax has yet to prove that it's even capable of producing a safe and efficacious vaccine for any indication.
22nd Jan 2018 - Motley Fool

Treat suspected flu with antivirals, hospital doctors are told

Patients admitted to acute hospitals in England with suspected flu should be treated with antiviral drugs as quickly as possible, NHS trusts have been told in a letter from the national medical director, Bruce Keogh. The value of antivirals such as oseltamivir (Tamiflu) in treating flu is hotly contested—a fact Keogh acknowledges in the letter, noting “divergent views” on how useful they are. However, given the current strain on services, he writes, “The question arises as to whether antiviral medication could reduce hospital stay, freeing up beds and relieving some of the pressure.”
22nd Jan 2018 - British Medical Journal

Tamiflu prescriptions up 640% from last year: 3 things to know

Prescriptions for Tamiflu in the U.S. have seen a more than six-fold increase this flu season compared to last year, according to an analysis from GoodRx. Researchers examined a large sample of U.S. pharmacy fills and found prescriptions for Tamiflu are up 640 percent from the same time last year. Physicians and pharmacists nationwide have struggled to acquire Tamiflu for patients amid increased demand for the drug, although the FDA has not yet confirmed an official shortage.
22nd Jan 2018 - Beckers Hospital Review

Google invests in Oxford"s "universal" flu jab

Google has invested £20 million in Oxford University spinout company Vaccitech, which is working to develop a new “universal” flu vaccine. Vaccitech’s new vaccine is set to be used as a complement to traditional vaccines, though not as a replacement. It is expected that the T-cells stimulated by the new vaccine, and the antigens stimulated by standard vaccines, would work together to provide comprehensive protection against the flu.
21st Jan 2018 - Cherwell Online


Industry News - Seqirus Media Monitoring - 22nd Jan 2018

    View this newsletter in full

Mounting Tamiflu terrors: Girl, 11 saw "the portal to hell" and had to be hospitalized for three months after she was treated for the flu

In the U.S., an 11-year-old girl from became convinced that she was hearing the devil's voice with insects crawling all over her body after she took Tamiflu last year. Lindsay Ellis's father, Charles, decided to go public with her harrowing story after reports emerged that another girl tried to jump out of a window under the influence of the flu treatment. Already this year, 30 children have died of the flu in the U.S., and parents are turning to Tamiflu
19th Jan 2018 - Daily Mail

Does Tamiflu Cause Hallucinations? 11-Year-Old Saw "Portal To Hell" After Taking It


20th Jan 2018 - Tech Times

Scientists Seek Universal Flu Shot 100 Years After Deadly Pandemic

Labs around the U.S. are hunting for a super flu shot that could eliminate the annual vaccination in favor of one every five years or 10 years, or maybe, eventually, a childhood immunization that could last for life. In New York, pioneering flu microbiologist Peter Palese uses “chimeric” viruses to redirect the immune system. GlaxoSmithKline and the Gates Foundation are funding initial safety tests.
19th Jan 2018 - Time


Industry News - Seqirus Media Monitoring - 19th Jan 2018

    View this newsletter in full

Science takes its best shot at fighting flu

There's no way to predict what strain of the shape-shifting flu virus could trigger another pandemic or, given modern medical tools, how bad it might be. But researchers hope they're finally closing in on stronger flu shots, ways to boost much-needed protection against ordinary winter influenza and guard against future pandemics at the same time. Labs around the country are hunting for a super-shot that could eliminate the annual fall vaccination in favor of one every five years or 10 years, or maybe, eventually, a childhood immunization that could last for life.
18th Jan 2018 - Times Colonist

Scientists are taking a new shot at a universal vaccine to prevent the regular winter flu and the next super-flu, too


18th Jan 2018 - Pittsburgh Post-Gazette

Firm advances human trials of revolutionary vaccine

No versatile influenza vaccine is on the market, but one of the most promising is being developed by FluGen, a spinoff from the University of Wisconsin–Madison. The startup has announced a plan to evaluate its innovative influenza vaccine in a trial of 100 people later this spring. For almost a decade, the company has been exploring a genetically altered virus that can reproduce only once in the human body. "Our vaccine contains a live virus that infects you but cannot make you sick," says CEO Paul Radspinner
18th Jan 2018 - medicalxpress.com

Researchers closing in on universal flu vaccine


18th Jan 2018 - WKOW

PHC takes steps to increase access to Tamiflu for Medi-Cal recipients

In California, due to the severity of the current flu season, Partnership HealthPlan of California is lifting its prior authorization requirements on prescriptions for Tamiflu and its generic versions in an effort to increase access to the antiviral drug for PHC’s Medi-Cal members. “California is experiencing one of the worst flu seasons in years,” Dr. Robert Moore, PHC’s Chief Medical Officer said. “In light of this urgent situation and because we want our members to have all the care they need to fight the flu, we are streamlining access to generic oseltamivir and brand name Tamiflu.”
18th Jan 2018 - Lake County News


Industry News - Seqirus Media Monitoring - 18th Jan 2018

    View this newsletter in full

NHS bosses urged GPs to purchase a cheaper flu jab that doesn't protect against deadly "Japanese flu", leaked files reveal

In the UK, health chiefs ordered GPs to order cheap flu vaccines which are ineffective against the strain of flu causing most havoc in the UK, leaked files show. NHS England asked doctors to purchase the trivalent jab. In guidance sent to local bosses, they warned that buying the quadrivalent jab would add 'significant cost pressures' amid concerns over funding
17th Jan 2018 - Daily Mail

NHS England vaccine advice 'increased risk of flu admissions'


17th Jan 2018 - Health Service Journal

Century after pandemic, science takes its best shot at flu

There's no way to predict what strain of the shape-shifting flu virus could trigger another pandemic or, given modern medical tools, how bad it might be. But researchers hope they're finally closing in on stronger flu shots, ways to boost much-needed protection against ordinary winter influenza and guard against future pandemics at the same time. Labs around the country are hunting for a super-shot that could eliminate the annual fall vaccination in favor of one every five years or 10 years, or maybe, eventually, a childhood immunization that could last for life.
17th Jan 2018 - ABC News

Century after pandemic, science takes its best shot at flu


17th Jan 2018 - Associated Press

What Makes This Flu Season So Bad

There are four different types of influenza virus, three of which infect people. Of those three, influenza A and B are the most common and each of those subsets develops different strains. H1N1 and H3N2, for example, are strains of influenza A, and they adapt by constantly changing their surface proteins. "The holy grail is to target a piece of the virus by antibody or t cell," says Tom Evans, the CEO of Vaccitech which is working on a universal vaccine they hope can be used to treat all strains of influenza A.
17th Jan 2018 - National Geographic

This Google-Backed Biotech Is Trying to Create a Universal Flu Vaccine

Google parent Alphabet’s venture arm GV is among the companies backing Vaccitech, which has set out to achieve one of medicine’s most-sought milestones: developing a universal flu vaccine. The universal vaccine is moving into mid-stage trials, which means successful studies could lead to a commercial launch by the mid-2020s, according to Vaccitech CEO Tom Evans.
17th Jan 2018 - Fortune

Curevac to launch phase I trial for RNActive prophylactic vaccine targeting seasonal influenza

CureVac has outlined key 2018 milestones in conjunction with its presentation at the 36th Annual J.P. Morgan Healthcare Conference. Among these is the launch of phase I trial for RNActive prophylactic vaccine targeting seasonal influenza
10th Jan 2018 - Curevac.com


Industry News - Seqirus Media Monitoring - 17th Jan 2018

    View this newsletter in full

Medicines regulator sets out no-deal Brexit plans to calm pharma industry fears

While the UK will work to secure a transition period based on current EU rules, the Medicines and Healthcare products Regulatory Agency said in the event of no deal and a split with the European Medicines Agency, it would be "pragmatic" in setting new UK regulatory requirements. Christiane Abouzeid, the head of regulatory affairs at the UK BioIndustry Association, said the update was welcome and "provides public clarity" on the UK’s current regulatory relationship with the European medicines network of member states and the EMA, as well as its planned approach to a potential no deal scenario.
16th Jan 2018 - City A.M.

UK drugs regulator plays down Brexit disruption threat


16th Jan 2018 - Reuters

Tamiflu Side Effects: 6-Year-Old Tried To Jump Out The Window, And It"s Not The Only Reported Case

In Texas, a six-year-old girl with influenza experienced strong side effects after taking Tamiflu. The girl started to hallucinate and ran away from school, then tried to jump out of a window. This is not the first time that people, especially children, have experienced severe side effects from Tamiflu. There have been a number of other cases in which kids and teenagers had nightmares, hallucinated, jumped out of windows, or showed other signs of abnormal behavior
16th Jan 2018 - Tech Times

Parents say 6-year-old hallucinated, tried to jump from window after taking Tamiflu


16th Jan 2018 - Fox6Now.com

6-year-old Texas girl suffered rare side effects after taking Tamiflu


16th Jan 2018 - WTVD-TV

Parents say 6-year-old hallucinated, tried to jump from window after taking Tamiflu


15th Jan 2018 - Kfor.com

Several Upstate pharmacies short on generic Tamiflu

In North Carolina, this flu season, Tamiflu is in high demand. But if you want to save money with the generic version of Tamiflu, that may be hard to come by. At many pharmacies across the Upstate, the generic Oseltamivir is on back order so it’s not available.
16th Jan 2018 - FOX Carolina

Tamiflu in high demand as Triad sees more flu activity


15th Jan 2018 - MyFox8.com

UK biotech Vaccitech raises £20m for universal flu shot

Vaccitech has attracted £20m in first-round financing from investors - including the GV venture capital arm of Google parent Alphabet - towards its universal flu vaccine programme. Vaccitech has started recruiting volunteers for a phase IIb trial of its candidate that will continue through the 2018/2019 flu season. BiondVax also has a two-dose candidate called M-001 in clinical development and said in December that it intends to start a phase III trial in the third quarter of this year.
16th Jan 2018 - PMLiVE

Google invests in UK vaccine pioneer Vaccitech


16th Jan 2018 - Pharma Phorum

Young Oxford Biotech Raises €22.5M to Develop a Universal Flu Vaccine


16th Jan 2018 - Labiotech.eu

The World's First Universal Flu Vaccine Is Already Undergoing Clinical Trials


16th Jan 2018 - Science Alert

Deadly flu outbreak hits Kentucky and Indiana

In the U.S., dozens of flu-related deaths have been reported in Kentucky and Indiana, and doctors are noticing the drastic spike in flu cases over the past two or three weeks. Many local pharmacies are reporting a limited supply of Tamiflu. Tamiflu’s parent company, Genentech, said there is not a shortage, but some places could be running out as cases spike quickly and they wait for new shipments
16th Jan 2018 - WDRB

What is the future for the vaccine industry?

Vaccine producers often point to urgent need to find an antidote to prevent a series epidemic spreading as a reason to slow research and production on other fronts, allowing for a hiatus, in some cases, of planned trials of new products coming onto the market to treat serious diseases. The writer believes drug companies are coming under a variety of pressures to respond and he questions the model
16th Jan 2018 - Quotidiano Sanita

Doctor eases concern over Tamiflu, after child experiences serious side effect

In the U.S., as the most severe flu season in years rages on there is new concern about possible side effects of Tamiflu, after a report of a child attempting to harm herself while on the medication. Dr. Frank Esper with the Cleveland Clinic says reactions like this are rare. However, psychiatric side effects of Tamiflu have been seen before in patients primarily of Asian heritage for reasons unknown
15th Jan 2018 - Fox8.com


Industry News - Seqirus Media Monitoring - 16th Jan 2018

    View this newsletter in full

6-year-old Texas girl suffered rare side effects after taking Tamiflu

A 6-year-old Texas girl had nervous system problems after taking Tamiflu. Her parents say she had hallucinations and possibly tried to harm herself after using the antiviral. Experts say those are some of the rare side effects of the drug. "I don't think the 16 hours of symptom relief from the flu is worth the possible side effects that we went through," her father said. His message for parents is to make sure you do your homework before taking Tamiflu
15th Jan 2018 - KTRK-TV

Hallucinations After Taking Tamiflu: How Much Is Real Versus Not Real?


15th Jan 2018 - Forbes

Family: 6-year-old hallucinated, tried to hurt herself after taking flu meds


15th Jan 2018 - KCCI Des Moines

6-year-old girl hallucinates, tries to jump out window after taking Tamiflu


15th Jan 2018 - New York Daiily News

Google-funded trials of a universal flu jab have already begun

Vaccitech is currently trialling a universal flu vaccine that aims to immunise people against all strains of one of the most major forms of the influenza virus, type A, in a single shot. Depending on the results of the trial, Evans and his team hope to eventually partner with a company that manufacturers conventional flu vaccines, and combine their products to create a more effective vaccine
15th Jan 2018 - Wired.co.uk

Universal Flu Vaccine Company Gets $27.1 Million in Funding


15th Jan 2018 - MD Magazine

Google is investing in a UK start-up that wants to cure the flu and prostate cancer


15th Jan 2018 - Evening Standard

UK startup developing flu jab attracts £20m investment


15th Jan 2018 - Pharma Times

Oxford University spinout Vaccitech gets £20m from backers including GV


15th Jan 2018 - UK Tech News

Alphabet's venture arm GV and Sequoia invest in UK biotech firm Vaccitech, an Oxford University spin out


14th Jan 2018 - City A.M.

Aviragen Vaxart merger to create $264m tablet vaccine firm

Aviragen Therapeutics has called on shareholders to back its proposed merger with oral vaccine delivery firm Vaxart. Vaxart's lead candidate is an oral solid dosage form of an influenza vaccine being examined in Phase II trials that has been found comparable to injectable vaccines. Aviragen is the maker of Relenza
15th Jan 2018 - In-PharmaTechnologist.com

Glaxo's Influenza Vaccine Gets FDA Nod for Label Expansion

GlaxoSmithKline received approval from the FDA’s Center for Biologics Evaluation and Research for the label expansion of FluarixQuadrivalent. The vaccine has been approved for infants six months or older. The vaccine, at present, is approved for active immunization against influenza A subtype and type B viruses, in persons three years of age and older
15th Jan 2018 - Nasdaq

Flu vaccine 10% effective

Philip Lee Miller, MD, Founder, CEO California Age Management Institute, writes that he doesn't recommend flu vaccines to his patients as he believes them to be ineffective. He prefers antiviral treatment, writing: "the most effective is oseltamivir (Tamiflu). A second choice is zanamivir (Relenza)" and concludes by giving his own "more novel and less toxic approach that has been effective across a wide variety of viral and flu syndromes"
15th Jan 2018 - HuffPost

Flu-pocalypse? Why scientists are scrambling to make a 'universal influenza vaccine'

Sanofi, who is one of the largest makers of flu vaccines, told FOX Business that it has been “continuously focused on improving influenza vaccines” over the years. “This is evident in our introduction of Fluzone High-Dose Influenza vaccine, the first and only flu vaccine shown to have superior efficacy against influenza compared to Fluzone vaccine in adults 65 and older, and our recent acquisition of Protein Sciences, which has developed a recombinant DNA technology system for the production of recombinant proteins. The company additionally has ongoing efforts to develop a broadly protective influenza vaccine that would be effective despite natural mutation (or genetic changes) of flu strains over time,” the company said.
15th Jan 2018 - Fox Business

Vaxigrip Tetra to be available to give to children over 6 months old

The Standing Committee on Vaccination (STIKO) updated its recommendation on influenza vaccine in December and called for the use of tetra- instead of the previously recommended trivalent vaccine. Therefore, Vaxigrip Tetra (Sanofi Pasteur) can be used immediately from the age of six months.
5th Jan 2018 - Apotheke Adhoc


Industry News - Seqirus Media Monitoring - 15th Jan 2018

    View this newsletter in full

Google backs bid by Oxford biotech Vaccitech to beat flu

Google has invested millions of pounds in an Oxford University spinout that is developing a universal flu vaccine. The Silicon Valley giant is among a clutch of investors ploughing a total of £20m into Vaccitech, a company designing a vaccine to protect against most strains of flu. If successful, Vaccitech’s product could end vaccine shortages and ineffective flu jabs, and prevent a repeat of the Spanish Flu pandemic
14th Jan 2018 - The Times

Alphabet's venture arm GV and Sequoia invest in UK biotech firm Vaccitech, an Oxford University spin out developing a flu vaccine


14th Jan 2018 - City AM

Flu Vaccine Fluarix Quadrivalent Approved For Children 6 Months+

In the U.S., the FDA's Center for Biologics Evaluation and Research expanded the indication for Fluarix Quadrivalent for use in people 6 months and older. During clinical trials with children aged 6 through 35 months, the most common adverse reactions from Fluarix were pain and redness.
13th Jan 2018 - Precision Vaccinations

FDA Expands Indication for Fluarix Quadrivalent Flu Vaccine


12th Jan 2018 - Medscape

GSK receives FDA approval for expanded indication for Fluarix Quadrivalent


12th Jan 2018 - PR Newswire

FDA Approves Expanded Indication for Quadrivalent Influenza Vaccine


12th Jan 2018 - Contagion Live.com

GSK's Influenza Vaccine Receives FDA Approval for Expanded Indication


12th Jan 2018 - MD Magazine

GSK receives FDA approval for expanded indication for Fluarix


12th Jan 2018 - Markets Insider

GSK receives FDA approval for expanded indication for Fluarix Quadrivalent for persons 6 months and older


11th Jan 2018 - GlaxoSmithKline

Young Girl Severely Hallucinates After Taking Tamiflu, Family Says

A six-year-old girl from Allen, Texas, reportedly suffered extreme side effects after taking Tamiflu, a preventive flu medication, her family said. The family has no intention of utilizing the drug again after Tamiflu allegedly caused their young child to experience hallucinations and even attempt to inflict harm on herself
13th Jan 2018 - International Business Times

Dad Warns Other Parents After Daughter Experienced Bizarre Side Effect After Taking Tamiflu


13th Jan 2018 - 963kklz.com

Girl, 6, Suffers Frightening Side Effects After Taking Tamiflu


12th Jan 2018 - CBS DFW

GPs are told to give patients Tamiflu pills amid worsening flu outbreak as Oxford professor says the drug is no better than paracetamol

In the UK, Tamiflu and other antivirals should be given to the most vulnerable people with symptoms of flu, according to a ‘health alert’ sent to all GPs. But officials also suggested the drugs be used as a preventative measure for elderly people, even if they have received the flu vaccine – which is feared not to work for over-65s this year. A leading scientist condemned the decision, saying there is no evidence antivirals are effective.
12th Jan 2018 - Daily Mail


Industry News - Seqirus Media Monitoring - 12th Jan 2018

    View this newsletter in full

FDA approves Lupin's Tamiflu generic

The Food and Drug Administration has approved a generic of Roche’s Tamiflu (oseltamivir phosphate) capsules from Lupin. The company’s generic will be available in 30-, 45- and 75-mg dosage strengths.
10th Jan 2018 - Drug Store News

Lupin gets USFDA nod for generic Tamiflu capsules


11th Jan 2018 - Myiris.com

Lupin gets USFDA approval for generic Tamiflu capsules


11th Jan 2018 - Elets

Flu outbreak prompts search for medicine

In Indiana, some pharmacies are having to order Tamiflu supplies more frequently than usual as there is high demand for the antiviral because of the nasty flu outbreak. Doctors says the flu shot hasn't been effective against this strain of the virus. Doctors says prevention with Tamiflu is not recommended.
12th Jan 2018 - WSBT-TV

Sanofi is able to fight the costs of importing vaccines because of its manufacturing plant in Mexico

Although many pharmaceutical companies have vaccines in their portfolio, Sanofi is unique in having its own manufacturing plant in Mexico, and thereby, bypassing the expense of importing vaccines from elsewhere - which is supported, in part, by its agreement with the Government of Mexico to help meet the health needs of its population
11th Jan 2018 - Expansion

Abbott will increase Influvac production at its Weesp plant by up to 50%

Abbott Healthcare wants to increase production of flu vaccine Influvac at a plant in Weesp by at least 50 percent. It plans to invest in the plant to adjust for this increase in production. Influvac, as the flu vaccine is called, is produced in chicken eggs. The current maximum contribution is 200,000 eggs per day. That should be raised to 300,000, according to a new planning report filed by Abbott Healthcare
11th Jan 2018 - Weesper Nieuws

Influvac Tetra vaccination to be reimbursed

In France, after Fluarix Tetra and Vaxigrip Tetra, it is Influvac Tetra's turn to become partly reimbursed (65% discount) for adults over 18 years old
11th Jan 2018 - Le Moniteur des pharmacies

Oscillococcinum: Can It Really Cure Flu Symptoms?

As flu continues to beat down on the U.S., different headlines have been boasting several remedies that allegedly offer quick and natural restorative powers to those who have fallen ill with the virus. Oscillococcinum, which markets itself like a natural oseltamivir, is one such product that has been gaining a lot of attention lately. However, the manufacturer of the product landed in hot water with the FDA in 2009/10 over purported claims of being able to cure the H1N1 influenza strain
11th Jan 2018 - Contagion Live.com

An "unsustainable" model: Drug makers signal interest in exiting vaccine development during crises

Finding a way that allows vaccine makers to help in an emergency without sustaining huge operational costs is critical to the success of future disease outbreak responses, experts say. A number of flu vaccine manufacturers were left on the hook with ordered but unpaid for vaccine during the mild 2009 H1N1 flu pandemic. By the time the vaccine was ready — after the peak of the outbreak — public fear of the new flu had subsided. Many people didn’t want the vaccine, and some countries refused to take their full orders. GSK, Sanofi Pasteur, and Novartis — which has since shed its vaccines operation — produced flu vaccine in that pandemic.
11th Jan 2018 - Stat News

BRIEF-Eurocine Vaccines Gets Authorized To Conduct Phase I/II Clinical Study

Eurocine Vaccines has obtained authorisation to conduct a phase I/II clinical study on quadrivalent flu vaccine candidate Immunose Flu
11th Jan 2018 - Reuters

Tamiflu "Flying Off The Shelves" As Flu Spreads

In the U.S., the flu is now widespread in 46 states and this year in Colorado, cases are three-to-four times higher than previous years. Adding to the stress, the uptick in flu cases combined with other respiratory issues, has resulted in a huge demand for anti-viral medication in pharmacies across the state. Tamiflu is flying off the shelves
10th Jan 2018 - CBS Local


Industry News - Seqirus Media Monitoring - 11th Jan 2018

    View this newsletter in full

Lupin receives FDA approval for generic Tamiflu Capsules

Pharma Major Lupin announced that it has received final approval for its Oseltamivir Phosphate Capsules USP,30 mg (base), 45 mg (base), and 75 mg (base) from the U.S. FDA to market a generic version of Roche's Tamiflu Capsules, 30 mg, 45 mg, and 75 mg
10th Jan 2018 - WebIndia 123

Flu season: Manufacturers say they have "sufficient" Tamiflu, Relenza

The CDC published the following yesterday concerning the antiviral drug supply: Manufacturers have stated they have sufficient product on hand to meet projected demand for the 2017-2018 flu season. As influenza antiviral drugs are mainly used seasonally, patients may want to consider calling a pharmacy in advance to see if they have drug on their shelf. If the pharmacy does not have product, they may be able to identify another pharmacy in the area that has antiviral drugs in stock.
10th Jan 2018 - Outbreak News Today

It's The Flu Season From Hell. Should We Take Tamiflu?

in response to H3N2, the CDC has recommended the use of antiviral influenza drugs, mainly Tamiflu (generally not considered a great drug). A review of Tamiflu's strengths and weaknesses, as well as Relenza's, the Cochrane findings, showed that neuraminidase inhibitors are poor drugs. A flu shot seems a better option
10th Jan 2018 - American Council on Science and Health


Industry News - Seqirus Media Monitoring - 10th Jan 2018

    View this newsletter in full

AstraZeneca and Eisai urge UK to remain part of EMA

AstraZeneca and Eisai have urged the UK to remain a member of the European Medicines Agency (EMA). The companies said they wanted the EMA to continue to oversee the movement and safety of drugs in the UK, despite the agency’s relocation. The push by the companies to remain under the EMA’s umbrella comes just days after the Financial Times reported that the UK is attempting to remain under EU regulation for medicines after Brexit.
10th Jan 2018 - Life Sciences Intellectual Property Review

Cepheid Receives FDA Clearance and CLIA Waiver for Xpert Xpress Flu Test

Cepheid announced it has received U.S. FDA 510(k) clearance and Clinical Laboratory Improvement Amendments waiver for the Xpert® Xpress Flu test. The test can be performed in near-patient settings, providing rapid and accurate molecular detection of Flu A and B RNA from patient specimens, in as little as 20 minutes.
9th Jan 2018 - PR Newswire.com

Get ready, some medical experts are predicting the worst flu season in history

Medical experts in the U.S. are worried that this year's flu season could be a nasty one that may be lethal. That's because this year's main flu strain, the influenza A virus, known as H3N2, is worse than the swine flu in 2009. A string of bad flu seasons has medical experts calling for the development of a universal influenza vaccine that would save lives. A handful of major pharmaceutical companies are supporting universal flu vaccine research, including GlaxoSmithKline; Janssen Vaccines and Sanofi.
9th Jan 2018 - CNBC


Industry News - Seqirus Media Monitoring - 9th Jan 2018

    View this newsletter in full

Dengvaxia probe: DOH checks death of 14 kids

In the Philippines, Dengvaxia’s manufacturer Sanofi Pasteur has been fined P100,000 for not meeting marketing requirements. A panel of experts from the Philippine General Hospital will review the circumstances behind the deaths of 14 children who were given the Dengvaxia antidengue vaccine under the government’s immunization program, Health Undersecretary Enrique Domingo said
8th Jan 2018 - Philippine Daily Inquirer

PAO ties 3 kids’ deaths to Dengvaxia


8th Jan 2018 - Manila Standard Today

PH probing 14 deaths amid dengue vaccine controversy


6th Jan 2018 - Concept News Central.com

UK in push to remain part of EU medicines agency after Brexit

Britain is pushing to remain under EU regulation for medicines after Brexit, in the latest sign that ministers want to stay close to Europe in some sectors despite the bloc warning that the UK cannot cherry-pick parts of the single market. The move follows calls for the UK’s chemicals and aviation industries to continue to be regulated by EU agencies, keeping them within Europe’s standards and safety regime and under the auspices of the European Court of Justice. Three senior government figures have told the Financial Times that the UK hopes to be regulated by the European Medicines Agency, even as the body moves from London’s Canary Wharf to a new post-Brexit home in Amsterdam.
7th Jan 2018 - Financial Times

‘We followed law’ - Sanofi Pasteur

In the Philippines, Sanofi Pasteur maintains it complied with laws and regulations after the country’s Food and Drug Administration suspended the French firm’s Dengvaxia vaccine’s certificate of product registration for a year. “As part of our standard company practices, Sanofi routinely conducts post-approval commitments to continuously evaluate the safety and effectiveness of our vaccines in the countries where they are in use,” Sanofi Pasteur said. “And we have done so in the Philippines with Dengvaxia.”
8th Jan 2018 - Business Mirror

Tamiflu shortage reported in some Bay Area Walgreens stores

The recent spike in flu cases around the Bay Area and California is not only crowding hospital emergency rooms with flu patients, it’s also leading to more demand for flu shots and antiviral medications to treat the virus. That means some drug stores around the region, like Walgreens, are reporting a limited supply of Tamiflu, said company spokesman Scott Goldberg.
8th Jan 2018 - The Mercury News

Prescription copy a must for sale of Tamiflu: Health dept

In India, to avoid misuse of the drug given to swine flu patients, the health department has directed authorized chemists and government hospitals to maintain a record of all patients who are sold Tamiflu.
8th Jan 2018 - Times of India

Sabin To Tackle Pandemic Flu

The Sabin Vaccine Institute, a non-profit global health organization dedicated to enabling vaccine innovation, making vaccines more accessible and expanding immunization across the globe, announced a new three-year $6.6 million grant to help speed the development of next generation influenza vaccines and support related immunization issues
8th Jan 2018 - PR Newswire


Industry News - Seqirus Media Monitoring - 8th Jan 2018

    View this newsletter in full

First quadruple flu vaccine now approved for six months or more (Vaxigrip Tetra)

To date in Germany, tetravalent flu vaccinations were available only for children from the age of three. From now, though, Vaxigrip Tetra can be used to vaccinate children of an earlier age - children from six months old . This was just announced by the manufacturer Sanofi Pasteur on Friday. Also the STIKO advisory committee is recommending some quadruple combinations, which contains an additional protection when compared to the triple shot.
7th Jan 2018 - DAZ.online


Industry News - Seqirus Media Monitoring - 5th Jan 2018

    View this newsletter in full

Emergent BioSolutions Initiates Phase 2 Clinical Study to Evaluate FLU-IGIV to Treat Serious Influenza A Infection

Emergent BioSolutions announced the initiation of a Phase 2 dose ranging study to evaluate the safety, pharmacokinetics, and clinical benefit of FLU-IGIV, the company's anti-influenza immune globulin being developed as an intravenous treatment for serious illness caused by influenza A infection in hospitalized patients.
4th Jan 2018 - NASDAQ

Emergent BioSolutions Commences Phase 2 Clinical Study to Evaluate FLU-IGIV to Treat Serious Influenza A Infection


4th Jan 2018 - Street Insider.com

BiondVax Universal Flu Vaccine Patent Granted in India

BiondVax Pharmaceuticals, developer of M-001, the Universal Flu Vaccine candidate currently in preparation for a Phase 3 clinical trial, announced today that one of its key patents titled "A Synthetic or Recombinant Influenza Multi-Epitope Polypeptide" has been granted in India.
4th Jan 2018 - New Kerala

Flu Shots Don't Give You The Flu -- Get Yours Now

Forbes contributor Judy Stone writes about the irresponsible spreading of fake news regarding the flu vaccine on Twitter, and the fact that it cannot give recipients the illness. She explains why the effectiveness of the vaccine varies, and whether or not antivirals like Tamiflu and Relenza shoud be relied on.
4th Jan 2018 - Forbes

Dispute brewing over exit of Protein Sciences CEO after Sanofi buyout

Not long after its acquisition by Sanofi, Protein Sciences is bidding adieu to its former leader. Yet Manon Cox says the departure wasn't on her terms, according to the Meriden Record-Journal. Cox will leave the company, a Sanofi spokesperson confirmed to FiercePharma. According to the Record-Journal, however, Cox claims she was forced out and has contacted an attorney.
4th Jan 2018 - FiercePharma


Industry News - Seqirus Media Monitoring - 4th Jan 2018

    View this newsletter in full

Antiviral prescribing authorised for flu as incidence spikes

In the UK, with surveillance data indicating an increase in flu cases in the community, GPs and other prescribers working in primary care may now prescribe antiviral medicines for the prophylaxis and treatment of flu at NHS expense. Information on at-risk groups and patients eligible for NHS treatment with either oseltamivir (Tamiflu), or zanamivir (Relenza), is available in PHE guidance on use of antiviral agents for the treatment and prophylaxis of seasonal flu.
3rd Jan 2018 - Pharmacy Magazine

Former Protein Sciences CEO says she was forced out as head of Meriden-based company

The former CEO of Protein Sciences said she had not agreed to the terms of her separation from Sanofi Pasteur and has consulted an attorney. Manon Cox, a 20-year Protein Sciences management leader, disagreed with Sanofi Pasteur’s statement that her “separation was done in compliance with her existing work contract.” Sanofi Pasteur management notified Cox and Protein Sciences founder and global business development director Daniel Adams that both were no longer employed at Sanofi
3rd Jan 2018 - My Record Journal.com


Industry News - Seqirus Media Monitoring - 3rd Jan 2018

    View this newsletter in full

BiondVax Universal Flu Vaccine Patent Granted in India

BiondVax, developer of M-001, the Universal Flu Vaccine candidate currently in preparation for a Phase 3 clinical trial, has announced that one of its key patents titled "A Synthetic or Recombinant Influenza Multi-Epitope Polypeptide" has been granted in India. The patent has now been granted in over 30 countries
2nd Jan 2018 - Markets Insider

BiondVax Universal Flu Vaccine Patent Granted in India


2nd Jan 2018 - PR Newswire.com

CEO of Meriden’s Protein Sciences Corp. leaving five months after sale to Sanofi Pasteur

Manon Cox, president and CEO of Protein Sciences, is leaving the company five months after its sale to Sanofi Pasteur, the company said. In a statement, Sanofi Pasteur said: "Sanofi Pasteur confirms that Manon Cox will leave Protein Sciences to pursue other opportunities." “Protein Sciences has been successfully and fully integrated into Sanofi Pasteur and, as such, there is no role of CEO for Protein Sciences. Separation has been done in compliance with Manon Cox’s existing working contract.” Cox, who led the company through federal approval of its signature Flublok vaccine, could not be reached for comment
2nd Jan 2018 - Record Journal.com

Pharma exec Cox to leave Protein Sciences following Sanofi takeover


2nd Jan 2018 - Hartford Business


Industry News - Seqirus Media Monitoring - 2nd Jan 2018

    View this newsletter in full

BiondVax receives EMA committee's permission to begin phase 3 trial of universal flu vaccine candidate, M-001

BiondVax has announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use reviewed its phase 3 trial plan, provided advice, and allowed the company to proceed with the phase 3 clinical trial plan for M-001, BiondVax’s universal flu vaccine candidate. The CHMP advice will facilitate procedures in the countries where the phase 3 study will take place. The CHMP response states that, “It is agreed that a single pivotal efficacy trial that provides a robust demonstration of efficacy against laboratory-proven influenza like illness (ILI) could suffice for an approval.”
29th Dec 2017 - Pharmabiz.com

Flu outbreak in Lufkin causes Tamiflu shortage

A flu epidemic is hitting East Texas hard. A local pharmacist describes how their pharmacy has responded to the increase demand of Tamiflu. “There have been days where we used up all our stock that we have, but then we've been able to get it in the next day,” said Registered Pharmacist, Jessica Ponder. At Brookshire Brothers Pharmacy in Lufkin, Texas they've had to use their standby source to restock Tamiflu
29th Dec 2017 - ABC 9 KTRE


Industry News - Seqirus Media Monitoring - 29th Dec 2017

    View this newsletter in full

Influenza Prevention: Make Sure Patients Understand the Vaccine

The Advisory Committee on Immunization Practices recommends that all Americans 6 months and older who do not have contraindications receive the flu vaccine. Health care providers should recommend the high-dose or adjuvanted flu vaccine for patients 65 and older.
27th Dec 2017 - Pharmacy Times

Perfecting the magic bullet

The world’s first widespread human testing of a flu vaccine began last month in September. More than 10,000 people aged 65 and over have been asked to take part in a study that is supported by the NIHR (National Institute for Health Research) and is being delivered by the University of Oxford in Berkshire and Oxfordshire. The vaccine was developed by Oxford University’s Jenner Institute with Vaccitech, a spin-out company from the institute
26th Dec 2017 - Independent Nurse

Minister directs to ensure arrangements for prevention, treatment of flu

Punjab Minister for Specialised Healthcare and Medical Education Khawaja Salman Rafique has said that hospitals must ensure the prevention and treatment of seasonal flu (H1, N1) across the province. He said that all district health authorities and medical superintendents of teaching hospitals should submit seasonal flu monitoring report on a daily basis. He directed all the medical superintendents and CEOs to ensure the availability of Tamiflu in sufficient quantity for the timely treatment of the patients
28th Dec 2017 - Pakistan Today


Industry News - Seqirus Media Monitoring - 28th Dec 2017

    View this newsletter in full

BiondVax Plans Phase 3 Clinical Trial Following Receipt of Scientific Advice from the European Medicines Agency

BiondVax announced that the European Medicines Agency's Committee for Medicinal Products for Human Use reviewed its Phase 3 trial plan, provided advice, and allowed it to proceed with the Phase 3 clinical trial plan for M-001, its universal flu vaccine candidate. The CHMP advice will facilitate procedures in the countries where the Phase 3 study will take place. The trial is expected to take place in Eastern Europe and begin prior to the 2018/19 flu season
27th Dec 2017 - GuruFocus.com

BiondVax can continue with its late-stage flu vaccine trial


27th Dec 2017 - Seeking Alpha

BiondVax Pharma Announces Plans for Phase 3 Clinical Trial Following Receipt of Scientific Advice from the European Medicines Agency


27th Dec 2017 - Streetinsider.com

BiondVax Plans Phase 3 Clinical Trial Following Receipt of Scientific Advice from the European Medicines Agency (EMA)


27th Dec 2017 - PR Newswire

Texas continues to hold top spot for influenza activity

Influenza is wreaking the most havoc on Texans, according to the Walgreens Flu Index. The tool—which follows the trend using nationwide retail prescription data for antivirals that treat the condition—identifies Tyler-Longview (Lufkin & Nacogdoches) as the country's most affected area for the week ended December 16
27th Dec 2017 - pharmacist.com

Jump in H3N2 flu prompts CDC warning, antiviral reminder

The U.S. CDC warned clinicians that flu activity has increased significantly in recent weeks, much of it from H3N2, which poses a heightened threat, especially to seniors and young children, and elevates the importance of prompt antiviral treatment. The CDC said predominant H3N2 activity has major implications for clinical treatment, given that the vaccine is generally less effective against that subtype, and that neuraminidase inhibitors, such as (oseltamivir) Tamiflu, will be a useful treatment adjunct.
27th Dec 2017 - CIDRAP


Industry News - Seqirus Media Monitoring - 27th Dec 2017

    View this newsletter in full

Triple Antiviral Drug Combination for Treatment of Influenza Fails to Provide Clinical Benefit

In what researchers refer to as the largest and most comprehensive study assessing combination antiviral therapy for the treatment of influenza, a triple antiviral drug combination significantly decreased viral shedding. However, the triple antiviral failed to provide more clinical benefit than a single agent with less virological effect. The randomized study included 50 sites across the US, Thailand, Mexico, Argentina, and Australia, and included 633 participants seeking outpatient treatment for influenza; the participants received either the triple combination of oseltamivir, amantadine, and ribavirin or monotherapy with oseltamivir and 2 placebo formulations
25th Dec 2017 - Contagion Live.com

Medical industry advances towards more efficient, customized 3D printed vaccinations

At a health conference in Bilbao, Spain about advancements in vaccinations, a number of professionals cited the potentials of 3D printing for advancing the efficiency of administering as well as customizing vaccines. Pedro Alsina, from the Institutional Relations of Sanofi, spoke about how 3D printing will enable the production of customized vaccines. Another key goal addressed at the conference was the development of more efficient vaccines, especially for the flu. “We must work to achieve a more immunogenic injection in the most vulnerable people and for the universal flu vaccine so that it is not necessary to go through the process once a year,” said Dr. Ramón Cisterna, a professor of microbiology and the president of AMYS
25th Dec 2017 - 3ders.org

The Coahuila Ministry of Health denied that there is a shortage of medicines used to fight influenza

The Ministry of Health in Coahuila denied that there was a shortage of Tamiflu, a drug used to fight influenza. In the last few days, some patients reported that several public health institutions were reporting that it was difficult to obtain medicine to fight the flu. However, Jorge Luna, in charge of the department of social communication at the Ministry of Health, reported that until now there has been no lack of Tamiflu has been reported at any hospital. There is a supply of Tamiflu. Treatment with it begins if there is confirmation of any type of influenza. It is not delivered without prior medical review and prescription by the attending physician," he said.
23rd Dec 2017 - Vanguardia.com.mx

NHS to cover expense of flu prophylaxis and treatment this winter

Community pharmacists, GPs and other prescribers in primary healthcare may now give some patients antiviral treatment for influenza at the expense of the NHS. But pharmacists have been requested to order antivirals only as needed and not to overstock, to reduce the likelihood of shortages in the supply chain. The NHS will cover the expense of supplying the antivirals oseltamivir (Tamiflu) and zanamivir (Relenza) to patients in clinical at‐risk groups, and also to those at risk of severe illness and/or complications if their influenza is not treated.
22nd Dec 2017 - Pharmaceutical-Journal.com

Is Novavax a Buy?

There's excitement among Novavax investors over the potential for its nanoparticle-based influenza vaccine, NanoFlu. Pre-clinical results from NanoFlu were so good that Novavax kicked its program into high gear. The opportunity for NanoFlu is huge. However, it had never been given to a human until September 2017. BIO's report of clinical development success rates between 2006 and 2015 found that fewer than 1-in-5 phase 1 programs in infectious diseases eventually win approval
24th Dec 2017 - Motley Fool

Is Novavax a Buy?


24th Dec 2017 - Nasdaq


Industry News - Seqirus Media Monitoring - 21st Dec 2017

    View this newsletter in full

Sector highlights: SGS Life Sciences interview

SGS Clinical Research has developed and launched a cGMP-manufactured, non-haemagglutinating, wild-type strain of Influenza A H3N2. This novel virus has consistent performance characteristics, closely emulating a wild type infection which can be used as a challenge agent in controlled, human infection studies to develop effective vaccines. Considering recent failures in global vaccination programmes versus H3N2 (which has been responsible for 3 of the last 4 global epidemics), a novel challenge agent capable of rapidly providing evidence regarding vaccine effectiveness, and which enables candidate selection prior to vaccination programmes, could positively affect future measurements of disease burden.
20th Dec 2017 - EPM Magazine

PSNC warns contractors not to create shortages by over-ordering stocks of antivirals

The PSNC has urged contractors not to create drugs shortages by over-ordering stocks of antiviral medicines after the Department of Health published an alert telling prescribers in primary care they can prescribe antivirals for the prophylaxis and treatment of flu at NHS expense. The alert, aimed at GPs and other prescribers in the community, was sent in response to the rise in levels of flu this winter.
20th Dec 2017 - Pharmacy.biz

Pharma firms face multi-million Brexit bill, MPs warned

Pharmaceutical companies face a multi-million euro bill in regulatory costs regardless of whether the UK reaches a ‘soft’ or ‘hard’ Brexit deal with the European Union, industry leaders warned. “Our working assumption is for between £60-£70 million in contingency planning costs in the scenario of a ‘no deal’ over the next three to four years,” GlaxoSmithKline’s Global Affairs President Phil Thompson told MPs on the House of Commons Health select committee. “Even if we have a smooth and orderly Brexit process there are going to be costs of that magnitude,” Thompson added
20th Dec 2017 - Euractiv.com

Pharma companies may be less likely to invest in the UK post-Brexit, MPs told

UK patient involvement in clinical trials will diminish post-Brexit making manufacturers less likely to want to invest here, MPs on the House of Commons Health Select Committee were told on Tuesday. But MPs also heard that unlocking the potential of patient data held by the NHS may be enough to persuade the pharmaceutical industry to continue to look to the UK for its involvement in developing new drugs and mitigate any disadvantages from leaving the EU. Hugo Fry, UK general manager of Sanofi suggested that finding itself outside the EU could create a “potential opportunity” if the UK could “lighten the burden of administration” around clinical trials
20th Dec 2017 - Pharmaceutical Journal

Novavax: Punts On NanoFlu, Accelerates RSV

Novavax issued a press release on Dec. 18, providing updates on its two main vaccine trials. The full data package for the NanoFlu flu vaccine will be completed by Feb. 2018; previous guidance stated interim data would be displayed before the end of 2017. Market reaction to the news was highly negative; traders positioned in anticipation of a major news event were disappointed
20th Dec 2017 - Seeking Alpha

Experts call for use of Sanofi's dengue vaccine to be halted in most cases

The use of the world’s first dengue vaccine should be temporarily suspended except in limited circumstances because of concerns that it could put some people at heightened risk of severe disease, according to prominent public health experts. That step, they say, is necessary after studies showed that the vaccine, manufactured by Sanofi Pasteur, can have an unfortunate effect: worsening — rather than preventing — future cases of dengue in some people who had not previously been infected with it.
19th Dec 2017 - Stat News

WHO expert committee to release recommendations on Dengvaxia by year end

The World Health Organization (WHO) is set to release recommendations following the dengue vaccine controversy before the year ends, the former Health Secretary said Tuesday.Growing concern about health risks linked to the vaccine Dengvaxia have left the public stumped on whether to finish the initially recommended three doses. Former Health Secretary Paulyn Ubial said she recommends recipients finish the dosage — but she also pointed out that the international organization had the final say.
19th Dec 2017 - CNN Philippines


Industry News - Seqirus Media Monitoring - 20th Dec 2017

    View this newsletter in full

Improved Nanovaccine Seeks to Destroy Flu Virus

Researchers from Iowa State University, the University of Iowa, and the University of Wisconsin-Madison are working together to develop and test what they think could be a better way to fight the flu. Based on preliminary studies, researchers believe the nanovaccine will activate both kinds of immune cells (T cells and B cells) and provide protection in the upper airway and the lower airway
19th Dec 2017 - Controlled Environments Magazine

Novavax shares fall on RSV, NanoFlu vaccine updates

Shares of Novavax fell 22 percent Tuesday after the company disappointed investors by saying it would announce data for the phase 1/2 trial of its NanoFlu seasonal flu vaccine candidate in February. Investors had been looking for results on the program this month. Company officials did not say what the latest data show about NanoFlu's effectiveness. But they said the vaccine could benefit from recent concerns about the status of seasonal flu vaccine effectiveness.
19th Dec 2017 - Biz Journals.com


Industry News - Seqirus Media Monitoring - 19th Dec 2017

    View this newsletter in full

Novavax Says Phase 3 Trial of RSV F Vaccine for Infants via Maternal Immunization Will Continue; Provides Update on Phase 1/2 Trial of NanoFlu Vaccine

Novavax announced the Phase 3 trial of its RSV F protein recombinant nanoparticle vaccine (RSV F Vaccine) for infants via maternal immunization will continue. It also provided an update on its nanoparticle influenza vaccine candidate with proprietary Matrix-M adjuvant (NanoFlu)
18th Dec 2017 - Street Insider

Novavax Continues Phase 3 Trial of the RSV F Vaccine for Infants via Maternal Immunization and Provides Update on Phase 1/2 Trial of the NanoFlu Vaccine


18th Dec 2017 - Nasdaq

Will Sanofi be the scapegoat for the Dengvaxia fiasco?

With the public pronouncements of current and former Philippines Department of Health officials during last Monday’s joint hearing of the Senate blue ribbon, health, and finance committees, it looks like Sanofi is being made out to be the scapegoat in the Dengvaxia vaccine fiasco. However flaws in the procurement process are being pointed out (flaws that are reminiscent of the Tamiflu procurement fiasco in the Philippines)
19th Dec 2017 - The Manila Times


Industry News - Seqirus Media Monitoring - 18th Dec 2017

    View this newsletter in full

All details about ageing, vaccination and public spending up for discussion

Massimiliano Di Domenico , head of institutional relations and communication for GSK Italia. "We believe that an aging population with an increased life expectancy, must be supported by an improvement in the quality of life across these sections of the population". Consequently vaccinations have become increasingly important, precisely for the elderly population, as a main way to prevent serious diseases. "In this context - commented Di Domenico - our company mission 'do more, feel better, live longer', has pushed us into organizing a meeting with representatives of the highest level of the political-institutional world, of civil society, of both the entrepreneurial and journalistic world - in order to discuss in a proactive and constructive manner - the importance of disease prevention in adulthood and, within this notion, the fundamental role of vaccination as an effective tool of primary prevention in these most advanced age groups ".
17th Dec 2017 - Formiche.net

Drug Company Under Fire After Revealing Dengue Vaccine May Harm Some

The Philippines government has begun investigations into the rollout of the dengue immunization program by Sanofi, which has come under fire for discounting early warnings that its vaccine could put some people at heightened risk of a severe form of the disease. The situation has become a public-relations debacle for the drugmaker, and the backlash has alarmed researchers who worry that Sanofi’s stumble could stoke mistrust in vaccines around the globe
17th Dec 2017 - New York Times

Arkansas pharmacies struggling to keep Tamiflu in stock

The Arkansas Department of Health says they are seeing a higher number of flu cases reported this week compared to the same week last year and the year before. With the recent uptick in flu cases, many central Arkansas pharmacies weren't quite prepared and many have been struggling to keep Tamiflu in stock
15th Dec 2017 - THV11.com

Sanofi ordered to pull dengue vaccine

Sanofi’s Dengvaxia dengue vaccine has been withdrawn in the Philippines, and the government is demanding a refund from the company of the PHP3.5 billion (£52 million) it had paid for the vaccines as part of an immunisation programme. The company was criticised by a joint hearing of the government’s public accountability and health & good government committees, according to a report in The Philippine Daily Inquirer
15th Dec 2017 - Chemistry World

Generic companies are flooding Korea with Tamiflu copies

The anti-influenza drug Tamiflu from Roche has lost patent protection - and South Korea generic companies are already pouncing to get a piece of the market pie by producing generic imitations . A total of 134 generic companies are registered across Southeast Asia's 50 million state seeking to copy the world's third best-known medicine after Viagra and Prozac.
15th Dec 2017 - Handelszeitung.ch

When will we get a drug that can actually cure the flu?

Various avenues are being explored by scientists to discover a drug that will cure the flu. There are medicines available now such as Tamiflu, but their effectiveness is limited as it has been used for 15 years now and many strains are resistant to it. Both Tamiflu and Relenza fight the replication process of the virus rather than the damage caused by inflammation of tissues. New medications targeting cells rather than the virus itself are more interesting, and likely to deliver better anti-flu drugs
15th Dec 2017 - Huffington Post

Swine flu vaccines stuck in Korea as KUMACA health crisis continues

The Ghana Health Service says the arrival of vaccines against swine flu as well as Tamiflu will be delayed for a few more days. The vaccines were expected in the country on Saturday but the Korean suppliers said that was not possible because of transport challenges. The GHS Director of Public Health said the Ghana Health Service will use Relenza (Zanamivir) to treat the students until the arrival of the vaccine
15th Dec 2017 - Ghana Web

H1N1 outbreak: WHO’s antiviral drugs arrive today

Antiviral drugs – Tamiflu – for the treatment of the H1N1 Influenza which has killed four students of the Kumasi Academy (KUMACA) were expected in Ghana on Friday. The WHO is supplying the drugs based on a request from government as it struggles to contain the situation at the school and other areas. Vaccines for the swine flu are also expected over the weekend.
15th Dec 2017 - StarrFM online.com

H1N1 outbreak: Vaccines, anti-viral agents arrive for KUMACA students


15th Dec 2017 - MyJoy Online


Industry News - Seqirus Media Monitoring - 15th Dec 2017

    View this newsletter in full

Communication is key to quashing suspicion around vaccination drives

The barrier that rumour-mongering presents to vaccine delivery logistics is so serious that the world’s premier pandemic preparedness assessment body, the Joint External Evaluation, or JEE Alliance, ranks "dynamic listening and rumour-management" as one of the most important risks governments must get under control.
14th Dec 2017 - Business Live

Scientists for EU co-founder questions UK participation in EU science post-Brexit

A leading data scientist has cast doubt on whether the UK can continue to participate in the Horizon 2020 programme after the country leaves the European Union, following the publication of a joint report. Steve Bates, chief executive of the BioIndustry Association welcomed the report but said it was now crucial that the UK and EU agree a transition period to ensure that the supply of medicines to patients in the UK and across Europe is not affected
14th Dec 2017 - Pharmaceutical Journal


Industry News - Seqirus Media Monitoring - 14th Dec 2017

    View this newsletter in full

Learning the Lessons of FluMist

FluMist is unlikely to be added back to the CDC's Advisory Committee on Immunization Practices recommendations for influenza vaccine any time soon. In an exclusive MedPage Today video, Andrew Pavia, MD, of the University of Utah, addresses key takeaways about FluMist, which was not recommended by the ACIP for use during the influenza season in 2016 or 2017. Pavia comments on how these lessons may be applicable to other potential influenza vaccines for both children and adults that may be presented to the ACIP for recommendation in the future
13th Dec 2017 - MedPage Today

Eurocine Vaccines Challenges the Flu

Eurocine Vaccines prepares for the next phase of development, a second clinical study with its first vaccine candidate Immunos FLU. Empowered by the two recently granted patents, in Australia and USA, and positive results from its clinical study, Eurocine Vaccines now takes the next step towards creating the first nasal influenza vaccine approved for children under the age of two
13th Dec 2017 - PR Newswire.com

Did Sanofi, WHO ignore warning signals on dengue vaccine?

When Sanofi published the results of clinical trials of children given its dengue vaccine two years ago, the overall findings were that it protected against the disease. But the trial also showed that in the third year after receiving the Dengvaxia inoculation, younger children were more likely to end up in hospital with a severe case of dengue than those who didn’t get the vaccine. Sanofi has rejected suggestions it ignored any risks or took any short-cuts. However, it has acknowledged that clinical tests of the vaccine did not fully investigate whether a previous dengue infection could influence the outcome.
13th Dec 2017 - Reuters

Supply and safety of medicines at risk due to Brexit, assessments show

The UK and EU have made enough progress to move on to a second phase of Brexit talks focusing on trade. But pharma and biotech trade groups in the UK want health to be the primary concern for both parties in the next round of talks, they have made clear. The BIA and ABPI have published a new report on the public health implications of Brexit, showing that these will be more severe if cooperation and trade relationships decline, having a detrimental effect on patients across the EU, the European Economic Area and in the UK
13th Dec 2017 - The Pharma Letter

BIA and ABPI release research on impact of Brexit, highlighting the need to safeguard public health

The Association of the British Pharmaceutical Industry (ABPI) and the UK BioIndustry Association (BIA) have released new research evaluating the impact of the UK’s exit from Europe. This collaborative research was used by Steve Bates (CEO of the BIA) in his evidence session to urge the UK government and that of the European Union to ‘safeguard public health in the UK and Europe by making the regulation and supply of medicines the first priority in phase two of Brexit talks’.
13th Dec 2017 - EPM Connecting Pharma

Sanofi to Highlight R&D Strategy and Innovative Pipeline at Analyst Meeting in Paris

Sanofi is hosting an analyst meeting in Paris to discuss its R&D strategy, development pipeline and milestones for 2018. The company will highlight the progress it has made against "Sustaining Innovation", a key pillar of its 2020 strategic roadmap, and advancing a differentiated portfolio addressing unmet needs. The company's pipeline spans 71 R&D projects, which includes 37 new molecular entities and novel vaccines
13th Dec 2017 - Street Insider


Industry News - Seqirus Media Monitoring - 13th Dec 2017

    View this newsletter in full

Pharma warning of Brexit impact to public-health emergencies

UK pharma industry leaders have warned of the potential impact of Brexit on Europe’s capacity to respond to a continent-wide public-health emergency, as they step up their drive to ensure the sector’s interests are addressed when the next phase of negotiations begins. The Association of the British Pharmaceutical Industry and the BioIndustry Association said that Europe’s ability to manage big public-health crises related to the use of medicines could be at risk if the UK were excluded from cross-EU incident management planning
12th Dec 2017 - Financial Times

Drug firms warn chaotic Brexit could harm Europe's ability to contain 'Zika-style' epidemic


12th Dec 2017 - Daily Telegraph

Sanofi Pasteur exec: Dengvaxia is ‘a safe and efficacious vaccine’

An official from Sanofi Pasteur, manufacturer of Dengvaxia dengue vaccine, has denied negligence on the part of the company, saying that permanently removing the vaccine from the Philippine market would be a disservice to Filipinos. “We at Sanofi Pasteur assure each and every one of you that Dengvaxia is, and continues to be, a safe and efficacious vaccine,” he added
12th Dec 2017 - Philippine Daily Inquirer

Dengue Fever Vaccine Suspension Criticized by Drugmaker Sanofi


12th Dec 2017 - The Street


Industry News - Seqirus Media Monitoring - 12th Dec 2017

    View this newsletter in full

Eurocine Vaccines Challenges the Flu

Eurocine Vaccines prepares for the next phase of development, a second clinical study with its first vaccine candidate Immunos FLU. Empowered by the two recently granted patents, in Australia and USA, and positive results from its clinical study, Eurocine Vaccines now takes the next step towards creating the first nasal influenza vaccine approved for children under the age of two
11th Dec 2017 - New Brunswick Herard

The CVS-Aetna Merger Will Be a Disaster for Small Drugstores

When CVS announced that it planned to buy Aetna in a deal worth $69 billion, some experts were cautiously optimistic that the outcome may be lower costs for consumers. However there are also plenty of reasons why this may be a bad deal for the consumer and spell the end for small drugstores in the U.S.
11th Dec 2017 - Slate Magazine

New inactivated quadrivalent flu vaccines to be available in France in 2018

At the start of the 2017-2018 flu season in France, inactivated trivalent flu vaccines were available, as well as quadrivalent Fluenz Tetra (MedImmune). Now, two inactivated quadrivalent flu vaccines have become available: Fluarix Tetra (GSK) and VaxiGrip Tetra (Sanofi Pasteur). Influvac Tetra (Mylan) should become available in the northern hemisphere in time for next flu season
11th Dec 2017 - Mes Vaccins.net


Industry News - Seqirus Media Monitoring - 11th Dec 2017

    View this newsletter in full

Walgreens puts out season's first weekly flu index

According to the first of Walgreens’ weekly “Flu Index” snapshots for the 2017-2018 U.S. flu season, the “designated market areas” of Brownsville, Harlingen, McAllen and Weslaco have more residents sick with the flu than anywhere else in the country. The ranking is based on weekly prescription data for antiviral medications — Tamiflu, for instance — from nearly 8,000 Walgreens locations around the United States and Puerto Rico
10th Dec 2017 - Brownsville Herald

Effectiveness of Flu Shot Is 60%—in a Good Year

How many people get the flu in any given year depends in part on the effectiveness of the vaccine. In a good year, people who get vaccinated are 60% less likely to get sick, but in most recent years, the protection has been worse. The way flu vaccines are manufactured may contribute to their effectiveness. New technologies produce viruses that are a closer match, but manufacturers are geared almost entirely to egg production: the U.S. government considers vaccine production so important that it contracts with Sanofi Pasteur to guarantee a year-round supply of eggs to ensure the U.S. could respond to a pandemic
9th Dec 2017 - Wall Street Journal

It's flu season: 4 easy steps to not becoming a statistic

Health experts recommend taking antiviral medicines to keep yourself from getting sick: two of the more popular products are oseltamivir (Tamiflu) or zanamivir (Relenza). Many doctors will prescribe these if there are a number of flu cases in a small community, such as a nursing home or school. Antivirals may help reduce many of the symptoms you experience with the flu, making it a milder and shorter bout of illness
8th Dec 2017 - Atlanta Journal Constitution

Gordon blames Aquino administration for giving vaccination "a bad name"

In the Philippines, Sen. Richard Gordon said on Sunday the controversy over the Dengvaxia dengue vaccine had given vaccination “a bad name,” and it was because the administration of former President Benigno Aquino III had failed to do its job. Immunizing people against diseases was not bad, he said. But he noted that Dengvaxia, which its manufacturer, Sanofi Pasteur, said could worsen symptoms in vaccinated people who had no previous exposure to the dengue virus had not been tested when the Aquino administration approved its use for children and adults in 2016
10th Dec 2017 - Inquirer.net


Industry News - Seqirus Media Monitoring - 8th Dec 2017

    View this newsletter in full

America, it's time to get ready for the flu

A roundup of useful information now the flu season has started in the U.S., including the fact there are 3 antivirals available and effective against the flu strains currently in circulation. They are: Tamiflu (oseltamivir), Relenza (zanamivir) and Rapivab (peramivir). The drugs stop new flu viruses from leaving their host cell and finding new cells to infect
7th Dec 2017 - Los Angeles Times

Philippines threatens Sanofi with legal action over dengue vaccine

The Philippines plans to sue Sanofi over its dengue fever vaccine in response to the French drugmaker’s warning that the drug could lead to severe infections in some cases, the country’s health secretary said on Thursday. The country’s regulators on Monday suspended sales of Dengvaxia, which has been used in the world’s first mass immunisation programme against dengue fever, after Sanofi said the drug could worsen symptoms of dengue fever among people who had not been infected by the virus before vaccination.
7th Dec 2017 - Financial Times

What the future of medicine looks like

Norbert Bischofberger, Vice President and Research Director of Gilead Sciences in California, one of the largest biotech companies in the world is a biochemist who helped develop the anti-influenza drug Tamiflu, anti-HIV drugs, and new anti-hepatitis C therapies that cure more than 90 percent of patients. On Tuesday he spoke at the Austrian Academy of Sciences in Vienna about the "Future of Medicine: Technology and Personalized Therapy".
7th Dec 2017 - Kurier.com


Industry News - Seqirus Media Monitoring - 7th Dec 2017

    View this newsletter in full

Third Respiratory Assay Now FDA Cleared on Hologic's New Panther Fusion System

Hologic announced today that it has received 510(k) clearance from the U.S. FDA for its Panther Fusion AdV/hMPV/RV assay, a multiplexed assay that runs on the new Panther Fusion system. The new assay detects Adenovirus, human Metapneumovirus, and Rhinovirus. It is the third diagnostic assay available on the Panther Fusion system, complementing the Panther Fusion Flu A/B/RSV assay and the Panther Fusion Paraflu assay, which both received clearance in October 2017.
6th Dec 2017 - PR Newswire

Flu cases double as experts worry this season could be particularly bad

This year's flu vaccine may not be as helpful as in years past. The one used in Australia was only 10 percent effective. Researchers warned the implications for the Northern Hemisphere may not be the same, although the vaccine Australia used has the same composition as the one the U.S. is using. As of Nov. 24, about 148.2 million doses of the vaccine have already been administered in the U.S. A spokeswoman for Sanofi Pasteur cautioned the research only analyzed Australia, so these findings may not reflect what will happen in the U.S.
6th Dec 2017 - CNBC

15 For '18: Key Clinical Data to Watch For Next Year

Among some of 2018’s most important clinical data are Moderna's experimental mRNA flu vaccines. This year, Moderna reported that its two experimental mRNA flu vaccines were well tolerated. Next year, Moderna plans to publish complete findings from the phase 1 studies of mRNA-1440 and mRNA-1851, meant to protect against the H10N8 and H7N9 flu strains, respectively. Both strains are thought to have pandemic potential
6th Dec 2017 - Xconomy

The 2 Likely Reasons Novavax Rocketed Higher by 25% in November

Shares of Novavax surged by 25% during the month of November, according to data from S&P Global Market Intelligence. The reasoning for the move appears to be traceable to two catalysts: encouraging third-quarter results and also the expectation of a topline readout in its phase 1/2 clinical trial involving NanoFlu before the end of the year
6th Dec 2017 - Motley Fool

Majority of Adults Are Unaware of Recommended Adult Vaccines

The majority of adults are uninformed about the vaccines that are recommended for their age, and many fail to receive the vaccines recommended in adulthood, according to a new Vaccinate for Life survey commissioned by GSK and conducted by Ipsos MORI. Leonard Friedland, MD, Vice President and Director of Scientific Affairs and Public Health, Vaccines, North America, for GSK said he believes the results of the survey indicate that adults are failing to take full advantage of the tools at their disposal to prevent serious illness and disease
6th Dec 2017 - Modern Medicine

Sanofi Discontinues Clostridium Difficile Candidate in Blow to Vaccine Unit

Shuttering of the Cdiffense program marks a second setback for Sanofi’s vaccines unit—albeit amid generally strong revenue growth, particularly in Europe. Unlike some of its peers in the industries, Sanofi has been investing more resources into vaccine development. Last month, the company announced that it would spend $200 million to expand a manufacturing facility in France to better support production demand for flu vaccines. And earlier this year, Sanofi bought Protein Sciences for $650 million upfront
5th Dec 2017 - Managed Care magazine

Flu vaccinations at your local supermarket

The US healthcare industry is facing massive changes, as demonstrated by the upcoming purchase of Aetna health insurance by the largest US drug and pharmacy chain, CVS. This is one of the world's largest acquisitions this year. Including assumed debt is about a purchase price of about 77 billion US dollars (64.7 billion euros). The regulators and shareholders still have to agree. The merger is intended to create a new group in the field of healthcare and health care. Economists wonder if similar transactions will occur in Europe as well.
5th Dec 2017 - DiePresse.com


Industry News - Seqirus Media Monitoring - 6th Dec 2017

    View this newsletter in full

Sanofi continues to seek clinical trial waiver in India for controversial dengue vaccine

Sanofi said it will continue to seek a phase 3 clinical trial waiver in India for its dengue vaccine, even as countries like the Philippines have initiated investigation on possible adverse effects of the vaccine on people. Sanofi has come under criticism for its lack of transparency while launching its vaccine
6th Dec 2017 - Economic Times

Why You May Feel Like Garbage After You Get the Flu Shot

You cannot catch the flu from a flu shot, but there can be reaction symptoms. Symptoms of the FluMist vaccine include runny nose or nasal congestion, fever, and sore throat. You can also experience muscle aches, decreased appetite, or lethargy
5th Dec 2017 - Mens Health

Sanofi discontinues C. diff candidate in blow to vaccine unit

Sanofi will shut down further development of its C. difficile vaccine following a review by an independent data monitoring committee that found the study unlikely to meet its primary goal. In its short release announcing the setback, the company said it would focus resources on six "key vaccine projects." Sanofi lists three other vaccines currently in Phase 3 in its pipeline, including a quadrivalent flu vaccine and a conjugate meningococcal vaccine
5th Dec 2017 - Biopharmadive.com


Industry News - Seqirus Media Monitoring - 5th Dec 2017

    View this newsletter in full

Philippines orders probe into Sanofi dengue vaccine for 730,000 children

The Philippines ordered an investigation on Monday into the immunization of more than 730,000 children with a vaccine for dengue that has been suspended following an announcement by Sanofi that it could worsen the disease in some cases. The WHO said it hoped to conduct a full review by year-end of data on the vaccine
4th Dec 2017 - Reuters

Philippines Orders Probe into Suspended Dengue Vaccine Administered to 730000 Kids


4th Dec 2017 - Scientific American

Risa says Sanofi must pay over Dengvaxia mess


4th Dec 2017 - InterAksyon

Philippines launches probe into dengue vaccine scare


4th Dec 2017 - BBC News

Sanofi says it is cooperating with gov't on dengue vaccine


4th Dec 2017 - ABC News

What you need to know about vaccine company Sanofi Pasteur


1st Dec 2017 - Rappler

Cloud, AI help Vancouver biotech detect deadly diseases in the air

A Vancouver startup that detects deadly pathogens in the air before they strike humans is getting a shot in the arm from IBM Corp.’s cloud and machine learning technologies. The OneTest platform from Fusion Genomics is designed to spot contagious diseases like Zika virus, avian flu and swine flu while they’re still airborne but haven’t infected humans yet
4th Dec 2017 - IT Business.ca

Trouble mounts for Sanofi dengue vaccine over safety concerns

The WHO hopes to review safety data on Sanofi’s dengue vaccine this month, while the Philippines ordered an investigation of its now suspended massive immunization program after the French drugmaker said it could actually worsen the disease in some cases. Sanofi attempted to allay concerns, saying in a statement that “the vast majority of those vaccinated to date live in high endemic settings and, therefore, will have had a prior dengue infection before vaccination.”
4th Dec 2017 - Reuters

CVS is said to agree to buy Aetna - deal could reshape the healthcare industry

CVS Health has agreed to buy Aetna for about $69 billion in a deal that would combine the drugstore giant with one of the biggest health insurers in the U.S. and has the potential to reshape the nation’s health care industry. The transaction reflects the increasingly blurred lines between the traditionally separate spheres of a rapidly changing industry. It represents an effort to make both companies more appealing to consumers as health care that was once delivered in a doctor’s office more often reaches consumers over the phone, at a retail clinic or via an app
3rd Dec 2017 - New York Times

CVS, Aetna executives defend $69 billion deal to skeptical Wall Street


4th Dec 2017 - Reuters


Industry News - Seqirus Media Monitoring - 4th Dec 2017

    View this newsletter in full

Shri J P Nadda reviews the preparedness on Seasonal Influenza (H1N1) Highlights importance of intensive vigil, early detection and treatment

In India, Shri J P Nadda, Union Minister of Health and Family Welfare, has issued directions to monitor seasonal influenza cases with particular focus on creating awareness, ensuring availability of medicines and vaccines at field level and effective and early treatment of patients as per protocol. During the meeting, it was observed that there are sufficient tablets of Oseltamivir for early treatment
2nd Dec 2017 - Business Standard

Nadda asks states to monitor H1N1 cases


2nd Dec 2017 - Press Trust of India

Location, location, location: Immunization delivery site matters

In vaccination, a certain subpopulation of dendritic cells is vital to triggering the body's adaptive immune system, report researchers at The Jackson Laboratory (JAX), Yale University and Astra-Zeneca. Their findings have important implications for vaccine delivery, as the usual method, intramuscular injection, is likely not the most effective way to target those dendritic cells.
1st Dec 2017 - Science Daily

The effectiveness of vaccines depends on where you inject them - study


2nd Dec 2017 - Alta Densidad

Virginia Tech flu season forecasting now part of AccuWeather

Researchers at Virginia Tech have developed a way to predict when the flu will impact certain areas and how many people could become sick. The tool will be part of AccuWeather's forecast beginning next year. This new platform gives people potential to curb the number of flu cases
30th Dec 2017 - WDBJ7

Brexit impact on UK pharma industry to be investigated

Brexit may affect the cost of medicines and hit UK pharmaceutical investment, a Commons committee head has warned. Rachel Reeves, who chairs the Business, Energy and Industrial Strategy committee, says access to new medical products may also be at risk. The MPs' inquiry comes despite the announcement of two big deals in the UK's pharma sector. The government said then that the decisions by MSD, known as Merck in North America, and Qiagen illustrated confidence in its industrial strategy for when the UK leaves the EU. More major investment for the sector is due to be announced soon, with GlaxoSmithKline expected to reveal a new research partnership
4th Dec 2017 - BBC News

Drugs giants warn of Brexit ‘disruption’ to their supply chain

The UK’s top pharmaceutical firms have warned MPs that a hard Brexit could cause “significant disruption” to the supply of medicines to patients. AstraZeneca and multinational giants including Johnson & Johnson, Roche and Merck have outlined their concerns in evidence submitted to the business select committee’s investigation into the 
potential impact of Brexit. The Association of the British Pharmaceutical Industry (ABPI) has also raised fears over the potential impact of a chaotic withdrawal from the EU
4th Dec 2017 - The Telegraph

Can we make a flu vaccine that lasts for life?

Peter Palese, a virologist at the Icahn School of Medicine at Mount Sinai, and his colleagues are developing vaccines that prompt your body to attack parts of the flu virus that aren’t constantly changing. “We are trying to redirect the immune system away from the decorative loops on the surface,” Palese says. The first versions of their vaccines are currently being tested in people by GSK and the Bill & Melinda Gates Foundation. Meanwhile, researchers in the UK are testing another flu vaccine that they hope will protect people for three or four years
2nd Dec 2017 - Popular Science

Where Will Novavax, Inc. Be in 5 Years?

Motley Fool writer Keith Speights explains why he thinks Novavax's NanoFlu will turn out to be a success in 5 years time, because of "overwhelmingly positive preclinical results". NanoFlu induced hemagglutination-inhibition and microneutralizing antibodies at much higher rates than Sanofi's current vaccines, Fluzone and Fluzone HD. Those responses were seen against a broad range of influenza subtypes
1st Dec 2017 - Madison.com


Industry News - Seqirus Media Monitoring - 1st Dec 2017

    View this newsletter in full

Johns Hopkins researchers discover mutation that may be key to return of popular nasal spray version of flu vaccine

Researchers believe they’ve figured out how to fix FluMist, which federal authorities told people to stop using last year because it offered little protection from the flu. A spokeswoman for MedImmune’s parent company, AstraZeneca, said they were aware of the findings and “look forward to reviewing the research.” The company, meanwhile, also has identified “multiple potential root causes and potential contributing factors” for the vaccine’s reduced effectiveness, she said
30th Nov 2017 - Baltimore Sun

Johns Hopkins researchers think they can fix flu mist vaccine


30th Nov 2017 - ABC2 News

Altering genetic mutation could enhance FluMist vaccine’s protective effect


30th Nov 2017 - News-Medical.com

Flu Scan for Nov 30, 2017; Feds on flu vaccine challenges; Mutation alteration for FluMist

Recent reports of mutations introduced by egg-based flu vaccine production arriving on the heels of a tough flu season in Australia raise worries about a similarly difficult season ahead for the U.S., experts said in a NEJM commentary. Researchers have identified a genetic mutation in the FluMist inhaled flu vaccine that might be used to restore the effectiveness of the vaccine.
30th Nov 2017 - CIDRAP


Industry News - Seqirus Media Monitoring - 30th Nov 2017

    View this newsletter in full

Genetic mutation could, if altered, boost flumist vaccine effectiveness, research suggests

Researchers at Johns Hopkins Bloomberg School of Public Health have discovered a genetic mutation in the FluMist intranasal flu vaccine that has the potential to be altered to enhance the vaccine's protective effect. When the researchers reversed the mutation in one of the viruses, the virus became more active, making copies of itself more quickly in cultured human nasal cells and inducing a stronger production of immune proteins
30th Nov 2017 - Science Codex

Health Dept takes stock of swine flu preparedness

In Chandigarh, India, the Health Department held a meeting to review the swine flu preparedness. Oseltamavir is now withdrawn from the X category drugs and can be sold under the schedule H1 drugs and the Cosmetics Act rules
29th Nov 2017 - The Tribune

UK and pharma industry call for transition period for medicines supply

With Brexit barely 15 months away, the UK government, as well as the European and British life science industry, is calling for a transition period on the regulation and supply of medicines in order to avoid potential disruptions in the market that will negatively affect patients. The European Council guidelines provide such transition arrangements, but according to the European Commission, it is still “too early” for this discussion
29th Nov 2017 - Euractiv.com

Bio-investment boasts do not diminish Brexit uncertainties

The UK government has outlined its industrial strategy as it prepares to leave the European Union and boasts of investments and collaborations driving the life science sector. However not all these investment boasts are clear-cut, and others have been put on hold as the companies 'wait and see'
29th Nov 2017 - Biopharma Reporter.com


Industry News - Seqirus Media Monitoring - 29th Nov 2017

    View this newsletter in full

Genetic mutation could, if altered, boost flumist vaccine effectiveness, research suggests

Researchers at Johns Hopkins Bloomberg School of Public Health have discovered a genetic mutation in the FluMist intranasal flu vaccine that has the potential to be altered to enhance the vaccine's protective effect. When the researchers reversed the mutation in one of the viruses, the virus became more active, making copies of itself more quickly in cultured human nasal cells and inducing a stronger production of immune proteins
28th Nov 2017 - EurekAlert

Genetic mutation could, if altered, boost flumist vaccine effectiveness, research suggests


28th Nov 2017 - Science Daily

Genetic mutation could, if altered, boost flumist vaccine effectiveness, research suggests


28th Nov 2017 - Medical Xpress

Lock up children if they get the flu, says health ministry

Young flu patients should be locked indoors for the first two days when they recuperate at home to stop them from suffering accidents such as jumping out of windows or falling off balconies, the Japanese health ministry has warned. External doors and windows should be locked and the young person should sleep in a room that has no access to a balcony, the alert states. It was sent out to all prefectural governments Nov. 27 as fatal accidents caused by the abnormal behavior of sufferers are still being reported regardless of whether they are taking antiviral medication or not
28th Nov 2017 - Asahi Shimbun

Chinese venture is healthy addition for Astrazeneca

Astrazeneca has stepped up its efforts to displace Pfizer as the largest pharmaceuticals multinational in China by launching a joint venture with the state-backed Chinese Future Industry Investment Fund. The pair are establishing a new company, Dizal Pharmaceutical, to discover, develop and commercialise new medicines for the market in China
28th Nov 2017 - The Times

Celia Schiffer joins collaboration to develop avian flu vaccine

Celia A. Schiffer, PhD, professor of biochemistry & molecular pharmacology and director of the Institute for Drug Resistance at UMass Medical School, is taking part in a $5.8 million NIH-funded collaboration to develop a protective vaccine against avian influenza A. Dr. Schiffer and colleague Nese Kurt Yilmaz, PhD, assistant professor of biochemistry & molecular pharmacology, will work with scientists with a wide range of influenza expertise at EpiVax, Sanofi Pasteur and the University of Georgia to develop a new vaccine capable of eliciting an immune response strong enough to protect humans from a new, high-mortality, avian influenza
28th Nov 2017 - umassmed.edu

AccuWeather Helps Brands Get Ahead of the Flu with Application of Virginia Tech's EpiCaster Outbreak Projections

AccuWeather has announced an agreement with the Biocomplexity Institute of Virginia Tech, enabling AccuWeather to leverage EpiCaster forecast data to deliver contextually relevant information to people in parts of the U.S. where the EpiCaster tool indicates flu outbreaks are likely -- more than three weeks in advance of outbreak occurrences. AccuWeather and institute researchers will map locations where flu outbreaks are more likely, benefiting AccuWeather app users and helping individuals and families take precautions during seasonal flu outbreaks
28th Nov 2017 - AccuWeather.com

Government’s Industrial Strategy paves way for industries of the future

The UK government has published its Industrial Strategy White Paper, showing how it will invest in skills, industry and infrastructure to help businesses create better, higher-paying jobs. Mike Thompson, chief executive of the Association of the British Pharmaceutical Industry said it was significantly important in providing a long-term strategic roadmap for UK businesses. Ahead of the publication of the White Paper, the government announced that MSD (Merck) is set to make a “major investment” into the UK with the opening of a new London-based life sciences discovery centre
28th Nov 2017 - Pharmaceutical-Journal.com


Industry News - Seqirus Media Monitoring - 28th Nov 2017

    View this newsletter in full

AstraZeneca steps up China push with new drug joint venture

AstraZeneca plans to turbo-charge its Chinese business through a new drug development joint venture with a state-backed private equity fund. The stand-alone business, Dizal Pharmaceutical, will be owned equally with the Chinese Future Industry Investment Fund (FIIF), which is part-owned by the China State Development & Investment Corporation, the companies said
27th Nov 2017 - Reuters

Azerbaijan's Healthcare Ministry on antiviral drugs linked to suicide attempts in Japan

Antiviral drugs that have been linked to suicidal tendencies in patients in Japan are not sold in Azerbaijan, the Center for Analytical Expertise of the country’s Healthcare Ministry told Trend on November 27th. Earlier, the Ministry of Health, Labor and Welfare of Japan released information on 54 recorded suicide attempts of children and teens who had used Tamiflu, Laninamivir and Relenza. These drugs cause abnormal behavior among children and teens, and Tamiflu stopped being recommended for them in Japan years ago
27th Nov 2017 - Trend News Agency

Protect yourself this flu season and reduce your risk of illness with preventative steps

Vaccination to prevent the flu is particularly important for people who are at high risk of serious complications from influenza. The Fluzone High-Dose seasonal influenza vaccine is designed specifically for people 65 years and older. A higher dose of antigen in the vaccine is supposed to give older people a better immune response, and therefore, better protection against flu
27th Nov 2017 - NWHerald.com

News Scan for Nov 27, 2017: Saudi MERS cases; Peds Tamiflu review

Oseltamivir (Tamiflu) treatment for flu in children reduces the length of illness and reduces the risk of ear infection, according to a new meta-analysis that folded in results from the latest randomized placebo-controlled trials. "Our analysis is reassuring that in uncomplicated influenza oseltamivir appears to be as safe and effective in children as among adults," the team wrote, noting that the drug's role in preventing ear infection is also important. They said the findings support current policies and reinforce recommendations that treatment is most useful when started early after illness inset
27th Nov 2017 - CIDRAP


Industry News - Seqirus Media Monitoring - 24th Nov 2017

    View this newsletter in full

Japan's government to urge preventive action by local authorities on accidents linked to flu drugs and fevers

The central government in Japan is urging local governments to take measures to reduce the risk of flu-linked accidents, after at least 54 events involving people with flu — mostly children — were reported last season across the nation. According to the ministry’s report about adverse effects, a total of 54 cases of abnormal behavior — including jumping or falling — were observed among patients who took flu medicines. Of those cases 38 were associated with Tamiflu, while another 11 and five cases were associated with Relenza and Inavir respectively
23rd Nov 2017 - The Japan Times

Japanese survey shows abnormal behaviour after patients take certain flu medications


23rd Nov 2017 - China Times

Japan asks local gov'ts to take steps to curb flu-linked accidents


23rd Nov 2017 - Japan Today

Vietnam will produce its own avian flu vaccine

Vietnam will produce its own vaccine against avian influenza A / H5N1 starting in 2018 to replace imported ones, according to the veterinary medicine company Navetco. The inactivated oil-emulsion vaccine was developed by the Navetco deputy general manager, Dr. Tran Xuan Hanh, and able to protect poultry against different avian flu viruses, including H5N1 and H5N6. The product was tested at the National Veterinary Medicines Control Center and meets safety standards. Navetco has also developed a set of standards for the manufacture, testing, preservation and use of the vaccine
23rd Nov 2017 - Vietnam+


Industry News - Seqirus Media Monitoring - 23rd Nov 2017

    View this newsletter in full

Novavax's November Jump: The Start Of Something Bigger?

Novavax shares have spiked this month; the rise has been driven principally by the expectation of topline data from the NanoFlu flu vaccine trial. NanoFlu offers a lot to be excited about, and has been a major factor in analyst upgrades over the past few months. The efficacy of NanoFlu in preclinical trials was certainly impressive
22nd Nov 2017 - Seeking Alpha

Russia’s Natsimbio to invest $100 million in establishment of vaccines production in Ufa

The National Immunobiological Company, Natsimbio, Russia’s leading vaccines’ producer, plans to invest 6 billion roubles (upwards of $100 million) in the construction of a plant for the production of vaccines in the Russian city of Ufa, according to recent statements of the company's general director Maryam Khubieva. The project will be implemented by Natsimbio’s subsidiary Microgen. The plant will produce vaccines for the national calendar of preventive vaccinations, as well as drugs that Microgen plans to produce as part of the technology transfer
20th Nov 2017 - Remedium.ru

Russia’s Natsimbio to invest $100 million in establishment of vaccines production in Ufa


20th Nov 2017 - The Pharma Letter


Industry News - Seqirus Media Monitoring - 22nd Nov 2017

    View this newsletter in full

Flu vaccine cost NHS £4,300 per dose

In the UK, the Department of Health and Social Care says the most expensive drug it bought last year was a flu vaccine - costing more than £4,300 a dose. A freedom of information request asked for the health system's dearest drugs, and the department listed 24 pharmaceutical products that cost more than £1,000 each. Topping the list was five doses of Imuvac, which immunises against H1N1 swine flu, at a total cost of £21,624.60
21st Nov 2017 - three.fm


Industry News - Seqirus Media Monitoring - 21st Nov 2017

    View this newsletter in full

BiondVax and NIH Sign Clinical Trial Agreement for a Phase 2 Trial in the U.S. with BiondVax's Universal Flu Vaccine

In the U.S., BiondVax announced the signing of the clinical trial agreement for a Phase 2 clinical trial with NIAID. The study is titled "A Phase II, Double-Blind, Multicenter, Randomized, Placebo-Controlled Trial to Assess the Safety, Reactogenicity, and Immunogenicity of Two Doses of Multimeric-001 (M-001) Followed by Seasonal Trivalent Influenza Vaccine." It is designed to evaluate the cell mediated immunity directly induced by BiondVax's universal flu vaccine candidate M-001, as well as M-001's priming effect to enhance the immunogenicity of current seasonal influenza vaccines
20th Nov 2017 - Yahoo Finance

BiondVax and NIH sign clinical trial agreement for phase 2 trial for universal flu vaccine


20th Nov 2017 - Reuters

BiondVax and NIH Sign Clinical Trial Agreement for a Phase 2 Trial in the US with BiondVax"s Universal Flu Vaccine


20th Nov 2017 - PR Newswire (press release)

BiondVax teams up the NIH's NIAID in mid-stage study of flu vaccine candidate M-001


20th Nov 2017 - Seeking Alpha

Vaxigrip influenza vaccine shipped to Ukraine was made in France

The influenza vaccine Vaxigrip shipped to Ukraine for the current epidemiological season was made in France, Head of the vaccines department of Sanofi in Ukraine Olena Yentina has told Interfax-Ukraine. A parliamentary committee had sent a request to the Health Ministry asking for all the documents concerning supplies of flu vaccine shipped by Sanofi to Ukraine as they believed it was made in India
20th Nov 2017 - Interfax-Ukraine


Industry News - Seqirus Media Monitoring - 20th Nov 2017

    View this newsletter in full

Sanofi: UGA, Sanofi Pasteur develop new broadly protective vaccines for H3N2 influenza

A collaborative R&D partnership between researchers at the University of Georgia and Sanofi Pasteur has resulted in the identification of a vaccine candidate that protects against multiple co-circulating strains of H3N2 influenza isolated over five seasons following testing in mouse and ferret models
19th Nov 2017 - 4 Traders

3 Reasons Novavax Stock Could Double in 2018

Despite its topsy-turvy moves over the last 11 months or so, next year could shape up to be much better for Novavax. Should NanoFlu prove to be as successful in the late-stage study as it was in pre-clinical testing going up against Sanofi's Fluzone and Fluzone HD, Novavax could have a huge winner on its hands
18th Nov 2017 - Madison.com

How to Prepare for Cold and Flu Season

The flu is an underappreciated danger that kills thousands each year. The first tip to stay safe is to get the flu vaccine, according to Dr. Julie Brandies, a physician at Advocate South Suburban Hospital in the greater Chicago metropolitan area. There’s virtually no reason to not get one. Antivirals like oseltamivir (Tamiflu) and zanamivir (Relenza) require a doctor’s prescription and only help if taken within 48 hours of symptoms starting
17th Nov 2017 - New York Times

This Canadian company is on the forefront of global efforts to stop the next pandemic

Vancouver-based gene sequencing company Fusion Genomics is using IBM’s cloud capabilities to revolutionize the diagnostic process, aiming to give physicians an eight-hour turnaround in correctly identifying any type of pathogen, from the common flu bug to avian flu and hepatitis.
17th Nov 2017 - Cantech Letter


Industry News - Seqirus Media Monitoring - 17th Nov 2017

    View this newsletter in full

Nasal flu spray stocks in short supply, public health says

Ottawa Public Health is cautioning parents that it is running short of FluMist inhalable flu protection. The health officials said more FluMist is on order and the city expects its supplies to be replenished by next week
16th Nov 2017 - Ottawa Citizen

Provincial shortage of FluMist


16th Nov 2017 - CTV Ottaw

FluMist Quadrivalent gains tentative approval

In Australia, following a review of FluMist Quadrivalent influenza virus vaccine nasal spray’s quality, safety and efficacy—the findings of which were published in an Australian Public Assessment Report—the TGA has approved the registration of FluMist Quadrivalent for the prevention of influenza in children and adolescents from 24 months to less than 18 years of age
16th Nov 2017 - Australian Journal of Pharmacy

New Swine Inactivated Mucosal Flu A Virus Vaccine from Aptimmune

Aptimmune introduces the industry’s first inactivated mucosal influenza A virus in swine (IAV-S) vaccine administered via nasal spray. Aptimmune’s IAV-S vaccine utilizes the BARRICADE proprietary vaccine formulation that gives swine producers and veterinarians a completely different approach to conventional inactivated injectable and live virus vaccines for safely preventing and managing respiratory disease
16th Nov 2017 - AgWired

Multinationals struggle in battle with local drugmakers

In Korea, an increasing number of multinational pharmaceutical giants are losing their battle against local drugmakers, armed with generic copies. Roche recently canceled its plan to release Tamiflu Suspension Powder 12 mg. The product had been approved by the health authorities, but the company did not launch it. Observers said Roche did not need to maintain the approval for the 12 mg product because generic copies of Tamiflu poured into the market, following the expiration of Tamiflu’s patent
16th Nov 2017 - Korea BioMed


Industry News - Seqirus Media Monitoring - 16th Nov 2017

    View this newsletter in full

Aptimmune launches inactivated mucosal influenza A virus vaccine in swine (IAV-S)

Aptimmune has introduced the industry’s first inactivated mucosal influenza A virus in swine (IAV-S) vaccine administered via nasal spray. Aptimmune’s IAV-S vaccine utilizes the BARRICADE proprietary vaccine formulation that gives swine producers and veterinarians a different approach to conventional inactivated injectable and live virus vaccines for safely preventing and managing respiratory disease
15th Nov 2017 - Feedstuffs.com

Sanofi: UGA Research Team Explores Impact of Age on Response to Influenza Vaccine

A team of researchers at the Center of Vaccines and Immunology at the University of Georgia has published a study that examines the relationship between age and previous exposure to influenza on a population's reaction to the flu vaccine. The study is the product of an ongoing collaboration between UGA and Sanofi Pasteur. The team examined volunteers aged 18 to 85 in four consecutive flu seasons between 2013 and 2016. Each volunteer was vaccinated with Fluzone
15th Nov 2017 - 4 Traders

Sanofi brings innovative medication to Saudi Arabia

Sanofi is planning to introduce innovative new medication in Saudi Arabia to help treat various diseases, as well as the most recent innovations in vaccines. “Our collaboration with the MoH also stretches into the vaccines area, supporting key projects like the National Flu Vaccination Program, which started in 2014 and has been hugely successful, especially in the target patient populations (i.e. chronic-disease patients, health care professionals, children and the elderly). The vaccination rates in the Kingdom are now among the best in the region, if not globally,” Ahmed Serag, Sanofi’s KSA country chair and general manager, said
16th Nov 2017 - Arab News


Industry News - Seqirus Media Monitoring - 15th Nov 2017

    View this newsletter in full

Cadila Healthcare's Q2 net up 33% to Rs 503 cr

In India, Cadila Healthcare reported a net profit growth of 33 per cent in second quarter ended September 30. During the quarter, the company launched four new products in the US including Mesalamine Delayed Release 1.2 g tablets and approval for 32 new products, including the generic version of Tamiflu suspension (Oseltamivir Powder for Oral Suspension 6 mg/ ml)
14th Nov 2017 - Business Standard

Fluarix Tetra to be reimbursed by French state healthcare

The trade publication for the pharmaceutical industry reports that in France, the flu vaccine Fluarix Tetra is set to be reimbursed at a rate of 65% by the state healthcare programme from 18th November 2017
14th Nov 2017 - Le Moniteur des Pharmacies

Opinion: Where's the data? Missing trial results undermine pandemic preparedness

In the fight to control global pandemics, public health agencies and governments face a monumental challenge: The results of around half of all clinical trials are not public, leaving huge gaps in medical knowledge. The invisibility of medical research results may make it difficult, if not impossible, to tell which drugs and vaccines work. Tamiflu remains a useful example of what can go wrong
14th Nov 2017 - Devex

New survey shines light on critical gaps in adult vaccination knowledge

A new survey shows that among some adults in America there is a lack of awareness around the immunizations they may need as adults. The survey, commissioned by GSK and conducted by Ipsos MORI, showed that fewer than three in ten Americans are aware of and have received the vaccines recommended for adults their age, with 65 percent of adults not up to date. Knowledge that vaccines prevent the flu and tetanus is high, but adult vaccination rates for these diseases and others remain low
14th Nov 2017 - Markets Insider.com

UGA research team explores impact of age on response to influenza vaccine

A team of researchers at the Center of Vaccines and Immunology at the University of Georgia has published a study that examines the relationship between age and previous exposure to influenza on a population's reaction to the flu vaccine. The study is the product of an ongoing collaboration between UGA and Sanofi Pasteur. The goal of this research is to develop a more broadly protective influenza vaccine that could protect against multiple strains of the virus as an improvement to the current vaccine
14th Nov 2017 - UGA Today

Celltrion to test combo therapy of new flu antibody drug, Tamiflu

In Korea, Celltrion said it plans to launch a clinical trial on a combination therapy of CT-P27, a new influenza antibody therapy to treat patients with influenza A, and Tamiflu. The Ministry of Food and Drug Safety approved the firm’s plan for phase 2a clinical trial on CT-P27. Celltrion hopes that CT-P27 can replace existing flu treatments such as Tamiflu
14th Nov 2017 - Korea BioMed


Industry News - Seqirus Media Monitoring - 14th Nov 2017

    View this newsletter in full

The US is In The Golden Age of Vaccine Development

“We are at a golden age right now in vaccinology. The opportunities that we have to take advantage of the knowledge we have gained from immunology, biology, microbiology, and genomics, and to translate this into advances in patient care—this is absolutely incredible.” Those were the words of Leonard Friedland, MD, vice president, director of scientific affairs and public health, Vaccines, North America, at GlaxoSmithKline, and a representative member of the National Vaccine Advisory Committee at the Vaccines + Immunity: Examining Modern Medicine meeting
13th Nov 2017 - Contagionlive.com

Why Don't EMA and FDA Speak With the Same Voice on Flu Treatments? Researchers Investigate

New research digs into cross-national regulatory divergences, with a focus on why some US labels for certain flu treatments say the medicines have not been proven to reduce complications while EU labels claim the opposite. The authors of the research published in Health Research Policy and Systems focus their work on Relenza (zanamivir), which represents the first neuraminidase inhibitor (NI), a class of drugs also including the controversial Tamiflu (oseltamivir)
13th Nov 2017 - Regulatory Focus

Flu immunizations not affected by lack of FluMist

Parents are getting their kids immunized against the flu despite the fact that the nasal injected FluMist is out and the needles are back. “Our original concern was that the live attenuated influenza vaccine, FluMist, had a unique appeal as it wasn’t a shot, and we were worried that its withdrawal would spark a substantial decrease in influenza immunization for children,” said Jonathan Modie, communications officer at Oregon Health Authority
13th Nov 2017 - La Grande Observer


Industry News - Seqirus Media Monitoring - 13th Nov 2017

    View this newsletter in full

Two-thirds of adults are not up-to-date on their vaccines, survey finds

Despite the World Health Organization citing immunization as one of the most powerful and cost-effective interventions in public health, a new survey conducted by Ipsos MORI and sponsored by GSK Vaccines in Brazil, Germany, India, Italy and the United States found that 68% of adults are not up-to-date with the vaccines recommended for them. Almost three in 10 adults report not having had any of the vaccines potentially relevant to them within the past five years
11th Nov 2017 - Drug Store News

What’s the Link Between Flu and MS Relapses?

In the U.S., the CDC is urging everyone age 6 months or older to get the flu vaccine. Doctors say the need for a flu shot is especially important for people with multiple sclerosis. Dr. Amesh Adalja, an infectious disease specialist, recommends that MS patients get a flu shot that covers four different strains of the flu. And a particular type of quadrivalent vaccine may be the most effective, he says. “There’s emerging data that the recombinant quadrivalent vaccine called Flublok has more protection”
10th Nov 2017 - US News Health

British Biotech Develops Vaccines that Ignite our Entire Immune System Against Disease

Vaccitech is taking current shortcomings to make a better vaccine. So far, Vaccitech looks to be succeeding. Its universal flu vaccine generates a strong T-cell response and a better antibody response than the standard flu virus alone. Vaccitech will come up against fellow Brits, VirionHealth, which achieved a £13M IPO to support the development of its universal vaccine
10th Nov 2017 - Labiotech.eu


Industry News - Seqirus Media Monitoring - 10th Nov 2017

    View this newsletter in full

Here's Why the Best Is Yet to Come for Novavax

After reporting some encouraging pre-clinical results for experimental flu vaccine NanoFlu in ferrets, Novavax has decided to take on Sanofi's market-share-leading flu vaccine, Fluzone High-Dose. Novaxax is presently conducting a combined phase 1/2 trial pitting its NanoFlu vaccine against Sanofi's Fluzone High-Dose
9th Nov 2017 - Madison.com

AstraZeneca brightens forecasts as sales decline slows

AstraZeneca said its profits are unlikely to fall as far as previously feared this year, after the decline in sales of its older drugs slowed in the third quarter. Revenue in the three months to September increased 9 per cent year on year to $6.2bn, slightly above consensus forecasts of $6bn. The company said the impact from the loss of exclusivity on some of its main products receded over the period, with product sales falling only 3 per cent, compared to 11 per cent over the first half of the year
9th Nov 2017 - Financial Times

AstraZeneca sales decline slows as it waits for medicine to work


9th Nov 2017 - CNBC

AstraZeneca is part of remedy for UK despite value focus


9th Nov 2017 - Sky News

AstraZeneca Misses Q3 Earnings, Tweaks 2017 EPS View


9th Nov 2017 - Nasdaq

AstraZeneca rides China wave as rival GlaxoSmithKline struggles

AstraZeneca is enjoying booming drug sales in China, helped by reforms to the country’s regulatory system and an increased sales force, in sharp contrast to its British rival GlaxoSmithKline. China revenue in the third quarter increased by 12 percent at AstraZeneca and the country now accounts for 15 percent of its global product sales - a far higher proportion than at other big pharma companies
9th Nov 2017 - Reuters

Bovine antibodies could prevent flu outbreaks

SAB Biotherapeutics utilizes advanced science to produce antibodies from cattle to treat a variety of health conditions. SAB has just started its first clinical trials on influenza, reports Dairy Herd Management. According to the article, “SAB’s cattle are ready to produce the treatment. The new facility could make enough of the antibody to meet worldwide demand, using just 20% of its capacity”
9th Nov 2017 - Beef Magazine


Industry News - Seqirus Media Monitoring - 9th Nov 2017

    View this newsletter in full

GlaxoSmithKline appoints Hal Barron as R&D chief

Emma Walmsley has taken the next step in reshaping GlaxoSmithKline’s R&D operation by appointing Hal Barron, a renowned US expert in drug development, as chief scientist to succeed Patrick Vallance. Dr Barron is the latest major appointment the chief executive has made as she looks to stamp her authority on the pharmaceuticals division and improve GSK’s lacklustre performance in finding new blockbuster drugs
8th Nov 2017 - Financial Times

Roche, Calico vet Hal Barron takes GSK R&D hot seat, as Vallance out


8th Nov 2017 - FierceBiotech

GSK Poaches R&D Veteran To Boost Drug Development Potential


8th Nov 2017 - PharmPro.com

Novavax in position to seek flu vaccine approval in 2019

Novavax could file for regulatory approval to commercialize its flu vaccine candidate as early as 2019. CEO Stanley Erck said the company fully enrolled its phase 1/2 clinical trial for its flu vaccine candidate and expects data back by the end of the year. "Assuming that a variety of stars line up, this could lead to a phase 3 pivotal trial this time next year," Erck said. That could mean the company would file a biologics license application by 2019
8th Nov 2017 - The Business Journal

Collaboration between GPs and pharmacists key to increased flu vaccine uptake

Primary care workers, including pharmacists and GPs, should collaborate rather than compete to boost influenza vaccine uptake, according to David Bearman, chair of Devon Local Pharmaceutical Committee. Bearman was speaking following the completion of a Pfizer-sponsored six-month pilot collaboration between the Beacon Medical Group, which covers 33,000 patients across five GP surgeries and local branches of Boots, Well Pharmacy and Day Lewis. The programme aimed to increase flu vaccination uptake by building reciprocal links between GPs and pharmacists
8th Nov 2017 - Pharmaceutical Journal

New needle-free vaccines could mean the end of the flu shot

An article in Chemical & Engineering News (C&EN) describes advances in injection-free vaccination methods that are showing promise. Now that FluMist is losing its appeal, other solutions are being researched: oral administration, a spring-powered injector to shoot a vaccine in a fluid stream through the skin and into the muscle, a much smaller needle, and finally a small patch covered with microneedles
8th Nov 2017 - Eurekalert

Flu season is here, and experts are already concerned

Last year's seasonal flu vaccine effectiveness was just 42%, the US CDC estimated. Even if vaccinated, people had inadequate protection against the flu. This limited effectiveness was due to a mutation that occurred in the influenza A (H3N2) vaccine strain, according to a study. This vaccine mutation resulted from an egg-based manufacturing process commonly used today
8th Nov 2017 - CNN

Experts Concerned About Effectiveness Of This Year’s Flu Vaccine


8th Nov 2017 - CBS Boston

Why the flu vaccination is so important to me

Olympian runner Paula Radcliffe explains why, being asthmatic, she takes flu vaccination seriously, and has teamed up with Sanofi Pasteur to encourage people to get their flu shot
8th Nov 2017 - Huffington Post UK


Industry News - Seqirus Media Monitoring - 8th Nov 2017

    View this newsletter in full

Alvogen becomes first authorised to commercialise generic equivalent for Tamiflu in powder form for oral suspension

Alvogen has received authorisation from the FDA for commercialisation in the U.S. of its generic equivalent of Tamiflu in 6mg powder form for oral suspension
7th Nov 2017 - iCrowdNewswire

Novavax Reports Third Quarter 2017 Financial Results

Novavax announced its financial results for the third quarter and nine months ended September 30, 2017. “We were very pleased to initiate and fully enroll the Phase 1/2 clinical trial of our NanoFlu vaccine candidate in older adults, following impressive results in preclinical challenge models. Given this timing, we are well positioned to announce data from the ongoing trial before the end of the year,” said Stanley C. Erck, President and CEO
7th Nov 2017 - EconoTimes

Novavax Reports Third Quarter 2017 Financial Results


7th Nov 2017 - Globenewswire.com

Sanofi's vaccines pick up pharma's slack—again—even as Dengvaxia languishes

Anyone hoping the launch for Sanofi's world-first dengue vaccine would ramp up after a lackluster first year is feeling only disappointment so far in 2017. Luckily for the French drugmaker, its other immunizations are performing far better. Sales for flu vaccines grew 1.8% to €951 million over last year
6th Nov 2017 - FiercePharma


Industry News - Seqirus Media Monitoring - 7th Nov 2017

    View this newsletter in full

Soriot ready to reveal if medicine is working

As Astrazeneca approaches Thursday’s third-quarter trading update, investors have been taking stock of where the failed Mystic trial has left the company. “Clearly Mystic was important to them, but it’s not the be all and end all,” said Richard Marwood, a senior fund manager at Royal London and an investor in Astrazeneca. “Maybe this realisation has come into the sentiment of shareholders. There are lots of irons in the fire still.”
6th Nov 2017 - The Times

Collaborative research identifies broadly cross-protective vaccines for H3N2 influenza

A collaborative research and development partnership between researchers at the University of Georgia and Sanofi Pasteur has resulted in the identification of a vaccine candidate that protects against multiple co-circulating strains of H3N2 influenza isolated over five seasons following testing in mouse and ferret models
6th Nov 2017 - Gears Of Biz

A Penn scientist says he knows why last year's flu vaccine was so bad

New research has found that a problem with the way flu vaccine is manufactured explains why many people who got flu shots last year got sick anyway. Scott Hensley and his team concluded that growing flu virus in chicken eggs introduced mutations that reduced vaccine effectiveness. Sanofi announced in July that it would acquire Protein Sciences, which makes Flublok, a non egg-based vaccine
6th Nov 2017 - philly.com


Industry News - Seqirus Media Monitoring - 6th Nov 2017

    View this newsletter in full

Influenza: GSK, free vaccinations for employees and family members

This year, GSK in Italy has decided to offer the quadrivalent flu vaccine free of charge, as well as the meningitis vaccine, to employees and family members who request it. Vaccinations will be given by the health service of the Verona-based GSK
5th Nov 2017 - Libero Quotidiano.it

Natco's partner Alvogen gets nod for influenza drug in US

Natco Pharma said its marketing partner Alvogen has received final approval to market oseltamivir phosphate powder used for the treatment of influenza in the US.
5th Nov 2017 - Economic Times

Human Vaccines Project Creates Research Program to Develop Universal Influenza Vaccines

The Human Vaccines Project recently announced the Universal Influenza Vaccine Initiative, a program that will aim to understand the human immune system’s role in the development of universal influenza vaccines. "There are many public and private sector resources dedicated to developing new and improved influenza vaccines, but they are all primarily focused on one part of the problem—making the vaccine,” said Wayne C. Koff, PhD, president and CEO of the Human Vaccines Project. “What makes the UIVI distinct is that we are focusing on understanding the second part of the puzzle—the human immune response. We have to find out what generates an effective immune response against influenza in all populations in order for a vaccine to be maximally effective"
3rd Nov 2017 - BioPharm International

Fed. Circ. Upholds Ruling That FluMist Didn't Kill Child

The Federal Circuit upheld a U.S. Court of Federal Claims special master’s decision that a flu vaccination made by AstraZeneca didn’t cause a girl with a mitochondrial disorder to die, finding that his ruling was “based on the record evidence and is not wholly implausible”
2nd Nov 2017 - Law360.com

New Vaccine Protects Against All Strains of H3N2 Influenza

A vaccine candidate that protects against multiple co-circulating strains of H3N2 influenza isolated over five seasons has been developed by a collaborative research and development partnership between researchers at the University of Georgia and Sanofi Pasteur
3rd Nov 2017 - Med India

Scientists Develop H3N2 Vaccine, Move Toward Universal Flu Shot


2nd Nov 2017 - Laboratory Equipment

Flu vaccine candidate protects against strains from 5 seasons


3rd Nov 2017 - Beckers Hospital Review

GlaxoSmithKline R&D chief Vallance to leave for government job: FT

GlaxoSmithKline’s long-standing president of R&D, Patrick Vallance, is said to be standing down. This is according to people “briefed on the situation” and quoted by London’s Financial Times. Vallance, who has been at the helm of the Big Pharma’s research for around six years, is reportedly leaving for a top science advisory post for the U.K. government
3rd Nov 2017 - FierceBiotech

GSK’s chief scientist leaves for senior UK government job


3rd Nov 2017 - Financial Times

Glaxosmithkline loses research boss to Whitehall


4th Nov 2017 - The Times

Here’s why this year's flu season was so bad

Australia has recorded 221,853 flu infections so far in 2017; a better vaccine could have reduced the rates, but not the high-dose Fluzone vaccine doctors were touting at the start of the week. Stopping flu viruses requires vaccines that are effective in those who most efficiently carry and spread the virus - pre-school and school-aged children
3rd Nov 2017 - Business Insider Australia


Industry News - Seqirus Media Monitoring - 3rd Nov 2017

    View this newsletter in full

Here’s why the 2017 flu season was so bad

Australia has recorded 221,853 flu infections so far in 2017; a better vaccine could have reduced the rates, but not the high-dose Fluzone vaccine doctors were touting at the start of the week. Stopping flu viruses requires vaccines that are effective in those who most efficiently carry and spread the virus – pre-school and school-aged children
2nd Nov 2017 - The Conversation

Here's why the 2017 flu season was so bad


2nd Nov 2017 - MENAFN.COM

Why high-dose flu vaccines wouldn't have stopped this year's horror season


2nd Nov 2017 - ABC Online

Here's why the 2017 flu season was so bad


2nd Nov 2017 - Medical Xpress

New broadly protective vaccines for H3N2 influenza

A collaborative research and development partnership between researchers at the University of Georgia and Sanofi Pasteur has resulted in the identification of a vaccine candidate that protects against multiple co-circulating strains of H3N2 influenza isolated over five seasons following testing in mouse and ferret models
2nd Nov 2017 - Science Daily

UGA, Sanofi Pasteur develop new broadly protective vaccines for H3N2 influenza


2nd Nov 2017 - EurekAlert

Team develops new broadly protective vaccines for H3N2 influenza


2nd Nov 2017 - Medical Xpress

Aviragen Therapeutics Reports First Quarter of Fiscal Year 2018 Financial Results

Aviragen announced its financial results for the three months ended September 30, 2017. “Earlier this week we were pleased to announce the culmination of our strategic review process with the signing of a definitive merger agreement with Vaxart, which we believe complements Aviragen’s focus on infectious diseases. With recently reported positive safety and efficacy data in both influenza and norovirus, Vaxart is well-positioned to create both short and long-term value for our stockholders,” said Joseph M. Patti, Ph.D., President and CEO of Aviragen
2nd Nov 2017 - Markets Insider

Flu proves to be a good revenue stream for Sanofi

Over the first 9 months of the year, Sanofi Pasteur's sales of flu vaccines were over a billion Euros. Sanofi is expanding one of its French plants in order to produce Vaxigrip Tetra; it is currently negotiating with the French government regarding pricing in France
2nd Nov 2017 - Le Monde

This Universal Jab Will Make the Flu a Horrible, Distant Memory

Dr. Anthony Fauci, the director of the National Institute of Allergy and Infectious Diseases (NIAID) under the National Institutes of Health, explains that “the efficacy of the seasonal [flu] vaccine is variable and never really is as effective as the vaccines we have for smallpox, measles, polio, and things like that.” He has made it a core mission of NIAID to develop a universal flu shot. The British are already ahead of the U.S. with human testing, with the NHS recruiting 500 patients aged 65 or older to take part in a new clinical trial to test an experimental flu vaccine
2nd Nov 2017 - The Daily Beast

Influenza surveillance with rapid test network a ‘win-win’ situation

Researchers have developed a method to transmit rapid influenza detection test results wirelessly, which may help realize the “long-sought after goal of real-time influenza surveillance,” according to findings in the Journal of the American Board of Family Medicine
2nd Nov 2017 - Healio.com


Industry News - Seqirus Media Monitoring - 2nd Nov 2017

    View this newsletter in full

FDA Grants Fast Track Designation to Visterra's VIS410 for Treatment of Hospitalized Patients with Influenza A

Visterra announced that the U.S. FDA has granted Fast Track designation to its lead product candidate, VIS410, a novel monoclonal antibody in development for the treatment of hospitalized patients with influenza A.
1st Nov 2017 - Business Wire

Flu not to be sneezed at

In Malaysia, flu is generally seen all year-round, with influenza A usually detected more frequently than influenza B. GSK has introduced Fluarix Tetra, an inactivated quadrivalent vaccine aimed to help curb the burden of flu and protect families across Malaysia. Unlike trivalent inactivated vaccines, Fluarix Tetra includes two A and two B strains, offering direct and broad protection against the four strains that account for almost all seasonal influenza cases globally
1st Nov 2017 - New Straits Times


Industry News - Seqirus Media Monitoring - 1st Nov 2017

    View this newsletter in full

Sanofi inks AI pact to learn more about flu vaccine responses

Sanofi Pasteur has tapped Berg's artificial intelligence capabilities to discover biomarkers that could help scientists learn more about individual flu vaccine responses. Sanofi Pasteur is running a longitudinal study on its licensed flu vaccines, while Berg will analyze the biological materials from individuals participating in that study using its bAIcis artificial intelligence tool. The goal is to identify “molecular signatures and biomarkers indicative of breadth and durability of the influenza vaccine immunological response”
31st Oct 2017 - FiercePharma

For an instant man-flu diagnosis on your phone, just swab right

An international flu symposium in Melbourne will hear an update from clinical trials of a device designed to give doctors and patients a simple and quick flu diagnosis. The ellume.lab works through an app instructing the ­patient or GP how to take a nasal swab and put the sample on a test cartridge which is inserted into a smartphone. The result is displayed on the phone along with advice on contacting medical services
1st Nov 2017 - The Australian

Novavax The Downtrodden Finally Finds A New Bull At Citi

Analysts at Citi turned bullish on Novavax; phase 1 and phase 2 data for its flu vaccine NanoFlu is expected to be released in the fourth quarter and will be followed up in first-quarter 2018 with the U.S. FDA's feedback. In the event that the FDA allows the company to proceed with an accelerated approval then a phase 3 program could be finalized by the end of next year
31st Oct 2017 - Benzinga

Novavax Stock Upgraded: 3 Things You Need to Know


31st Oct 2017 - Madison.com

Mexicans bring a new approach to the production of biopharmaceutical vaccines

University students and Mexican specialists are participating in the process of research and development of vaccines, in partnership with Sinergium Biotech, located in the province of Buenos Aires.
31st Oct 2017 - Hoy Tamaulipas

Aviragen, Vaxart merge to develop oral vaccines for influenza, norovirus and RSV

For some antigens like norovirus and RSV, there are no approved vaccines. For others, like the seasonal flu, immunization rates are often far from ideal. Now, a new company, the product of a merger between Aviragen Therapeutics and Vaxart, aims to develop oral vaccines against these diseases. An H1N1 influenza vaccine is currently farthest in the company’s pipeline
31st Oct 2017 - Fierce Pharma


Industry News - Seqirus Media Monitoring - 31st Oct 2017

    View this newsletter in full

BERG Enters Into an Agreement With Sanofi Pasteur to Identify Biomarkers of Flu Vaccine Performance

BERG, a biopharmaceutical company that merges biology with technology, announced a new research effort with Sanofi Pasteur: BERG will generate and model data using its proprietary Interrogative Biology platform to assess potential biomarkers of seasonal influenza vaccination outcomes in an unbiased and data-driven manner
30th Oct 2017 - PR Newswire UK

Sanofi turns to artificial intelligence to beat flu


30th Oct 2017 - Financial Times

Sanofi launches a campaign to create an avian flu vaccine for the future


31st Oct 2017 - Sciences et Avenir

Vaccin contre la grippe: Sanofi va faire appel à l"intelligence artificielle


30th Oct 2017 - La Libre.be

BERG Enters Into an Agreement With Sanofi Pasteur to Identify Biomarkers of Flu Vaccine Performance


30th Oct 2017 - Business Insider

Sanofi s"allie avec un spécialiste de l"IA pour développer un vaccin antigrippal


30th Oct 2017 - Usine Nouvelle

Iraq militia "funded" by British drug giant Astrazeneca: Lawyers claim bribes paid for weapons that killed soldiers

Astrazeneca is accused of funding a terrorist militia responsible for killing British soldiers in Iraq. The pharmaceuticals giant is one of several firms being dragged into a US court over allegations it bribed health officials who were aligned with Jaysh al-Mahdi, one of the most violent insurgent groups in Iraq
30th Oct 2017 - This is Money

Aviragen Therapeutics and Vaxart Enter into Merger Agreement

Aviragen Therapeutics, which is focused on the discovery and development of direct-acting antivirals to treat infections that have limited therapeutic options, and Vaxart, focused on developing oral recombinant vaccines based on its proprietary delivery platform that allows for administration by tablet rather than by injection, have entered into a definitive merger agreement. The merger will result in a combined company, Vaxart, focused on developing orally-delivered therapeutics and prophylactics to address a variety of viral infections
30th Oct 2017 - Econotimes.com

Budget vaccine blamed for record flu season

Immunisation Coalition chair Professor Paul Van Buynder has suggested that a cheap version of the flu vaccine may have influenced 2017’s “disaster year”. A stronger vaccine that costs slightly more per dose, Fluzone High-Dose, which has been found to be 24% more effective in preventing the flu, is not registered for use in Australia. Sanofi, supplier of flu vaccine in Australia, said that “suggestions the high rate of influenza in Australia in 2017 are in part a result of the supply of ‘cheap’ vaccine is incorrect”
30th Oct 2017 - Australian Journal of Pharmacies

Cheap flu vaccine blamed for horror season


30th Oct 2017 - Newburgh Gazette

Korea’s Pharmaceutical Exports Reach 3.6 Trillion Won

South Korea’s Green Cross won a US$37 million flu vaccine order through participation in a bid to supply vaccines for the Pan American Health Organization (PAHO) in March this year, ranking first in terms of market share in the international organization procurement market in the flu and varicella vaccine sector
30th Oct 2017 - Korea BioMed

Vaxart's oral flu vaccine tablet shows promise in human challenge trial

A phase 2 human-challenge trial of an oral tablet recombinant H1 flu vaccine showed similar protection as injectable quadrivalent flu vaccine, Vaxart said. The oral vaccine also showed favorable safety and tolerability profiles
30th Oct 2017 - CIDRAP

Korea strives to develop vaccines to reduce dependency on import

Government and business officials are trying hard to make Korea an independent country in vaccine supply. Vaccine shortage crises, including the H1N1 outbreak in 2009, and the annual polio vaccine shortage have emphasized the need to develop vaccines
30th Oct 2017 - Korea Biomedical Review


Industry News - Seqirus Media Monitoring - 30th Oct 2017

    View this newsletter in full

What Australia"s bad flu season might mean for us

FluMist is gone for now, but not forgotten by those who abhore needles. After studies showed that the nasal spray option did not protect as well against the H1N1 flu strain, manufacturers pulled it off the market. They’re working on a more effective version and as soon as they have one available — perhaps as early as next year — it likely will be available once more, experts say
28th Oct 2017 - USA Today

New initiative to accelerate development of universal influenza vaccines

The Human Vaccines Project has announced the launch of the Universal Influenza Vaccine Initiative (UIVI), a first-of-its-kind program that will address the underlying scientific barrier impeding the development of broadly protective, universal influenza vaccines: the human immune response
28th Oct 2017 - European Pharmaceutical Review

Flu vaccine make-up day

The flu vaccine for the 2017-2018 influenza season is now available at Argonne. This year the quadrivalent flu vaccine being offered is Flucelvax, which does not pose any risks for egg or latex allergies and does not contain thimerosal or antibiotics
26th Oct 2017 - anl.gov

Zydus Nesher Pharma gets USFDA nod to market influenza drug

Zydus Cadila said Nesher Pharmaceuticals, a subsidiary of its US arm, has received final approval from the US health regulator to market Oseltamivir used for treatment and prevention of influenza
29th Oct 2017 - health.economictimes.indiatimes.com


Industry News - Seqirus Media Monitoring - 27th Oct 2017

    View this newsletter in full

The Human Vaccines Project Launches New Initiative To Accelerate Development Of Universally Effective Influenza Vaccines

The Human Vaccines Project has announced the launch of the Universal Influenza Vaccine Initiative (UIVI), a first-of-its-kind program that will address the underlying scientific barrier impeding the development of broadly protective, universal influenza vaccines: the human immune response. The Project's influenza vaccine initiative will launch a series of influenza vaccine clinical trials in globally diverse populations beginning early in 2018
26th Oct 2017 - Streetinsider.com

The Human Vaccines Project Launches New Initiative To Accelerate Development Of Universally Effective Influenza Vaccines


26th Oct 2017 - The Business Journal

Vanderbilt leads international effort to create universal flu vaccine


26th Oct 2017 - WKRN

The Human Vaccines Project Launches New Initiative To Accelerate Development Of Universally Effective Influenza Vaccines


26th Oct 2017 - Business Insider

Vaxart Announces Positive Topline Results for its Oral Tablet

Vaxart announced today that its H1 influenza oral tablet vaccine demonstrated similar protection against influenza virus as the market-leading injectable quadrivalent influenza vaccine (QIV) in a clinical trial. These results met the efficacy objectives of the Phase 2 influenza A clinical study. The oral tablet vaccine also demonstrated a favorable safety and tolerability profile
26th Oct 2017 - Business Wire

GlaxoSmithKline"s new boss struggles to sell cure for drugmaker

Nearly seven months into the job, GlaxoSmithKline’s new chief executive is facing a battle to convince investors she has the right prescription for growth at Britain’s biggest drugmaker. Her declared interest in Pfizer’s consumer health unit - expected to carry a price tag of some $15 billion, or maybe more - has crystallized concerns
26th Oct 2017 - Reuters

Union suit: Essentia Health workers ordered to get flu shot or be fired

A labor union in the Duluth area wants a federal judge to prevent Essentia Health from firing employees who refuse to get a flu shot.
26th Oct 2017 - Minneapolis Star Tribune

New products boost Q3 sales at GSK

Vaccines sales remained flat at £1.7 billion, as a strong performance from meningitis vaccines and continued delivery from influenza products was countered by increased competitive pressures elsewhere.
26th Oct 2017 - PharmaTimes

GSK finances on target but wider picture brings 6% share price drop

There did not appear too much to worry investors in GlaxoSmithKline’s third-quarter financial results. In Vaccines, the top-seller was the influenza product Fluarix/FluLaval, with sales that rose 6% to £343 million
26th Oct 2017 - The Pharma Letter

GlaxoSmithKline Q3 2017: Bear Signals


26th Oct 2017 - Seeking Alpha

Contraflu Raises Funds to Run Pivotal Clinical Trial for Product to Target Drug-Resistant Influenza

The registration of Cont®aFlu in the EU will open up bidding to big pharma companies active in the flu market looking for a “definite blockbuster” in the niche. It marks the first patented OTC product for the self-treatment of flu that meets all customer needs, the company said in a press statement
26th Oct 2017 - Digital Journal


Industry News - Seqirus Media Monitoring - 26th Oct 2017

    View this newsletter in full

GlaxoSmithKline Q3 Pre-tax Profit Rises; Backs FY Adj. EPS Growth View

GlaxoSmithKline reported that its profit before tax for the third-quarter 2017 rose to 1.71 billion pounds from 1.27 billion pounds in the same quarter last year. Vaccines sales were up 5% AER, but flat CER, with a strong performance from Meningitis vaccines and continued delivery from influenza products offset by the impact of increased competitive pressures on Infanrix, Pediarix
25th Oct 2017 - Nasdaq

GSK shares dive on underwhelming update as CEO warns of Brexit costs this year

More than £4bn has been wiped off the market value of GSK after investors took a dim view of the company’s potential bid for Pfizer’s consumer health business and its perceived lukewarm commitment to a dividend
25th Oct 2017 - Telegraph

Correction to Glaxo Will Consider Bid for Pfizer Update

GlaxoSmithKline would consider a bid for Pfizer's consumer-health business should the U.S. company put it up for sale, Chief Executive Emma Walmsley said; GSK consumer-health sales grew in the last quarter, though revenue from vaccines was flat, largely because of strong demand for flu shots in the year-earlier period
25th Oct 2017 - Fox Business.com


Industry News - Seqirus Media Monitoring - 25th Oct 2017

    View this newsletter in full

U.S. vaccine panel to discuss waning effectiveness, new shots

The issue of waning vaccine protection is expected to be discussed when the Advisory Committee on Immunization Practices meets in Atlanta. The vaccine panel will hear an update about a nasal-spray version of flu vaccine that it stopped recommending after health officials said it wasn't working in U.S. kids
24th Oct 2017 - New York Daily News

U.S. panel to discuss vaccines' waning effectiveness, new shots


24th Oct 2017 - Philly Voice.com

U.S. vaccine panel to discuss waning effectiveness, new shots


24th Oct 2017 - Journal Gazette

U.S. vaccine panel to discuss waning effectiveness, new shots


24th Oct 2017 - Fox Business

Astrazeneca and GlaxoSmithKline top UK R&D spenders

The pharmaceutical industry accounted for nearly half of research and development spending in the UK, with Astrazeneca and GlaxoSmithKline the two biggest spenders, according to a new study
24th Oct 2017 - City A.M.

GlaxoSmithKline earnings: Vaccine sales in focus

GlaxoSmithKline will report its third-quarter earnings Wednesday; vaccines sales may take a dent because of a tough comparison with last year, when Glaxo had a strong flu season
24th Oct 2017 - MarketWatch

Vaccines may struggle as new flu strains emerge

In Ireland, the Health Service Executive is bracing itself for a winter flu crisis, following signals that existing vaccines may be unable to cope with new strains emerging in Australia and China
23rd Oct 2017 - Irish Times

Sanofi asks the world 'How are you?' in latest corporate branding campaign


24th Oct 2017 - PR Week

Shortage of swine flu vaccine in state: Official

A senior health official has alleged there is a shortage of swine flu vaccine in Maharashtra despite the government’s claims. On an average, 15-20 fresh positive cases of swine flu are being detected every day; every patient complaining of high-grade fever, cold, runny nose, and diarrhoea is meant to be given oseltamivir
25th Oct 2017 - Asian Age


Industry News - Seqirus Media Monitoring - 24th Oct 2017

    View this newsletter in full

Rapid Micro Biosystems Awarded a Contract by Biomedical Advanced Research and Development Authority (BARDA) for the Implementation of a Rapid Sterility Test for Vaccines

Rapid Micro Biosystems announced the receipt of a $7.3 million contract from the Biomedical Advanced Research and Development Authority (BARDA) for the implementation of a rapid sterility test for vaccines, as part of BARDA’s Advance Development of Medical Countermeasures for Pandemic Influenza, which focuses on improving the government’s responsiveness to future pandemic threats
23rd Oct 2017 - Globenewswire.com

Sanofi debuts new corporate signature, campaign to 'Empower Life' around the world

Sanofi launched a new corporate signature summing up its mission in two words: “Empowering Life.” The dedicated webpage offers more detail, including initiatives and stories about how Sanofi is doing just that. Some of the highlighted examples include reducing the burden of influenza, innovating in rare diseases, managing diabetes, preventing malaria and fighting pain
23rd Oct 2017 - Fiercepharma

Sanofi asks the world - 'How are you?' - in latest corporate branding


23rd Oct 2017 - PR Week

Warwick University: spin out VirionHealth raises £13M to develop anti-viral drugs

VirionHealth has raised up to £13 million in series A funding from the specialist life sciences venture capital group Abingworth. VirionHealth is exploiting its technology as the basis of a broad-spectrum therapy, potentially simplifying and accelerating treatment by removing the need for differential diagnosis. Initially focusing on influenza and respiratory syncytial virus, Virion says its technology can combat a range of viruses with a single therapeutic agent
23rd Oct 2017 - Science Business

Vaccines Demonstrates CureVac's RNActive Vaccine is Superior to Licensed Vaccines

CureVac announced the publication of a study demonstrating that vaccines based on its sequence optimized, chemically unmodified mRNA formulated in optimized lipid nanoparticles (LNPs) are highly immunogenic and well tolerated. The results showed that a single intramuscular vaccination with LNP-formulated, chemically unmodified mRNAs encoding rabies or influenza antigens leads to a strong induction of local innate immune responses and systemic adaptive immune responses. Notably, the humoral and cellular immune responses induced by LNP-formulated mRNA vaccines against rabies and influenza H3N2 were superior to Rabipur and Fluad
23rd Oct 2017 - PR Newswire.com

Flu clinics open in Calgary but kids' nasal spray not available

Several leading pharmacies in Calgary, Canada, said while they provide the regular flu shots they won’t be offering for sale FluMist this year, some saying it hasn’t been “approved” by health care authorities. In a statement, the AHS said the product “is no longer recommended by the National Advisory Committee on Immunization as a preferential vaccine for children, so Alberta Health didn’t order it.”
23rd Oct 2017 - Calgary Herald

Health leaders urge Albertans to get vaccinated as free flu clinics open


23rd Oct 2017 - Edmonton Sun

Flu shots start today across Alberta

Free vaccinations are now available in Alberta, Canada, for anyone aged six months and older at public health clinics, pharmacies and doctor’s offices across the province. This year's vaccine, called Fluzone, contains four strains of influenza virus and is being offered as an injection. FluMist will not be available
23rd Oct 2017 - Metro News.ca


Industry News - Seqirus Media Monitoring - 23rd Oct 2017

    View this newsletter in full

AstraZeneca EVP: Brexit is hindering our hiring

People are turning down jobs at AstraZeneca because of uncertainty about their right to stay in the United Kingdom after Brexit, according to Mene Pangalos. The AstraZeneca EVP said the ongoing lack of clarity about what will happen to Europeans in the U.K. after March 2019 is leading some scientists to opt for jobs in other countries
19th Oct 2017 - FierceBiotech

There is not enough Tamiflu in the pharmacies around Monterrey

Before the beginning of the flu season, Monterrey in Mexico is experiencing a shortage of Tamiflu, even though the flu vaccine campaign has begun
21st Oct 2017 - Multimedios.com

Flu Scan for Oct 20, 2017 - IV zanamivir in kids; H5N8 in Italy

A phase 2 study of intravenous (IV) zanamivir in children hospitalized with severe influenza found that treatment was safe, reduced viral load, and was associated with clinical improvement, researchers reported in an online edition of Pediatrics
19th Oct 2017 - CIDRAP


Industry News - Seqirus Media Monitoring - 20th Oct 2017

    View this newsletter in full

Roche 9-month Group Sales Rise; Confirms FY17 Forecast - Quick Facts

Roche reported that its Group sales for the first nine months of the year increased 5% to 39.43 billion Swiss francs from last year's 37.51 billion francs; there were lower sales of Tarceva, Avastin and Tamiflu
19th Oct 2017 - Nasdaq.com

Roche Q3 sales beat forecasts as Ocrevus shines


19th Oct 2017 - The Financial

ROCHE: ventes neuf mois en hausse de 5%


19th Oct 2017 - Boursarama

Neue Medikamente sorgen für Umsatzplus


19th Oct 2017 - Bluewin.ch

Neue Medikamente treiben Roche an


19th Oct 2017 - Basler Zeitung

Maryland is developing the next generation of life-saving vaccines

Immunomic Therapeutics' Athanasia Anagnostou writes in favour of vaccinations and urges people in her state of Maryland to get vaccinated against the flu and talk to their family doctor to ensure their vaccinations are up to date
19th Oct 2017 - Baltimore Sun

3 Reasons Cara Therapeutics Is a Better Growth Stock Than Novavax

Novavax announced very promising results from preclinical testing of its NanoFlu influenza vaccine in August. The vaccine could turn out to be a big winner for the company, but it's still early. Novavax began a phase 1/2 study in September. There are quite a few hurdles to jump before the company can claim success with NanoFlu.
19th Oct 2017 - Madison.com


Industry News - Seqirus Media Monitoring - 19th Oct 2017

    View this newsletter in full

FluGen Awarded $14.4 million by the Department of Defense to Test Universal Flu Vaccine Against Mismatched Strains

FluGen has been awarded a grant of $14.4 million through the DOD’s Congressionally Directed Medical Research Programs Peer Reviewed Medical Research Program’s mechanism to conduct clinical challenge-studies against mismatched influenza strains with its lead universal flu vaccine, RedeeFlu
18th Oct 2017 - BusinessWire.com

Can You Treat The Flu?

Flu treatment might include antiviral medications such as Tamiflu, available only by prescription. They lessen the severity and the duration of the illness, but are not effective unless started within 48 hours of symptom onset
18th Oct 2017 - New Hampshire Magazine

Ugly side of the common flu

Influenza may be a commonly-occurring respiratory tract infection in Malaysia but its severity should not be underestimated. Currently, there are two categories of vaccines available, and recently, GlaxoSmithKline introduced Fluarix Tetra, an inactivated QIV, indicated to protect adults and children over three years old
18th Oct 2017 - Astro Awani


Industry News - Seqirus Media Monitoring - 18th Oct 2017

    View this newsletter in full

Pharmacists Play Key Role in Boosting Adult Vaccination Rates

Pharmacists are central to promoting adult vaccinations, according to an interactive discussion held at the National Community Pharmacists Association (NCPA) Annual Convention. Although improvements have already been made in certain areas, such as influenza vaccination, there is still more work to be done
17th Oct 2017 - Pharmacy Times

Sanofi: New influenza vaccine facility, first of its kind in France

A new influenza vaccine facility in France will allow Sanofi Pasteur to expand supply of VaxigripTetra to up to 70 countries in six continents. Sanofi plans to complete the expansion by 2021, subject to relevant health authority approvals and will begin producing vaccines in this new facility in 2022
17th Oct 2017 - 4-traders.com

Flu vaccines in France: which one and where?

The flu vaccination campaign has started in France with the aim of reaching 75% of the population. Just like last year, Vaxigrip, Immugrip and Influvac are covered by national health insurance
17th Oct 2017 - Pratique.fr


Industry News - Seqirus Media Monitoring - 17th Oct 2017

    View this newsletter in full

Vaccine currently under development may harness your immune system to target the flu virus

The story of the development of the Universal Flu vaccine, which, it is believed, will protect people against pandemics and annual outbreaks once it gets to the stage of being successfully tested and approved
16th Oct 2017 - NordJyske.dk

Duke Institute Tapped to Build a Rapid-Response System for Viral Pandemics

The Duke Human Vaccine Institute has received a $12.8 million, 30-month grant to develop a system capable of halting viral pandemics within 60 days. The program, called DARPA Pandemic Prevention Platform (P3), seeks to combine expertise in virology, immunology and clinical manufacturing to rapidly identify and respond to disease outbreaks such as SARS, pandemic influenza and Zika before they spread widely
16th Oct 2017 - Infection Control Today


Industry News - Seqirus Media Monitoring - 16th Oct 2017

    View this newsletter in full

Nation bracing for tight supply of flu vaccines this winter

Japan may face a shortage of influenza vaccines this winter due to a production delay. The supply volume is currently projected at some 25.28 million units, equivalent to 50.56 million doses, about 1.14 million units lower than the estimated amount used during the previous flu season and the second-lowest level in 10 years
14th Oct 2017 - Japan Times

Flu vaccination is a good investment against the potential disastrous economic risk of a flu epidemic

There is a huge cost to society if we don't ensure that people are vaccinated against the flu, according to Sanofi-Pasteur VP, David Loew. Across Europe, the influenza virus is responsible for 40,000 deaths each year, well above the 25,000 deaths due to road traffic accidents
13th Oct 2017 - Challenges.fr

Baloxavir Marboxil Demonstrates Positive Phase 3 Influenza Results

Positive phase 3 CAPSTONE-1 trial results of S-033188 (baloxavir marboxil) in otherwise healthy influenza patients were presented by Shiongoi at IDWeek 2017. Nonclinical studies of baloxavir marboxil demonstrated its anti-viral spectrum against not only seasonal influenza strains but also oseltamivir-resistant flu strains and avian flu strains, of which potential outbreak is a global public health concern
13th Oct 2017 - MD Magazine

Sanofi to Inject $202m into Expanding French Production Facility to Increase Supply of Key Flu Vaccine

Sanofi said that it will invest 170 million euros into expanding its vaccine manufacturing site in the Normandy region of France as it seeks to ramp up the supply of one of its key flu vaccines, VaxigripTetra
13th Oct 2017 - The Standard

Sanofi Pasteur to withdraw ID Flu from Korean market

Sanofi Pasteur Korea said Friday that it plans to pull their Intradermal (ID) Flu product from Korea. The decision comes after the Ministry of Food and Drug Safety dealt sales suspension of the drug for six months for failing to apply for re-examination
13th Oct 2017 - Korea Biomedical Review

Doncaster LPC holds GPs to account over flu jab threats

In Doncaster, UK, local pharmacists reported a GP surgery for threatening to withhold repeat prescriptions from patients who did not get their flu jab at the practice
13th Oct 2017 - Chemist+Druggist


Industry News - Seqirus Media Monitoring - 13th Oct 2017

    View this newsletter in full

Sanofi invests 170 million euros in French vaccines facility - Reuters

Sanofi will invest 170 million euros to expand its vaccines manufacturing site at Val-de-Reuil in north-western France, in a drive aimed at boosting the production of one of its influenza vaccines; the new facility would allow its Sanofi Pasteur vaccines division to expand the supply of the VaxigripTetra product to up to 70 countries
12th Oct 2017 - Reuters

Sanofi to Expand Influenza Vaccine Production Facility


12th Oct 2017 - BioPharm International

Grippe : Sanofi veut augmenter sa production de vaccin


12th Oct 2017 - Les Echos

Sanofi to Expand Seasonal Flu Vaccine Manufacturing Site - Genetic Engineering & Biotechnology News


12th Oct 2017 - Genetic Engineering & Biotechnology News

Sanofi invests €170m to expand flu jab facility


12th Oct 2017 - European Biotechnology

Sanofi baut neue Anlage für Grippeimpfstoffe in Frankreich


12th Oct 2017 - Finanz Nachtrichten.de

Sanofi invests €170 million in new vaccine production facility in France


12th Oct 2017 - Markets Insider

Sanofi agrandit son site normand de vaccins anti-grippe


12th Oct 2017 - Boursarama.com

Sanofi invests €170m to expand flu jab facility


12th Oct 2017 - European Biotechnology

Sanofi pumps €170m into flu vaccine production


12th Oct 2017 - Financial Times

Sanofi commits €170M to expand flu vaccines production


12th Oct 2017 - Pharmadive.com

Sanofi Pasteur investit 170 millions à Val de Reuil, plus grand site au monde de production de vaccin antigrippal


12th Oct 2017 - Usine Nouvelle

Le géant pharmaceutique Sanofi investit 170 millions d’euros dans l’Eure


12th Oct 2017 - Ouest France

Vaccins: Sanofi modernise ses installations en France


12th Oct 2017 - Le Figaro

No More Seasonal Flu Shots: British Biotech"s Universal Vaccine Raises £13M

VirionHealth kicks off the development of a broad spectrum antiviral for all influenza strains and other viruses like RSV with a £13M investment in Series A; it is developing a new type of antiviral therapy, FluPro, based on natural antivirals, with the potential to target multiple types of viruses at once
12th Oct 2017 - Labiotech.eu (blog)


Industry News - Seqirus Media Monitoring - 12th Oct 2017

    View this newsletter in full

Do companies abuse the drugs stocking system to save money?

SRF asks if international drugs giants are holding back supplies of drugs to help boost pricing
11th Oct 2017 - SRF.ch

Flu vaccines MUST be used to avoid deadly complications, urges Paula Radcliffe

Flu vaccines must be taken by asthma, diabetes and heart disease sufferers, urged three-time London marathon winner Paula Radcliffe. Doctors have been worrying about the small numbers of at-risk patients being vaccinated, according to Sanofi Pasteur
12th Oct 2017 - Express.co.uk


Industry News - Seqirus Media Monitoring - 11th Oct 2017

    View this newsletter in full

GlaxoSmithKline ranked worst in business group's list of well-run companies in the UK

GSK has been ranked bottom in a list of the UK's top companies for good governance; it came in at number 103 in the Institute of Director's 2017 good governance report
10th Oct 2017 - Independent

Anvisa announces changes for flu vaccines for the 2018 seasonal flu season based on WHO recommendations

With the pending flu season upon the nation Anvisa has announced the changes to the vaccines that are to be used in the country to combat this winter’s flu outbreak
9th Oct 2017 - Gazeta Online.com.br

Recommended flu vaccines

The Health Directorate in Luxembourg today called on groups considered at risk to be vaccinated against the flu, and the vaccine is already available in the country's pharmacies and may be prescribed by doctors.
10th Oct 2017 - Luxemburger Wort


Industry News - Seqirus Media Monitoring - 10th Oct 2017

    View this newsletter in full

Brazil will start to make flu vaccine from the beginning of 2018

Brazil will start to make flu vaccine from the beginning of 2018. The Instituto of Butantan is planning to make 60,000 flu vaccine doses
30th Sep 2017 - Folha PE.com

Investigational Flu Drug a Near Match for Oseltamivir

In a Phase III trial, an investigational anti-influenza drug (a cap-dependent endonuclease inhibitor), was quicker than oseltamivir in reducing virus levels in patients and cutting viral shedding, according to Simon Portsmouth, MD, of Shionogi, which is developing the drug
8th Oct 2017 - Medpage Today

Stronger pill plan to check swine flu

The Maharashtra government is planning to introduce amantadine, an anti-viral drug stronger than oseltamivir, to contain swine flu virus that has so far claimed 626 lives in the state this year
9th Oct 2017 - Times of India

Influenza vaccines will fight three types of virus in 2018 (according to WHO instructions)

Anvisa said trivalent influenza vaccines for the year 2018 should be within the following specifications: a virus similar to influenza A / Michigan / 45/2015 (H1N1) virus pdm09 - virus A / Singapore / INFIMH-16-0019 / 2016 (H3N2) and a virus similar to influenza B virus / Phuket / 3073/2013. However, Quadrivalent influenza vaccines containing two types of influenza B virus strains should also contain a virus similar to the B / Brisbane / 60/2008 influenza virus.
9th Oct 2017 - Brazilian Government

Butantan inicia produção de vacina contra gripe


29th Sep 2017 - JTV Online


Industry News - Seqirus Media Monitoring - 9th Oct 2017

    View this newsletter in full

CAPSTONE-1: New antiviral superior to placebo at reducing influenza symptoms

Treatment with the cap-dependent endonuclease inhibitor S-033188 was superior to placebo in alleviating influenza symptoms, and the agent was superior to both placebo and the antiviral oseltamivir in virologic outcomes, according to data from the phase 3 CAPTSTONE-1 trial
7th Oct 2017 - Healio.com

Tamiflu shortage resolves as flu infections slow

Professor Paul VanBuynder, of the Gold Coast Health Service and the Immunisation Coalition, told the media that the uptick in flu cases this year cannot be attributed to increased reporting, nor to GPs’ take-up of desktop testing methods. The Sydney Morning Herald reported that the flu vaccine’s effectiveness may have dropped below 40% this year due to flaws in its manufacturing and design
6th Oct 2017 - Australian Journal of Pharmacies

Hologic's Panther Fusion Flu A/B/RSV Assay Gets FDA Approval

Hologic announced the receipt of 510(k) clearance from the FDA for Panther Fusion Flu A/B/RSV assay running on the new Panther Fusion system
6th Oct 2017 - Nasdaq.com

Hologic's Panther Fusion Flu A/B/RSV Assay Gets FDA Approval


6th Oct 2017 - Genome Web

Incentives, IP and smaller companies: the story of CureVac

CureVac has developed an innovative technology for the easy and quick production of safe, efficacious and cost-effective immunotherapeutic agents for a wide range of diseases. It has several candidates for the prevention of infectious diseases, including an influenza vaccine, in preclinical development
7th Oct 2017 - The Pharma Letter

Cows to grow human antibodies at farm near Canton

Some people don’t respond to flu shots, but an influenza therapeutic produced by SAB could help them. “We think we have a solution, and we are working on it,” CEO and co-founder Eddie Sullivan said, adding that they are working toward the first clinical trials on influenza
7th Oct 2017 - Sioux City Journal

New vaccine on way could be a gamechanger for flu — here’s how

A potentially groundbreaking seasonal flu vaccine developed by a team from Oxford University will be tested on around 2,000 humans aged 65 and above living in Berkshire and Oxfordshire in the UK
9th Oct 2017 - Indian Express


Industry News - Seqirus Media Monitoring - 6th Oct 2017

    View this newsletter in full

Flu vaccine shortage in Queensland pharmacies again

Queensland pharmacies are in the midst of yet another shortage of Tamiflu, as sick patients turn to local compound pharmacists to produce the medication
5th Oct 2017 - Courier Mail

Woman claims she suffered narcolepsy after receiving swine flu vaccine

The Health Products Regulatory Authority has been joined as a defendant in a personal injury case by a woman who claims she suffered narcolepsy after receiving a vaccine for the swine flu virus. Aoife Bennett is among an estimated 70 people who have brought cases against the Minister for Health, the HSE and Glaxosmithkline over being given the Pandemrix vaccine
5th Oct 2017 - Irish Examiner

Woman suing State over swine flu jab is one of 70 cases initiated


5th Oct 2017 - Irish Times

Woman suing State after claims she got narcolepsy from swine flu vaccine


5th Oct 2017 - Irish Independent

Shionogi To Present S-033188 Phase 3 CAPSTONE-1 Study Results For Treatment Of Influenza At IDWeek 2017

Shionogi announced it will report results of a S-033188 Phase 3 study in otherwise healthy influenza patients (CAPSTONE-1) at IDWeek 2017. S-033188 is a novel cap-dependent endonuclease inhibitor with potent anti-viral efficacy for the treatment of influenza
5th Oct 2017 - PR Newswire.com

Shionogi To Present S-033188 Phase 3 CAPSTONE-1 Study Results For Treatment Of Influenza At IDWeek 2017


5th Oct 2017 - Business Insider

Panther Fusion Flu A/B/RSV Assay Now FDA Cleared on Hologic's New Panther Fusion System

Hologic announced that it has received 510(k) clearance from the United States Food and Drug Administration for its Panther Fusion Flu A/B/RSV assay running on the new Panther Fusion system
5th Oct 2017 - PR Newswire.com

Visterra adds $24M to series C to take flu drug to phase 2b

Visterra has extended its series C round to fund the advance of its lead candidate into phase 2b. It now has the money to wrap up a phase 2a of influenza A treatment VIS410 in ambulatory patients and start a phase 2b of the same monoclonal antibody in hospitalized patients
5th Oct 2017 - Fierce Biotech

'Less precise' study offers another take on FluMist performance

A new study provides data showing the live attenuated inactive virus (LAIV) FluMist vaccine was effective in children during the 2015-16 flu season, seemingly contradicting work published 2 months ago that suggested the vaccine offered no protection to recipients in that age-group that year
5th Oct 2017 - CIDRAP

Oxford team to test universal influenza vaccine

Researchers at Oxford University and the biotech firm Vaccitech plan to launch a 2-year clinical trial involving more than 2,000 patients to evaluate a universal influenza vaccine
5th Oct 2017 - Pharmacist.com


Industry News - Seqirus Media Monitoring - 5th Oct 2017

    View this newsletter in full

Atriva captures $3.5m seed funding

German biotech Atriva has received $3.5m to fund clinical development and proof of concept for its lead candidate targeting influenza by 2018 and 2019
4th Oct 2017 - Global University Venturing

New universal flu jab being trialled

The world's first widespread human testing of a flu vaccine which researchers hope will protect more over 65-year-olds against influenza has begun in the NHS. More than 10,000 people aged 65 and over will be asked to take part in a study delivered by the University of Oxford
4th Oct 2017 - Newbury Today

Influenza vaccine to protect against flu to last for four years


4th Oct 2017 - Daily Telegraph

Oxford University to Test Universal Flu Vaccine in World First


4th Oct 2017 - Asharq Al-Aawsat

Universal flu vaccine to begin human trials this winter


4th Oct 2017 - New Atlas

World-first trial for universal flu vaccine


4th Oct 2017 - Medical Express

Universal Flu Vaccine Entering Human Trials


4th Oct 2017 - PBS.org

Trade body touts accomplishments of Australian biotech sector

AusBiotech has released its annual report, showcasing the accomplishments of the Australian biopharmaceutical sector and lobbying for the preservation of tax incentives for research and development. While the biotech sector is led by CSL, smaller companies have been noted for significant growth potential
3rd Oct 2017 - The Pharma Letter

Flu vaccines still useful despite mismatch with WHO recommendations, Hong Kong experts say

Hong Kong health chiefs and local doctors said that the city’s flu vaccinations should still be effective, despite the shots containing a different strain to the one most recently recommended by the global health watchdog
4th Oct 2017 - South China Morning Post


Industry News - Seqirus Media Monitoring - 4th Oct 2017

    View this newsletter in full

Oxford team to test universal flu vaccine in world first

A seasonal flu vaccine that would be the first in the world to fight all types of the virus is to be tested in a two-year clinical trial involving more than 2,000 patients by researchers in Oxford
3rd Oct 2017 - Reuters

Vaccitech 'universal' flu shot set for phase 2 study in U.K.


3rd Oct 2017 - FiercePharma

Researchers to test universal flu vaccine in world first


3rd Oct 2017 - Globe and Mail

UK team to test universal flu vaccine


3rd Oct 2017 - Sky News Australia

Researchers to test universal flu vaccine they hope will provide better and longer-lasting protection


3rd Oct 2017 - abc.net.au

Universal flu vaccine to be tested


3rd Oct 2017 - Times of Malta

Oxford team to test universal flu vaccine in world first


3rd Oct 2017 - Gulf Times

Oxford team to test universal flu vaccine in world first


3rd Oct 2017 - Nasdaq.com

UK team to test universal flu vaccine


3rd Oct 2017 - Herald Sun

Oxford team to test universal flu vaccine in world first


3rd Oct 2017 - Pharmalive.com

Universeel griepvaccin schudt farma-industrie wakker


3rd Oct 2017 - De Tijd

Oxford Team to Test First Universal Flu Vaccine


3rd Oct 2017 - P&T community

'Universal' flu vaccine to be tested


3rd Oct 2017 - Pharma Times

Quarterly Performance of GlaxoSmithKline’s Vaccines Segment

European markets reported increased sales for GSK’s Fluarix and FluLaval from the influenza vaccines portfolio in the second quarter of 2017
3rd Oct 2017 - Market Realist

Flu vaccine: NHS patients wanted to test 'universal' jab

Researchers are seeking about 500 NHS patients to try out a new "universal" vaccine against seasonal flu. Patients aged 65 or older and living in Berkshire and Oxfordshire will be invited to take part in the trial
3rd Oct 2017 - BBC

Universal flu vaccine begins widespread human testing in UK


3rd Oct 2017 - Irish Times

Flu symptoms: THESE areas of the UK are trialling a new more protective jab


3rd Oct 2017 - Express.co.uk

Oxfordshire patients asked to take part in 'world-first' trial of new flu jab


3rd Oct 2017 - Oxford Mail

10,000 to be tested in world’s first universal flu jab trial


3rd Oct 2017 - Belfast Telegraph

Second-Generation Rapid Influenza Test Clears FDA

The U.S. FDA has cleared for marketing the Alere i Influenza A & B 2 rapid molecular diagnostic test for use in children and adults. This is a "second-generation rapid molecular assay, which delivers lab accurate results in less time, with the ability to report a positive result in as little as 5 minutes," the company said
3rd Oct 2017 - Medscape.com

Biotech vaccine for influenza season is available in Mexico

In Mexico, trivalent Flublok has been authorised for sale and is suitable for most people as it does not contain egg. Flublok is authorised for ages 18+
3rd Oct 2017 - Notmex.gob.mx


Industry News - Seqirus Media Monitoring - 3rd Oct 2017

    View this newsletter in full

Vaccines update – what vaccines will be available against flu this season

An update from Ukrainian health authorities includes several vaccines: Influvac, Waxin, GIS Flu and Vaxigrip in the available vaccines list
2nd Oct 2017 - kp.ua

ADImmune readies flu vaccine for China and U.S.

ADImmune’s flu vaccine is now available to people around Taiwan after the company obtained the approval of the health authorities. In the U.S., quadrivalent vaccines which ADImmune developed in collaboration with Protein Sciences have been approved by the U.S. FDA and will soon be available in that market
2nd Oct 2017 - Focus Taiwan

Regeneron Announces New Collaborations with HHS to Develop Antibodies Against Ebola, Influenza and Multiple Other Emerging Pathogens

Regeneron announced two new collaborations with the Biomedical Advanced Research and Development Authority to develop new treatments combating infectious diseases, the first being focused on discovery, research, development and manufacturing of a portfolio of antibodies targeting up to 10 pathogens that pose significant risk to public health, starting with Influenza virus
2nd Oct 2017 - Business Insider

Regeneron Pharmaceuticals ‍announces new collaborations with HHS to develop antibodies against ebola, influenza, multiple other emerging pathogens​


2nd Oct 2017 - Reuters

Regeneron Announces New Collaborations with HHS to Develop Antibodies Against Ebola, Influenza and Multiple Other Emerging Pathogens


2nd Oct 2017 - PR Newswire.com

Regeneron Announces New Collaborations with HHS to Develop Antibodies Against Ebola, Influenza and Multiple Other Emerging Pathogens


2nd Oct 2017 - Yahoo Finance

Alere Receives FDA Clearance for Alere i Influenza A & B 2 Rapid Molecular Test

Alere announced that its Alere i Influenza A & B 2 test has received 510(k) marketing clearance from the U.S. Food and Drug Administration for the detection of influenza A and B infection in children and adults
2nd Oct 2017 - Yahoo Finance

Alere receives FDA clearance for Alere i Influenza A & B 2 rapid molecular test


2nd Oct 2017 - Reuters

Alere Announces FDA Clearance for Alere i Influenza A & B 2 Rapid Molecular Test


2nd Oct 2017 - Street Insider.com

Alere Announces FDA Clearance For I Influenza A & B 2 Rapid Molecular Test


2nd Oct 2017 - Nasdaq


Industry News - Seqirus Media Monitoring - 2nd Oct 2017

    View this newsletter in full

New quadrivalent flu vaccine for the winter is here

Sanofi’s VaxiGrip, a quadrivalent vaccine against the flu, is now available in Italy for the 2017/2018 flu season, taking protection from 3 to 4 strains
29th Sep 2017 - Libero Quotidiano

Instituto Butantan starts producing flu vaccine

In Brazil, the Butantan Institute, an agency linked to the State Department of Health and responsible for more than half of the vaccines produced in the country, has started producing the flu vaccine that will be used in the 2018 National Immunization Program
29th Sep 2017 - Sao Paulo.sp.gov.br

No nasal flu vaccine again this year: FluMist not recommended for 2017

For the second consecutive year, the CDC is recommending against using a nasal flu vaccine. Last year's advisory meant most doctors and pharmacies didn't stock FluMist, a practice that's likely to occur again this year. FluMist didn't provide adequate protection against influenza
29th Sep 2017 - wtvy.com

No nasal flu vaccine again this year: FluMist not recommended for 2017


29th Oct 2017 - al.com

Flu season: CDC once again recommends against nasal vaccine


29th Sep 2017 - silive.com

CDC recommends against 'ineffective' form of flu vaccine


29th Sep 2017 - pennlive.com

Armyworms Used to Make Flublok Influenza Vaccine

Currently, there is one influenza vaccine produced using recombinant technology that is approved by the FDA, Flublok. In 2013, trivalent Flublok was approved for use in adults between the ages of 18 to 49 years old. In 2016, the FDA further approved the quadrivalent vaccine for use in anyone over the age of 18
1st Oct 2017 - The Vaccine Reaction


Industry News - Seqirus Media Monitoring - 29th Sep 2017

    View this newsletter in full

Novartis, Berkeley sign drug chemistry pact

Novartis’s research head expects an alliance with a University of California chemistry lab to produce drug candidates within three years as the Swiss company accelerates its hunt for new medicines
28th Sep 2017 - Reuters

Novartis, Berkeley sign drug chemistry pact


28th Sep 2017 - Chemical & Engineering News

UC Berkeley deal showcases Novartis' new focus on academic tie-ups


28th Sep 2017 - Biz Journals.com

Novartis forges UC Berkeley pact, sees drug hopefuls in three years


28th Sep 2017 - Pharma Live

Novartis partners with UC Berkeley to pursue 'undruggable' disease targets


28th Sep 2017 - News-Medical.net

CEVA Animal Health Lab produces H5N8 vaccine

In France, CEVA Animal Health Labs have produced a H5N8 vaccine which seems efficient and would not be used systematically in birds but could prove useful during outbreaks
28th Sep 2017 - Sud Radio.fr

Four influenza vaccines have been re-registered in the Ukraine

Four influenza vaccines have been re-registered in the Ukraine – these include According to the Ministry of Health, the following vaccinations have been re-registered: INFLUWAK / INFLUVAC (Netherlands), INFLUENZA VAKSIN (China), JISI FLU / GC FLU (Korea) and VACCIHRIP / VAXIGRIP (France)
28th Sep 2017 - Ukrinform.ua

Flu Shots Aren't 100% Effective, But They're The Best Protection Available

The CDC recommends that all people six months old and up, including pregnant women, get vaccinated every year against influenza and is once again recommending against the use of FluMist
28th Sep 2017 - Forbes

Scripps Research-led study points to new flu drugs

New and more powerful drugs to stop influenza may be possible, according to a study by scientists from The Scripps Research Institute and Janssen Research & Development, a unit of Johnson & Johnson. The study exploits a vulnerable site on the flu virus that existing drugs such as Tamiflu don’t target
28th Sep 2017 - San Diego Union Tribune

Scientists develop broad-spectrum inhibitors of influenza virus


28th Sep 2017 - Phys.org

Flu vaccine not as effective this year

Melbourne-based biotech Aus Bio is undertaking preclinical research into a drug it says will need to be taken only once every 12 days to prevent the flu (Tamiflu is taken twice a day). University of Melbourne virologist Professor Lorena Brown said the drug compounds would change the shape of the influenza virus, so it was no longer infectious
28th Sep 2017 - Daily Liberal.com.au


Industry News - Seqirus Media Monitoring - 27th Sep 2017

    View this newsletter in full

Medicago Announces Phase 3 Study of VLP Quadrivalent Influenza Vaccine

Medicago announced the start of a Phase 3 efficacy study for its seasonal quadrivalent influenza vaccine (QIV) candidate. This study is in support of Medicago's flu program and expected launch of the vaccine in time for the 2020 influenza season in Canada, USA and Europe
26th Sep 2017 - PR Newswire.com

Medicago Announces Phase 3 Study of VLP Quadrivalent Influenza Vaccine


26th Sep 2017 - Business Insider

Vulnerable groups may be put at risk

Many German doctors are angry about not being able to offer the best prices for flu vaccinations for four strains of flu as insurers holdback on agreed pay-outs for the vaccine protection needed
26th Sep 2017 - LN Online

Dr. Marie-Paule Kieny Appointed To The Human Vaccines Project Board Of Directors

The Human Vaccines Project has appointed Dr. Marie-Paule Kieny to its Board of Directors. Dr. Kieny is currently Director of Research at Institut National de la Santé et de la Recherché Médicale (INSERM) where she connects INSERM with the international health research community, and has held several positions at the World Health Organization
26th Sep 2017 - PR Newsire.com

CDC does not recommend flu mist as flu shot alternative this season

In Honolulu, the flu season has started. The CDC says now is the time to get the flu vaccine, but to get the shot and not FluMist
26th Sep 2017 - kitv.com

Flu Vaccines for the 2017/2018 season? What do they contain when can we get vaccinated?

In Poland, two flu vaccines are recommended for the 2017/2018 flu season: Sanofi Pasteur’s Vaxigrip Tetra and BGP Products’ Influvac
26th Sep 2017 - Silesion.pl


Industry News - Seqirus Media Monitoring - 26th Sep 2017

    View this newsletter in full

Bill Gates hopes talk with Trump on vaccine programs was ‘enlightening’

Bill Gates said in an interview broadcast Sunday that he hopes his conversation with President Trump about vaccines was “enlightening”
24th Sep 2017 - The Hill

Influenza - Sanofi Pasteur announced a new Quadrivalent flu vaccine Vaxigrip Tetra is available

With the influenza season starting, Sanofi Pasteur has announced that a new quadrivalent flu vaccine (Vaxigrip Tetra) is available. Mario Merlo , General Manager Sanofi Pasteur Italy and Malta, said that the company was working on progressively converting the entire range of flu vaccines from trivalent to quadrivalent
25th Sep 2017 - Healthdesk.it

Sanofi Pasteur has announced that a new quadrivalent flu vaccine (Vaxigrip Tetra) is available


25th Sep 2017 - Quotidiano Sanita.it

FluBlok Quadrivalent comparable to IIV4 in young adults

A comparison of recombinant and inactivated quadrivalent influenza vaccines found that the two vaccines (Protein Sciences’ Flublok Quadrivalent and GSK’s Fluarix Quadrivalent) demonstrated similar immunogenicity, safety and tolerability among patients aged 18 to 49 years
25th Sep 2017 - Healio.com

Monthly visits to pharmacies hit 2m

In Ireland, 78,939 people received our flu vaccination in a community pharmacy in the 2016/2017 season
25th Sep 2017 - Irish Examiner

Northern Beaches hospitals see 200% rise in people with flu

Northern Sydney Public Health Director Michael Staff said this year there were four strains of the flu virus, and he would not know how effective the flu vaccine had been until statistics were collated, but early data suggested the jab had been very efficient against three of the strains
24th Sep 2017 - Daily Telegraph

Fears of Irish flu crisis as experts appeal for early vaccinations

An appeal has been issued for people to get a flu vaccine early this year. Hospitals across Ireland are bracing themselves for the worst after a heavy flu outbreak in the Southern Hemisphere during its winter
25th Sep 2017 - Irish Mirror

Novartis’s new chief sets sights on ‘productivity revolution’

The incoming chief executive of Novartis, Vas Narasimhan, has vowed to slash drug development costs, eyeing savings of up to 25 per cent on multibillion-dollar clinical trials as part of a “productivity revolution”
25th Sep 2017 - Financial Times

BioCryst Pharmaceuticals : RAPIVAB Receives FDA Approval for a Pediatric Indication

BioCryst announced that the U.S. FDA has approved a supplemental New Drug Application for RAPIVAB (peramivir injection), extending its availability for the treatment of acute uncomplicated influenza to pediatric patients 2 years and older who have been symptomatic for no more than two days
25th Sep 2017 - 4-traders.com

Research leads to better flu vaccine

FluGen’s lead vaccine, M2SR or RedeeFlu, tricks the body into believing it is infected without making you sick, by cutting a piece of the virus out so that it can enter your system but not multiply like a real virus would
24th Sep 2017 - Madison.com


Industry News - Seqirus Media Monitoring - 25th Sep 2017

    View this newsletter in full

BioCryst scores FDA approval on flu treatment for children

On the heels of an $80 million public offering, BioCryst has landed U.S. Food and Drug Administration approval for Rapivab, its injectable flu treatment in pediatric patients
21st Sep 2017 - Biz Journals.com

SK Chemicals awarded ‘2017 New Drug Grand Prize’

SK Chemicals has received the “2017 New Drug Grand Prize” from the Korean Ministry of Food and Drug Safety. “This is recognition of SK Chemicals’ innovative R&D achievements in the biotechnology field such as vaccines and blood products,” the company said. SK Chemicals has commercialized Skycellflu, the world's first quadrivalent cell culture flu vaccine
22nd Sep 2017 - Korea Biomed

Atriva reaches a development milestone and receives an additional tranche of running seed financing to develop its influenza therapeutic to clinical stage

The next generation of Antiviral Therapies: Co-Led by Stichting Participatie Atriva and High-Tech Gründerfonds (HTGF), Atriva Therapeutics GmbH has received a second tranche of its running seed financing in total of € 3 Mn from Dutch, German and Canadian investors, after lead compound ATR-002 (Atriva’s antiviral MEK-Inhibitor against Influenza) has passed an important preclinical milestone paving the way to clinical development stage.
21st Sep 2017 - High-Tech GruenderFonds.de

Vaccines prevent 3m deaths each year

After the 27th National Vaccination Symposium, GlaxoSmithKline Medical Advisor Prof. Dr. Anıl Dutta said that vaccination prevented many diseases every year and that a significant number of diseases were eliminated in many countries thanks to regular vaccination
23rd Sep 2017 - Haber.com

Doctors, experts say no to FluMist for upcoming flu season

Flu season is quickly approaching which means parents are prepping for some unhappy kids as, once again, the FluMist is being tossed aside in favor of the flu shot. Last year, the American Academy of Pediatrics had already stopped recommending the nasal spray saying it was barely effective at preventing the virus
25th Sep 2017 - Wave3.com

Why Novavax, Inc. Could Be a Gold Mine for Growth Investors

In August, Novavax announced that its flu vaccine produced superior hemagglutinin antigen inhibition antibody responses in ferrets compared to Sanofi's Fluzone and Fluzone HD. The preclinical results were so impressive that Novavax is rushing to advance the vaccine, which it now calls NanoFlu
23rd Sep 2017 - Madison.com

Pharma in talks to bring super flu vaccine to Australia

Australian Health Minister Greg Hunt asked chief medical officer Brendan Murphy to look at ways to boost the strength or effectiveness of the influenza vaccine next year. “Sanofi Pasteur has begun very high-level, preliminary discussions with Australia’s chief medical officer regarding our high-dose influenza vaccine. We are committed to assist both the Health Department and the Australian community to reduce the impact of influenza now and in the future” said a Sanofi spokesperson
25th Sep 2017 - The Australian

Here's A Play In BioCryst Pharmaceuticals That Markets Just Missed

For a company that just picked up a major FDA approval, BioCryst is trading remarkably flat. Premarket on Thursday, September 21, the company announced that the FDA has approved its RAPIVAB asset for pediatric use
22nd Sep 2017 - Insider Financial

Irish Medicines regulator faces legal suit over flu vaccine

The Irish medicines regulator is to be sued for its alleged failure to act upon safety concerns that were conveyed to it about the Pandemrix flu vaccine.
24th Sep 2017 - Business Post Ireland


Industry News - Seqirus Media Monitoring - 22nd Sep 2017

    View this newsletter in full

Billionaires Are Gobbling Up This Beaten-Down Biotech Stock: Should You?

If Novavax can somehow change the trajectory of its RSV program, its stock could rise fast, but no deep-pocketed partner has yet stepped forward to offer Novavax a much-needed lifeline, which seems to reflect the industry's dire view of the vaccine's prospects moving forward
21st Sep 2017 - Motley Fool

US Health Department partners with Janssen Research & Development to develop new flu vaccines

A new public-private partnership between the federal government and Janssen Research & Development LLC seeks to jointly innovate new products in the constantly evolving battle against influenza.
21st Sep 2017 - Homeland Preparedness News

BioCryst’s RAPIVAB (peramivir injection) Receives FDA Approval for a Pediatric Indication

BioCryst clinched approval from the U.S. FDA for its supplemental new drug application for Rapivab (peramivir injection). The approval marks "the first new influenza antiviral for pediatric use in over 10 years," said BioCryst president and CEO Jon P. Stonehouse
21st Sep 2017 - Globe Newswire.com

FDA OKs BioCryst's Rapivab for Pediatric Indication


21st Sep 2017 - The Street

Rapivab Gains Pediatric Influenza Indication


21st Sep 2017 - MPR.com

Can BioCryst Turn Itself Around With This FDA Approval?


21st Sep 2017 - 247wallst.com

BioCryst Flat After FDA Nod


21st Sep 2017 - Baystreet.ca

Here’s Why BioCryst Pharmaceuticals, Inc. Shares Popped Today


21st Sep 2017 - Smarter Analyst

BioCryst Pharmaceuticals is also gaining thanks to big FDA news


21st Sep 2017 - Schaeffer Research

Combination vaccines expand range of prevention

Combination vaccines, which can prevent more viruses with fewer injections, have recently come to the market one after the other.
21st Sep 2017 - Korea Biomed


Industry News - Seqirus Media Monitoring - 21st Sep 2017

    View this newsletter in full

No FluMist vaccines again this flu season

Columbia Public Health and Human Services will not be offering nasal sprays as a part of their flu vaccine lineup this flu season; in a study from the CDC, FluMist was found to be almost useless in preventing the flu in the time it has been used
18th Sep 2017 - komu.com

In Estonia, the Health board decides children can be vaccinated against flu, but not yet with the new vaccine Vaxigrip Tetral

In Estonia, the Health board decides children can be vaccinated against flu but not yet with the new vaccine Vaxigrip Tetral
20th Sep 2017 - Post Times Tervis

Altimmune to start Phase 2 study of intranasal flu vaccine

Altimmune was cleared by the FDA to start a Phase 2 clinical study of their intranasal flu vaccine. Altimmune says the vaccine, NasoVAX, has the potential to stimulate a broader and quicker immune response than approved flu vaccines
20th Sep 2017 - The Daily Record

Altimmune Announces its Phase 2 Flu Vaccine Trial with NasoVAX Open for Enrollment


20th Sep 2017 - Globe Newswire.com

NanoFlu Gives Novavax Room To Manoeuvre

Since taking a starring role in Novavax’s Q2 earnings report, NanoFlu has come to the fore of some analysts’ attention. Novavax has announced the official commencement of a Phase 1/2 clinical trial; results will be released by the end of 2017. While still highly preliminary, positive results would elevate share price immediately, open partnership opportunities, and even raise the possibility of a buyout
20th Sep 2017 - Seeking Alpha

J&J and HHS Team Up on Flu Vaccine and Drug R&D

The US Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response announced a public-private partnership with Janssen R&D to drive advanced development of a portfolio of therapeutic products to prevent or treat infections caused by emerging infectious diseases, including influenza viruses with pandemic potential
20th Sep 2017 - Biopharm International

J&J, Department of Health and Human Services to Partner on Fighting Influenza


19th Sep 2017 - Drug Discovery & Development

Novavax Initiates Phase 1/2 Trial of NanoFlu(TM) Vaccine in Older Adults

Novavax announced the enrollment of the first participant in a Phase 1/2 clinical trial of its nanoparticle influenza vaccine candidate including its proprietary Matrix-M adjuvant (NanoFlu) in older adults
19th Sep 2017 - Nasdaq.com


Industry News - Seqirus Media Monitoring - 20th Sep 2017

    View this newsletter in full

Grant of $ 5.8 million for vaccine development is to be used to protect against avian influenza through the "Immune History" project - a collaboration co-sponsored by EpiVax

EpiVax announced a new NIH-funded collaboration to develop a protective avian influenza A (H7N9) vaccine. EpiVax's first-generation engineered H7N9 product is currently under clinical trial in Adelaide, Australia
19th Sep 2017 - ots.at

Grant of $ 5.8 million for vaccine development is to be used to protect against avian influenza through the "Immune History" project - a collaboration co-sponsored by EpiVax


19th Sep 2017 - Kyodo News

New mum critical as doctors call for for super flu vaccine

A young mother is fighting for her life after contracting a powerful flu strain. She is the latest victim in a deepening crisis that has prompted Health Minister Greg Hunt and the nation’s top doctor to investigate “new and strengthened vaccines” available overseas, such as Sanofi Pasteur’s Fluzone High Dose
20th Sep 2017 - The Australian

Novavax Initiates Phase 1/2 Trial of NanoFlu Vaccine in Older Adults

Novavax announced the enrolment of the first participant in a Phase 1/2 clinical trial of its nanoparticle influenza vaccine candidate including its proprietary Matrix- adjuvant (NanoFlu) in older adults. The primary objective of the trial is to assess the safety and immunogenicity of two concentrations (15 µg or 60 µg) of NanoFlu compared to Fluzone High-Dose
19th Sep 2017 - Globenewswire.com

Novavax, Inc. Gets Phase 1/2 Trial Enrollment Started in NanoFlu Vaccine in Older Adults


19th Sep 2017 - Smarter Analyst

Novavax Initiates Phase 1/2 Trial of NanoFlu Vaccine in Older Adults


19th Sep 2017 - Pipeline Review.com

Novavax Initiates Phase 1/2 Trial of NanoFlu Vaccine in Older Adults


19th Sep 2017 - Business Insider

Novavax Initiates Phase 1/2 Trial of NanoFlu Vaccine in Older Adults


19th Sep 2017 - EIN Newsdesk

Novavax Initiates Phase 1/2 Trial of NanoFlu Vaccine in Older Adults


19th Sep 2017 - Pharmiweb.com

Novavax Begins Phase 1/2 Trial of NanoFlu Vaccine in Older Adults


19th Sep 2017 - Street Insider.com

Looking to take on Sanofi's Fluzone HD, NovaVax is kicking off a phase 1/2 study of its NanoFlu candidate in older adults


19th Sep 2017 - FiercePharma

InDevR licenses Mount Sinai influenza antibodies for VaxArray neuraminidase potency assay

InDevR has entered into an exclusive, world-wide license agreement for monoclonal antibodies developed by scientists at the Icahn School of Medicine at Mount Sinai. The license agreement will provide InDevR with a unique set of anti-neuraminidase monoclonal antibodies for rapid, subtype specific quantification of neuraminidase in the multiplexed VaxArray system
19th Sep 2017 - Eurekalert

InDevR Licenses Mount Sinai Influenza Antibodies for VaxArray Neuraminidase Potency Assay


19th Sep 2017 - Business Insider

FluGen Announces Expanded Role for Clinical Advisory Board: Dr. Robert Belshe to Chair

FluGen announced that Dr. Robert Belshe was named Chairman of the Company’s Clinical Advisory Board, and that it is expanding the roles of all members of the CAB to guide the company through the clinical development of RedeeFlu, a novel intranasal flu vaccine that mimics natural infection without causing illness
19th Sep 2017 - Digital Journal

FluGen Announces Expanded Role for Clinical Advisory Board: Dr. Robert Belshe to Chair


19th Sep 2017 - Businesswire.com

FluGen Announces Expanded Role for Clinical Advisory Board: Dr. Robert Belshe to Chair


19th Sep 2017 - Pharmiweb.com

Johnson & Johnson, BARDA join forces to prep for pandemic flu, inking deal for vaccine and drug R&D

After seeing recent deadly outbreaks catch medical communities off guard, vaccine experts may be happy to see a new collaboration between Johnson & Johnson and a U.S. development agency take shape: the groups have paired up for pandemic flu preparedness, focusing on a vaccine program and other flu drug candidates from J&J
19th Sep 2017 - FiercePharma

A shot in the arm

Thailand’s vaccine factory in Saraburi province is now near completion. It is expected to produce the first batch of flu vaccine in 2020. Operated by the GPO, this is Thailand's first manufacturing centre for flu shots
19th Sep 2017 - Bangkok Post

No FluMist again this year (and answers to your other flu vaccine questions)

The nasal flu mist vaccine is once again not available this year, due to its ineffectiveness two years ago
19th Sep 2017 - abc27.com


Industry News - Seqirus Media Monitoring - 19th Sep 2017

    View this newsletter in full

Calls for elderly to be given extra influenza vaccination after deadly flu season

Offering a booster vaccine for Australians aged over 65, midway through flu season, could help combat the flu's spread. In the U.S., a stronger and more effective flu vaccine for the elderly, Fluzone, has been used since 2009. Sanofi Pasteur said the company was looking to have the drug approved by Australian regulators
17th Sep 2017 - Bunbury Mail

Cadila Healthcare gains 2% on USFDA nod for Oseltamivir powder

Neshar Pharmaceuticals, a subsidiary of Zydus Pharmaceuticals USA, has received final approval from the USFDA to market Oseltamivir powder for oral suspension, 6mg/ml
18th Sep 2017 - Money Control

Zydus arm gets USFDAs final nod for Oseltamivir powder


18th Sep 2017 - MyIris.com

FDA clears first generic oseltamivir phosphate for oral suspension


18th Sep 2017 - Pharmacist.com

Cadila Healthcare in pink of health after USFDA nod for influenza drug


18th Sep 2017 - Business Standard

Sanofi Pasteur supplies vaccine against flu to Ukraine

Vaccines against the flu produced by Sanofi Pasteur are already in the medical warehouses of Ukraine, the head of the vaccines department of the company Olena Yentina told Interfax-Ukraine
18th Sep 2017 - Kyiv Post

Should you take an antiviral drug when you get the flu?

Antiviral medications, such as oseltamivir (Tamiflu) or zanamivir (Relenza), may reduce flu symptoms and help you recover a day or two earlier. But oseltamivir came under fire a few months ago for a lack of effectiveness
19th Sep 2017 - Harvard Health

J&J collaborates with US Department of HHS to develop therapeutics & vaccines to fight influenza

Johnson & Johnson announced that Janssen Research & Development are collaborating with the US Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response to develop a comprehensive portfolio of therapeutics and vaccines to protect communities in the event of an influenza pandemic and other infectious disease threats
18th Sep 2017 - Pharmabiz.com

BiondVax Announces Closing of $10 Million Public Offering of American Depositary Shares and Exercise of Over-allotment Option

BiondVax has closed an underwritten public offering of 1,500,000 American Depositary Shares, each ADS representing forty of its ordinary shares which are listed on the Tel Aviv Stock Exchange, at a price to the public of $6.00 per ADS
18th Sep 2017 - Business Insider

$5.8 Million Awarded For Vaccine Engineering Will Use "Immune History" To Protect Against Bird Flu, A Collaboration Led By EpiVax

EpiVax announced a new NIH-funded collaboration to develop a protective avian influenza A (H7N9) vaccine with scientists from UMASS Medical School, Protein Sciences, recently acquired by Sanofi Pasteur, and The University of Georgia $5.8 Million Awarded For Vaccine Engineering Will Use "Immune History" To Protect
18th Sep 2017 - Business Insider

$5.8 Million Awarded For Vaccine Engineering Will Use "Immune History" To Protect Against Bird Flu, A Collaboration Led By EpiVax


18th Sep 2017 - PR Newswire.co.uk

Un consorcio liderado por EpiVax ganó un subsidio de U$S 5,8 M para desarrollar una vacuna usando ingeniería genética


18th Sep 2017 - PR Newswire.com

Calls for elderly to be given extra influenza vaccination after deadly flu season

Offering a booster vaccine for Australians aged over 65, midway through flu season, could help combat the flu's spread. In the U.S., a stronger and more effective flu vaccine for the elderly, Fluzone, has been used since 2009. Sanofi Pasteur said the company was looking to have the drug approved by Australian regulators
17th Sep 2017 - Bunbury Mail

Calls for elderly to be given extra influenza vaccination after deadly flu season


17th Sep 2017 - Esperance Express

NHS urged to prepare for heavy flu burden this winter

On 12 September, Sanofi Pasteur announced that its quadrivalent influenza vaccine will be available in the UK for the first time this winter, although not elsewhere in Europe
18th Sep 2017 - Pharmaceutical-Journal


Industry News - Seqirus Media Monitoring - 18th Sep 2017

    View this newsletter in full

FDA Clears First Generic Tamiflu for Oral Suspension

The US Food and Drug Administration has approved the first generic version of oseltamivir phosphate (Tamiflu, Roche) for oral suspension 6 mg(base)/mL, made by Nesher Pharmaceuticals
15th Sep 2017 - Medscape.com

Generic for Liquid Tamiflu Approved


15th Sep 2017 - Medpage Today.com

Zydus subsidiary gets USFDA nod for Oseltamivir powder Oral Suspension


17th Sep 2017 - India Infoline

Zydus’ Nesher Pharma gets USFDA nod to market influenza drug


16th Sep 2017 - Financial Express

Zydus' Nesher gets USFDA nod to market influenza drug


16th Sep 2017 - Business Standard

The flu vaccine is already on its way to Utena

In September and October, the Utena Primary Health Care Center in Lithuania will receive 849 doses of Influvac. The Influvac vaccine for the 2017-2018 influenza season was purchased by public funds for the vaccination of at-risk groups
16th Sep 2017 - Udiena.lt

Calls for elderly to be given extra influenza vaccination after deadly flu season

In Australia, a deadly strain of flu has killed 94 people in Victorian aged-care facilities so far this year, leading to calls for more frequent vaccination against the virus for those who are most vulnerable. In the U.S., a stronger and more effective flu vaccine for the elderly, Fluzone, has been used since 2009. Sanofi Pasteur said the company was looking to have the drug approved by Australian regulators
16th Sep 2017 - The Age

Calls for elderly to be given extra influenza vaccination after deadly flu season


17th Sep 2017 - Bendigo Advertiser

Calls for elderly to be given extra influenza vaccination after deadly flu season


17th Sep 2017 - Newcastle Herald


Industry News - Seqirus Media Monitoring - 14th Sep 2017

    View this newsletter in full

S-033188 Phase 3 CAPSTONE-1 Study Results for Treatment of Influenza Presented at the European Scientific Working Group on Influenza Conference

Results of a S-033188 Phase 3 study in influenza patients (CAPSTONE-1) were released at the European Scientific Working Group on Influenza Conference. Additionally, Shionogi presented data on the nonclinical activity of this investigational drug against A/H7N9
13th Sep 2017 - PR Newswire.com

BiondVax Announces Public Offering of American Depositary Shares

BiondVax, a company focused on developing and commercializing M-001, a universal flu vaccine candidate, today announced that it intends to offer for sale its American Depositary Shares, each representing forty of its ordinary shares which are listed on the Tel Aviv Stock Exchange
13th Sep 2017 - PR Newswire.com

This coming winter’s flu vaccine has been bought and has already arrived in Lithuania

In Lithuania, the Infectious Diseases and AIDS Center (ULAC) reports that Influvac, a vaccine for influenza season 2017-2018, was purchased and has already been delivered for at-risk patients vaccination
13th Sep 2017 - 15min.lt

Vietnam's vaccine against influenza A / H5N1 is expected to hit the market in early 2018

Tran Xuan Hanh, deputy general director of Navetco Central Veterinary Drug Company, has mastered the technology of producing avian influenza vaccines and successfully produced them
13th Sep 2017 - vtc.vn

Fluzone or Flulaval: What Does the CDC say?

This year, providers caring for children under the age of 3 years have two options for an approved flu vaccine: Fluzone and Flulaval. Dosing is different, however. For Fluzone, a child under age 3 should receive 0.25 cc and for Flulaval, 0.5 cc, which is the adult dose as well. Both vaccines have the same amount of antigen in a 0.5 cc dose. This means a toddler getting Flulaval gets twice the dose of antigen as compared to a child receiving Fluzone
14th Sep 2017 - Patient Care Online


Industry News - Seqirus Media Monitoring - 13th Sep 2017

    View this newsletter in full

Resolve health initiative aims to save 100m lives worldwide

A new initiative to save 100 million lives globally through simple interventions such as cutting down on salt and banning trans fats, as well as getting countries prepared for epidemics from flu to SARS, is being launched with $225m of philanthropic funding, by Dr Tom Frieden, former director of the CDC in the United States
12th Sep 2017 - The Guardian

Former CDC chief launches $225 million global health initiative


12th Sep 2017 - Washington Post

Former CDC Director Frieden Takes Aim at Heart Disease, Epidemics


12th Sep 2017 - Wall Street Journal

Frieden’s Next Act: Heart Disease and Preparing for New Epidemics


12th Sep 2017 - New York Times

Tom Frieden's New Venture Combines 2 Disparate Health Threats


12th Sep 2017 - NPR.org

Former CDC director Tom Frieden to launch new global health initiative


12th Sep 2017 - Stat News

Former US CDC director takes aim at outbreaks, heart disease


13th Sep 2017 - Channel News Asia

Sanofi names a new president in France

Guillaume Leroy will be the new head of Sanofi France from October 1st, replacing Philippe Luscan ; he will coordinate all of Sanofi’s activities in France and represent the company in dealings with French authorities and professional bodies
12th Sep 2017 - Le Figaro

Sanofi will soon have a new president of France


12th Sep 2017 - Boursarama.com

A new flu vaccine is now available in the Czech Republic

The VaxigripTetra vaccine was approved in the European Union in 2016 and is now also approved for use in the Czech Republic. The 2017-2018 flu season in the northern hemisphere will be the first influenza season when VaxigripTetra will be available for populations aged 3 years and over in 24 countries
12th Sep 2017 - Zdravotnictvi Medicina

UK first EU market for Sanofi Pasteur quadrivalent flu vaccine

Sanofi Pasteur announced that, for the first time, it is making available its quadrivalent influenza vaccine in the UK, making it the first European country to market Sanofi Pasteur’s quadrivalent influenza vaccine
12th Sep 2017 - The Pharma Letter

Sanofi Pasteur's quadrivalent influenza vaccine now available for the 2017-2018 influenza season

Sanofi Pasteur's quadrivalent influenza vaccine now available for the 2017-2018 influenza season
12th Sep 2017 - Pharmiweb.com

BioCryst Pharmaceuticals Commences Public Offering of Common Stock

BioCryst Pharmaceuticals announced that it is offering to sell $80 million of its common stock in an underwritten public offering
12th Sep 2017 - The News Reports.com


Industry News - Seqirus Media Monitoring - 12th Sep 2017

    View this newsletter in full

Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Participants ≥65 Years in the US

This randomized, modified double-blind, active-controlled, multi-center trial will assess the safety and immunogenicity of the high-dose quadrivalent influenza vaccine (QIV-HD) compared to either the licensed or investigational high-dose trivalent influenza vaccine (TIV-HD) in adults.
12th Sep 2017 - Clinical Trials.gov


Industry News - Seqirus Media Monitoring - 11th Sep 2017

    View this newsletter in full

IRI arms cough/cold retailers with new tool to boost performance

IRI has launched IRI Illness Tracking, a new solution that pinpoints consumers who suffer from cough, cold, influenza and allergy symptoms throughout the year, so that over-the-counter product marketers and retailers can grow sales during the flu season through better planning and activation programs
8th Sep 2017 - Drug Store News

Parents 'distraught' over delay in getting vaccine documents

Lawyers acting for families who say their children suffered significant health problems following a controversial swine flu vaccine are due in court next month as part an effort to force the State to release crucial documents. GSK’s Pandemrix has been linked to narcolepsy
9th Sep 2017 - Irish Independent

Evotec and ABIVAX Enter into Strategic Collaboration to Develop Novel Antiviral Agents

Evotec and ABIVAX announced a strategic collaboration to discover and develop novel treatments for multiple serious viral infectious diseases. Targets in RSV, Influenza and Dengue viral infections have already been identified by ABIVAX
7th Sep 2017 - Business Insider

Public trusts supermarkets more than pharma – poll

A survey commissioned by Roche revealed that the public trusts supermarkets more than pharmaceutical companies; Roche wants to take a lead in the debate about how to build public trust in pharma. Almost a decade ago Roche faced strong criticism when it dragged its feet when asked to provide unpublished trial data on Tamiflu when the Cochrane Collaboration wanted to reassess its efficacy
7th Sep 2017 - Pharmaphorum.com


Industry News - Seqirus Media Monitoring - 8th Sep 2017

    View this newsletter in full

Glaxo has succeeded in getting its influenza virus waste emissions into the nearby river under control

GSK vaccine plant wastewater expelled viruses and genetically modified pathogens into Dresden waste water for 13 years, and although local health authorities say there was no risk to the public, they are still very relieved because remedial work by Glaxo has brought this worrying defect back under control
8th Sep 2017 - Sachsische Zeitung

Tamiflu shortages across pharmacies

There is currently a shortage of Tamiflu products across Australian pharmacies and wholesalers, the TGA confirms. Manufacturer Roche says pharmacies and wholesalers are running low on stock due to “exceptionally high seasonal demand”
7th Sep 2017 - Australian Journal of Pharmacy


Industry News - Seqirus Media Monitoring - 7th Sep 2017

    View this newsletter in full

Irvine firm's £1.3 million expansion to help lead fight against Alzheimer’s disease

The £1.3 million expansion of Merck in Irvine will help lead the fight against Alzheimer’s disease; the facility, which produces materials for rheumatoid arthritis, cancer, flu, diabetes and dementia medicines, currently supports 170 jobs
6th Sep 2017 - Daily Record

Major £1.3 million expansion for life science firm's Irvine facility


6th Sep 2017 - Irvine Times

Idyll Respiratory (IFV-RSV) Panel receives 510(k) clearance by US FDA

Biocartis announced that its Idylla Respiratory Panel has been granted 510(k) clearance by the US Food and Drug Administration. Developed by Janssen Diagnostics, the respiratory panel detects various strains of the influenza virus and respiratory syncytial virus
5th Sep 2017 - Webwire.com

Biocartis Group NV: Idylla(TM) Respiratory (IFV-RSV) Panel receives 510(k) clearance by US FDA


5th Sep 2017 - Globe Newswire.com

Biocartis Receives FDA Clearance for Viral Detection Panel


5th Sep 2017 - Genome Web

Idylla Respiratory (IFV-RSV) Panel receives 510(k) clearance by US FDA


5th Sep 2017 - twst.com

Tamiflu supplies running dry as flu epidemic tightens its grip on the nation

The flu epidemic gripping Australia has led to a nationwide shortage of the anti-viral medication Tamiflu. A Federal Department of Health spokeswoman said the "temporary" shortfall affected all Tamiflu products
6th Sep 2017 - Sydney Morning Herald

Nationwide shortage of anti-viral drug as flu epidemic spreads across Australia


6th Sep 2017 - Yahoo News Australia

Tamiflu supplies run dry as flu epidemic tightens grip


6th Sep 2017 - Newcastle Star

Epidemic hits supplies of flu jab


6th Sep 2017 - Daily Liberal


Industry News - Seqirus Media Monitoring - 6th Sep 2017

    View this newsletter in full

Sanofi completes purchase of Protein Sciences

Sanofi has absorbed another competitor, Protein Sciences, and in the process has increased its vaccine portfolio against the flu
5th Sep 2017 - Noticias ao Minuto

Tamiflu shortage spreads across Australia

The Tamiflu shortage that hit Queensland last month has now spread across Australia. The TGA and manufacturer Roche have warned supplies are dwindling due to exceptionally high seasonal demand
5th Sep 2017 - Pharmacy News.com.au

FluGen Announces C. Boyd Clarke Has Been Named Executive Chairman

C. Boyd Clarke has joined FluGen as Executive Chairman effective immediately. He said: “I am excited to work with the investment syndicate including WARF, Venture Investors, SWIB and Knox, and to help the team in the development our flu vaccine, RedeeFlu™, as it moves into the next round of clinical studies”
5th Sep 2017 - Businesswire.com

Prices for drugs in Russia could increase by 15%-20% next month

Prices for drugs in Russia may increase by 15%-20% as soon as October, according to predictions by the Russian Ministry of Health; due to the forthcoming surge of seasonal diseases, such as flu, prices for the drugs designed for its treatment will significantly increase
5th Sep 2017 - The Pharma Letter.com


Industry News - Seqirus Media Monitoring - 5th Sep 2017

    View this newsletter in full

Experts to scrutinise the 2017 flu vaccine

Experts say this season's record flu outbreak in Australia suggests that next year's vaccine may need to provide greater protection against the Influenza A (H3) strain
4th Sep 2017 - sbs.com.au

A better flu vaccine needed, says expert


4th Sep 2017 - news.com.au

Award winners believe that vaccines are vital for health

Winners of the Sanofi Pasteur ‘Vaccination to provide opportunities in 2017’ competition believe that vaccinations are vital for health; they explained that vaccinations in Mexico are a massive, never-ending task
4th Sep 2017 - Yucatan.com.mx

Changing of the guard at Novartis as Jimenez to step down

The CEO of Novartis, Joseph Jimenez, has announced he will be stepping down in 2018. After eight years at the helm, he will be replaced by Vasant Narasimhan. Mr Jimenez has predicted a return to sales growth next year, citing a development pipeline of 12 possible “blockbuster” products
4th Sep 2017 - Swiss Info.ch

Novartis names chief to replace Jimenez who is to step down


4th Sep 2017 - Financial Times

Novartis CEO Jimenez to Quit, Giving Reins to Harvard Doctor


4th Sep 2017 - Bloomberg

Novartis names drugs chief as CEO to deliver return to growth


4th Sep 2017 - Reuters

Novartis Calls for the Doctor


4th Sep 2017 - Bloomberg Business Week

Novartis CEO Jimenez to quit giving reins to Vasant Narasimhan


4th Sep 2017 - Economic Times

Novartis CEO Jimenez to step down early next year


4th Sep 2017 - abcnews.com

Sanofi Acquires Protein Sciences, for Up To $750M

Sanofi has completed the acquisition of Protein Sciences; through the acquisition, Sanofi Pasteur adds a promising product to its influenza vaccine portfolio: Flublok
4th Sep 2017 - Finsmes.com


Industry News - Seqirus Media Monitoring - 4th Sep 2017

    View this newsletter in full

With 600 H1N1 deaths since Jan, govt should promote influenza vaccine, says WHO

At a time when 600 people have succumbed to H1N1 virus in India this year, World Health Organization’s India representative Dr Henk Bekedam has urged the government to promote influenza vaccination
2nd Sep 2017 - Hindustan Times

Vaccination giant recognises the hard vaccination work done by institutions

Sanofi Pasteur held the third edition of its Vaccination for Opportunity Prize which aims to promote the benefits of immunization at a local and regional administration level
1st Sep 2017 - SIPSE.com


Industry News - Seqirus Media Monitoring - 1st Sep 2017

    View this newsletter in full

GlaxoSmithKline’s Vaccines Business in 2Q17

GlaxoSmithKline’s vaccine business includes meningitis vaccines, influenza vaccines, and the established vaccines in its portfolio. The revenues were driven by a strong performance across each of the franchises
31st Aug 2017 - Market Realist.com

Universal flu vaccine co BiondVax to delist from TASE

BiondVax has decided to voluntarily delist from the Tel Aviv Stock Exchange, while maintaining a continued listing on NASDAQ. Following a €20 million funding agreement with the EIB and as it progresses towards Phase III clinical trials and construction of its commercial mid-size manufacturing facility, BiondVax's board decided to focus efforts on the international scene
31st Aug 2017 - Globes.co.il

Dual-Listed BiondVax to Voluntarily Delist from Tel Aviv Stock Exchange


31st Aug 2017 - Business Insider

BiondVax Provides Second Quarter 2017 Financial Results and Update

BiondVax announced its financial results for the quarter ended June 30, 2017; CEO Dr. Ron Babecoff commented, "This quarter's significant achievements including the €20 million EIB funding and positive Phase 2b clinical trial results enable us continue towards launching our Phase 3 program and constructing our mid-size manufacturing facility towards commercialization"
31st Aug 2017 - Benzinga.com

BiondVax Provides Second Quarter 2017 Financial Results and Update


31st Aug 2017 - Guru Focus.com


Industry News - Seqirus Media Monitoring - 31st Aug 2017

    View this newsletter in full

Worries about a Galveston Bio-Lab

Concern is rising for the safety of a biological lab containing deadly diseases on Galveston island, which has been hit by the massive storm devastating southeast Texas. According to its website, the high security national bio-containment lab’s mission is to develop “therapies, vaccines, and diagnostic tests for naturally occurring emerging diseases such as SARS, West Nile encephalitis and avian influenza – as well as for microbes that might be employed by terrorists.”
30th Aug 2017 - Consortium News


Industry News - Seqirus Media Monitoring - 30th Aug 2017

    View this newsletter in full

Life-saving flu vaccines at heart of £160 million boost for life sciences

A new national centre to investigate cures for influenza will be at the heart of a £160 million Government boost for the UK’s research sector, ministers will announce
30th Aug 2017 - Telegraph

Sanofi Pasteur launches 4-strain influenza vaccine in Korea

Sanofi Pasteur said it would officially launch its new quadrivalent influenza vaccine in South Korea next month: Vaxigrip Tetra is able to protect against four strains of influenza -- two influenza strains (H1N1, H3N2) and two influenza B strains (Yamagata, Victoria)
29th Aug 2017 - Korea Herald

Sanofi Pasteur launches new quadrivalent influenza vaccine


29th Aug 2017 - Korea Biomed

Sanofi Pasteur unveils 4-strain influenza vaccine


30th Aug 2017 - Korea Times

PharmaJet announces Quadrivalent Influenza Vaccine for Needle-free delivery begins shipping for 2017-18 flu season

PharmaJet announced that shipping has begun for the quadrivalent influenza vaccine for needle-free delivery with the PharmaJet Stratis device for the 2017-18 influenza season
29th Aug 2017 - PR Newswire.com

PharmaJet announces availability of quadrivalent influenza vaccine


29th Aug 2017 - Drug Store News

Sanofi completes acquisition of vaccines biotech company

Sanofi has announced the completion of its acquisition of Protein Sciences, following Federal Trade Commission approval; this acquisition adds a recombinant protein-based influenza vaccine, Flublok, to the portfolio of Sanofi’s vaccines business unit
29th Aug 2017 - EPM Magazine

Sanofi Closes Acquisition of Protein Sciences


28th Aug 2017 - BioPharm International

Sanofi rachète un spécialiste des vaccins contre la grippe


28th Aug 2017 - bfmbusiness.bfmtv.com

Sanofi finalise le rachat de Protein Sciences pour 750 millions de dollars


28th Aug 2017 - La Tribune

Flu Shots Available at East Haven Fall Festival

Healthy Choices Fastvax will be administering Flublok Influenza Vaccine, in East Haven, Connecticut; Flublok is an egg-free flu vaccine, made without antibiotics, thimerosal, latex or flu virus
29th Aug 2017 - patch.com

News of Note—Sanofi, FluMist and more

A roundup of flu vaccine industry news
29th Aug 2017 - FiercePharma


Industry News - Seqirus Media Monitoring - 29th Aug 2017

    View this newsletter in full

SK Chem supplies world’s first quadrivalent flu vaccine

SK Chemicals said it has started supplying the world's first quadrivalent cell culture-based flu vaccine “SKY CellFlu Quadrivalent” for the local Korean market
28th Aug 2017 - Korea Biomed

MedImmune, AstraZeneca may face another brutal season for FluMist

MedImmune already sustained a stunning plunge in FluMist sales last year, and the CDC has recommended for the second time against using Flumist this year
28th Aug 2017 - Washington Business Journal

CDC updates 2017-2018 flu season vaccine recommendations

The CDC upated its flu season vaccine recommendations: vaccine viruses included in the 2017–18 U.S. trivalent influenza vaccines will be an A/Michigan/45/2015 (H1N1)pdm09–like virus, an A/Hong Kong/4801/2014 (H3N2)-like virus, and a B/Brisbane/60/2008–like virus (Victoria lineage). Quadrivalent influenza vaccines will contain these three viruses and an additional influenza B vaccine virus, a B/Phuket/3073/2013–like virus (Yamagata lineage)
28th Aug 2017 - Drug Store News

Sanofi finishes purchase of Meriden's Protein Sciences

Sanofi has completed the acquisition of Protein Sciences; through the acquisition, Sanofi adds a promising product to its influenza vaccine portfolio: Flublok, the only recombinant protein-based influenza vaccine approved by the FDA
28th Aug 2017 - Nasdaq.com

Sanofi finishes purchase of Meriden's Protein Sciences


28th Aug 2017 - Hartford Business

Sanofi completes the acquisition of Protein Sciences


28th Aug 2017 - Menafn.com

Sanofi completes the acquisition of Protein Sciences


28th Aug 2017 - Pharmiweb.com

Sanofi acquires Connecticut-based vaccines biotechnology company, Protein Sciences


28th Aug 2017 - Pharmabiz.com

Sanofi: acquisition de Protein Sciences finalisée.


28th Aug 2017 - Boursorama.com

A suivre aujourd'hui... Sanofi


28th Aug 2017 - Capital.fr

Sanofi, completata l’acquisizione di Protein Sciences


28th Aug 2017 - About Pharma.com

Sanofi boucle le rachat de Protein Sciences pour au moins $650M


28th Aug 2017 - Boursier.com

Sanofi finalise l’acquisition de la biotech américaine Protein Sciences


28th Aug 2017 - Usine Nouvelle


Industry News - Seqirus Media Monitoring - 25th Aug 2017

    View this newsletter in full

Quadrivalent influenza vaccines enter fierce sales competition

The competition among quadrivalent products is intensifying in Korea. On top of six vaccine brands -- Fluarix Tetra by GSK, GC Fluquadribalant by Green Cross, SKYCellflu Quadrivalent by SK Chemical, Boryung Tetra Vaccine by Borung Biopharma, Kovax flu 4ga PF by Korea Vaccine, and Teratect by Il-Yang Pharm –– that won approvals last year, three new products -- Vaxigriptetra by Sanofi-Pasteur, Vaxiflu quadrivalent vaccine by Dong-A ST and Boryung Tetra by Boryung Biopharma -- jumped into the fray this year
24th Aug 2017 - Korea Biomed.com


Industry News - Seqirus Media Monitoring - 24th Aug 2017

    View this newsletter in full

Regulators add sleep disorder to Tamiflu side effects

In Korea, the Ministry of Food and Drug Safety said that it has added sleep disorders to the side effects of influenza medication oseltamivir, also known as Tamiflu
23rd Aug 2017 - Korea Biomed

Daewoong releases improved influenza treatment

Daewoong Pharmaceutical has released its influenza treatment Tamivict with “improved patient convenience,” the company said
23rd Aug 2017 - Korea Biomed

Biotech company expands headquarters in Gaithersburg, plans to add 45 new jobs

Altimmune will relocate new employees acquired as a result of its merger with Pharmathene, and existing employees, to a new location in Gaithersburg; its lead product, NasoVAX, a flu vaccine, is expected to begin Phase 2 development in the coming weeks
23rd Aug 2017 - Montgomery Community Media

Novavax’s NanoFlu Has Potential to Lead the Influenza Market: CEO

New data “suggest that NanoFlu has the potential to elicit a broader, more robust immune response, resulting in greater protection than the market-leading licensed influenza vaccine in older adults, Sanofi’s Fluzone High-Dose”, said Novavax’s R&D President, after pre-clinical study results came out
23rd Aug 2017 - Smarter Analyst

Novavax Stock: Gaining On Preclinical Data


23rd Aug 2017 - cnafinance.com

Novavax’ Preclinical Influenza Nanoparticle Study Published in Vaccine


23rd Aug 2017 - pharmiweb.com

Novavax Reports Publication of Pre-Clinical Influenza Nanoparticle Study for Nanoparticle Influenza Vaccine Candidate with Proprietary Matrix-M Adjuvant (NanoFlu)


23rd Aug 2017 - Street Insider.com

Novavax’ Preclinical Influenza Nanoparticle Study Published in Vaccine


23rd Aug 2017 - Globe Newswire.com


Industry News - Seqirus Media Monitoring - 23rd Aug 2017

    View this newsletter in full

Altimmune Submits Investigational New Drug Application for NasoVAX in Preparation for Phase 2 Trial

Altimmune has submitted an Investigational New Drug application to the U.S Food and Drug Administration for NasoVAX, its intranasally administered recombinant flu vaccine
21st Aug 2017 - Globe Newswire.com

Altimmune moving to new headquarters

Altimmune is moving to larger headquarters to accommodate new employees and anticipated growth following its merger with PharmAthene; Altimmune is developing immunotherapy drugs, including a recombinant flu vaccine administered nasally
22nd Aug 2017 - Baltimore Sun

Altimmune Expands HQ in Gaithersburg, Adds 45 Jobs


22nd Aug 2017 - Patch.com

Novavax: The Case For Going Long

With Novavax forecasting revenue of $375 million from NanoFlu alone in 2022, it's easy to see why analysts would be enamored with this biotech's newest toy
22nd Aug 2017 - Seeking Alpha

Amneal launches generic form of Tamiflu

Amneal Pharmaceuticals has launched oseltamivir phosphate capsules, USP, in three strengths: 30-mg, 45-mg and 75-mg. The Amneal generic is an AB-rated therapeutic equivalent to Tamiflu
22nd Aug 2017 - Drug Store News


Industry News - Seqirus Media Monitoring - 22nd Aug 2017

    View this newsletter in full

Oseltamivir syrup in short supply

Children in the 0-5 years age group fall in the high-risk category for swine flu, but many paediatricians and chemists across Gujarat say there is not enough fluvir (oseltamivir drug) syrup
22nd Aug 2017 - Times of India

ICMR partners with IVI, invests Rs 3.20 crore for vaccine development in India

The Indian Council of Medical Research has entered into an agreement to collaborate on vaccine research and development with International Vaccine Institute; influenza is a potential area of interest for vaccine development
21st Aug 2017 - Economic Times

Custom-Made Molecules

Synthetic Genomics’ new digital-to-biological converter (DBC) can, upon receipt of a DNA sequence, prepare appropriate oligos, carry out DNA synthesis, and then convert that DNA into a vaccine, or any RNA molecule or protein; so far, the DBC has been programmed to make fluorescent proteins, antibody polypeptides, an RNA virus (H1N1 influenza), and an influenza vaccine
21st Aug 2017 - The Scientist


Industry News - Seqirus Media Monitoring - 21st Aug 2017

    View this newsletter in full

Flu drug shortage: Queensland pharmacies running low on Tamiflu

Supplies of Tamiflu are running low in Queensland in the midst of one of the worst influenza seasons on record; more supplies might need to be imported from interstate or overseas
18th Aug 2017 - abc.net.au

Chemists are running out of flu drugs as outbreak worsens


18th Aug 2017 - Yahoo News Australia

Queensland suffers severe antiviral drug shortage